The most current laboratory reference ranges are included in the laboratory report from the LIS.
Laboratory testing information is also available on The Ohio State Wexner Medical Center Labs Test Catalog Website. https://theohiostatelabs.testcatalog.org/

This document applies all laboratory testing at OSUWMC Clinical Laboratories. This includes:
James Genetics Laboratories: 2001 Polaris Pkwy, Innovations Centre Suite 1500, Columbus OH 43240
Morehouse Laboratory: 1st Fl Morehouse Medical Plaza Tower, 2050 Kenny Rd, Columbus OH 43221
Spielman Laboratory: 1145 Olentangy River Rd Rm 2030, Columbus Oh 43212
Clinical Laboratories (UH): 410 West 10th Avenue, Columbus OH 43210
Clinical Laboratories (UHE): 181 Taylor Avenue, Columbus OH 43203
James West Campus Laboratory (JWC): 2121 Kenny Rd, Columbus, OH 43221

Test Name	Synonym	Reference Values		Interpretation	Method Description	Source of Reference Range	Technical Range / AMR	Reportable Range / CRR
		Female	Male					
Arterial Blood Gas (Full Panel)	GASALL	**PH** 0-29 days: 7.29-7.45 30+ days: 7.35-7.45 **PCO2** 0-29 days: 27-40 mm Hg 30+ days: 32-48 mm Hg **PO2** 83-108 mm Hg **HCO3** 0-29 days: 17-24 mmol/L 30+ days: 22-28 mmol/L **OSAT** 0-365 days: 40-90 % 1+ years: 94-98 % **BASE** -3.0-3.0 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **LACT** 0.5-1.6 mmol/L **NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **ICA** 4.60-5.30 mg/dL **BGHGB** 0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL **BGHCT (Calculated) - Radiometer** 0-14 days: 40-57 % 15-30 days: 32-45 % 31-60 days: 28-35 % 61-179 days: 30-37 % 180-2 years: 31-38 % 2-5 years: 31-38 % 6-11 years: 32-40 % 12-17 years: 33-40 % 18+ years: 34-46 % **BGHCT (Calculated) - GEM 5000/7000** 0-15 days: 40-60 % 15-30 days: 32-44 % 30-60 days: 28-34 % 60-180 days: 30-37 % 180-2 years: 31-38 % 2-6 years: 31-38 % 6-12 years: 32-40 % 12-18 years: 32-40 % 18+ years: 34-46 % **O2HGB** 94-98 % **COHGB** ≤1.5 % **MTHGB** ≤1.5 %	**PH** 0-29 days: 7.29-7.45 30+ days: 7.35-7.45 **PCO2** 0-29 days: 27-40 mm Hg 30+ days: 32-48 mm Hg **PO2** 83-108 mm Hg **HCO3** 0-29 days: 17-24 mmol/L 30+ days: 22-28 mmol/L **OSAT** 0-365 days: 40-90 % 1+ years: 94-98 % **BASE** -3.0-3.0 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **LACT** 0.5-1.6 mmol/L **NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **ICA** 4.60-5.30 mg/dL **BGHGB** 0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL **BGHCT (Calculated) - Radiometer** 0-14 days: 40-54 % 15-30 days: 31-45 % 31-60 days: 27-38 % 61-179 days: 29-37 % 180-2 years: 31-38 % 2-5 years: 31-38 % 6-11 years: 32-40 % 12-17 years: 34-44 % 18+ years: 40-50 % **BGHCT (Calculated) - GEM 5000/7000** 0-15 days: 42-57 % 15-30 days: 30-46 % 30-60 days: 27-38 % 60-180 days: 29-37 % 180-2 years: 30-38 % 2-6 years: 31-38 % 6-12 years: 32-40 % 12-18 years: 33-44 % 18+ years: 40-50 % **O2HGB** 94-98 % **COHGB** ≤1.5 % **MTHGB** ≤1.5 %	**pO2, Glucose, Lactate:** Amperometry **pH, pCO2, K, Na, iCA:** Potentiometry **HCO3 GEM:** Log (HCO_3 (c)) = pH + log(pCO_2) – 7.608 mmol/L **HCT:** 3.0 x tHb **COHGB:** Co-oximetry; COHb% = 100 x (COHb/THb) % **MTHGB:** Co-oximetry; MetHb% = 100 x (MetHb/THb) % **O2HGB:** Co-oximetry; O2Hb% = 100 x (O2Hb/THb) % **Total HGB:** Co-oximetry; THb = O2Hb + COb + MetHb + HHb **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%) **Base excess GEM:** HCO3- - 24.8 + 16.2 x (pH - 7.4)	pH: Clinical Guide to Laboratory Tests 3rd Edition, Tietz, 1995. HCO3 Arterial: Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.3) 201206B. sO2 Arterial: Clinical Guide to Laboratory Tests 3rd Edition, Tietz, 1995. pO2 Arterial: Clinical Guide to Laboratory Tests, Tietz, 1995 & Fundamentals of Clinical Chem, 1987. pCO2 Arterial: Clinical Guide to Laboratory Tests, Tietz, 1995 & Fundamentals of Clinical Chem, 1987 Base excess: Contemporary Practice in Clinical Chemistry 3rd Edition 2016. Chapter 32. Table 32-1 p450. Glucose: Clinical Guide to Laboratory Tests, 3rd Edition Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999. Lactate: ABL 800 Flex Reference Manual, 2008, verified by GEM Validation Study, 2021. Na: Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.165). Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995. Lower limit adjusted and verified with GEM Validation Study, 2021. K: Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995. Clinical Guide to Laboratory Tests, Tietz, 1995. Upper limit adjusted and verified with GEM Validation Study, 2021. ICA: Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.102). HCT: Derived from total hemoglobin reference interval. ABL 800 FLEX Reference Manual, 2008. Derived from total hemoglobin reference interval based on GEM calculation of HCT. HGB: OSU Internal Normal Range Study, October 2018. Verified with GEM Validation Study, 2021. O2HGB, COHGB, MTHGB: ABL 800 Flex Reference Manual 2008, verified by GEM Validation Study, 2021. Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics Sixth Edition, 2018.	**Radiometer ABL800:** PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 1-1,030 mg/dL LACT: 0.0-30.0 mmol/L NA: 80-175 mmol/L K: 1.0-14.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB:4.8-23.5 g/dL HCTc: 14-71% O2HGB: 0-100 % COHGB: 0.0-50.0 % MTHGB: 0.0-30.0 % **GEM 5000:** PH: 7.00-7.92 PCO2: 18-125 mm Hg PO2: 35-529 mm Hg HCO3: 0-100 mmol/L sO2: 0-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 16-685 mg/dL LACT: 0.3-17.0 mmol/L NA: 100-180 mmol/L K: 1.0-10.0 mmol/L LACT: 0.3-17.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB: 5.0-20.0 g/dL HCTc: 15-60% O2HGB: 0-100 % COHGB: 0.0-75.0 % MTHGB: 0.0-30.0 %	**Radiometer ABL800:** PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 1-1,030 mg/dL LACT: 0.0-30.0 mmol/L NA: 80-175 mmol/L K: 1.0-14.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB:4.8-23.5 g/dL HCTc: 14-71% O2HGB: 0-100 % COHGB: 0.0-50.0 % MTHGB: 0.0-30.0 % **GEM 5000:** PH: 7.00-7.92 PCO2: 18-125 mm Hg PO2: 35-529 mm Hg HCO3: 0-100 mmol/L sO2: 0-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 16-685 mg/dL LACT: 0.3-17.0 mmol/L NA: 100-180 mmol/L K: 1.0-10.0 mmol/L LACT: 0.3-17.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB: 5.0-20.0 g/dL HCTc: 15-60% O2HGB: 0-100 % COHGB: 0.0-75.0 % MTHGB: 0.0-30.0 %

Arterial Blood Gas	GAS5	**PH** 0-29 days: 7.29-7.45 30+ days: 7.35-7.45 **PCO2** 0-29 days: 27-40 mm Hg 30+ days: 32-48 mm Hg **PO2** 83-108 mm Hg **HCO3** 0-29 days: 17-24 mmol/L 30+ days: 22-28 mmol/L **OSAT** 0-365 days: 40-90 % 1+ years: 94-98 % **BASE** -3.0-3.0 mmol/L		**pO2:** Amperometry **pH, pCO2:** Potentiometry **Base excess GEM:** HCO3- - 24.8 + 16.2 x (pH - 7.4) **HCO3 GEM:** Log (HCO_3 (c)) = pH + log(pCO_2) – 7.608 mmol/L **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%)	See Arterial Blood Gas (Full Panel)	See Arterial Blood Gas (Full Panel)	See Arterial Blood Gas (Full Panel)
Arterial Blood Gas Plus Serial Lactate	GAS5L 2HRLACT	**PH** 0-29 days: 7.29-7.45 30+ days: 7.35-7.45 **PCO2** 0-29 days: 27-40 mm Hg 30+ days: 32-48 mm Hg **PO2** 83-108 mm Hg **HCO3** 0-29 days: 17-24 mmol/L 30+ days: 22-28 mmol/L **OSAT** 0-365 days: 40-90 % 1+ years: 94-98 % **BASE** -3.0-3.0 mmol/L **LACT** 0.5-1.6 mmol/L		**pO2, Lactate:** Amperometry **pH, pCO2:** Potentiometry **Base excess GEM:** HCO3- - 24.8 + 16.2 x (pH - 7.4) **HCO3 GEM:** Log (HCO_3 (c)) = pH + log(pCO_2) – 7.608 mmol/L **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%)	See Arterial Blood Gas (Full Panel)	See Arterial Blood Gas (Full Panel)	See Arterial Blood Gas (Full Panel)
Arterial Blood Gas, Umbilical Cord	GASCA	**PH** 7.23-7.33 **PCO2** 41-58 mm Hg **PO2** 12-24 mm Hg **HCO3** 20-25 mmol/L **OSAT** 3-69 % **BASE** -3.0-3.0 mmol/L		**pO2:** Amperometry **pH, pCO2:** Potentiometry **Base:** Calculation of the expression that approximates the amount of acid or base required to titrate one liter of blood back to a normal pH of 7.40 **HCO3:** Calculation **sO2:** Cooximetry	pH, pCO2, pO2, HCO3: Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995. sO2: Brit Journ Obst Gyn 8-2000 Vol 107 pp 987-994 Cord Bld O2 SAT in vigorous infants at birth: What is normal? Base: Email_Cord blood Gas RR Physician Established Base Excess_11-2020	PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % BASE: -30.0-30.0 mmol/L	PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % BASE: -30.0-30.0 mmol/L
Carboxyhemoglobin	COHGB	≤1.5 %	Carboxyhemoglobin is elevated in patients exposed to high exogenous sources of carbon monoxide such as cigarette smoke, vehicle exhaust, etc. or increased endogenous production such as hemolysis.	Co-oximetry; COHb% = 100 x (COHb/THb) %	See Arterial Blood Gas (Full Panel)	**Radiometer ABL800:** 0.0-50.0 % **GEM 5000:** 0.0-75.0%	**Radiometer ABL800:** 0.0-50.0 % **GEM 5000:** 0.0-75.0%
Cooximetry, Whole Blood	COOXB	**O2HGB** 94-98 % **MTHGB** ≤1.5 % **COHGB** ≤1.5 % **BGHGB** 0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL **OSATA** 0-365 days: 40-90 % 1+ years: 94-98 % **OSATV** 70-80 % **OSATMV** 60-80%	**O2HGB** 94-98 % **MTHGB** ≤1.5 % **COHGB** ≤1.5 % **BGHGB** 0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL **OSATA** 0-365 days: 40-90 % 1+ years: 94-98 % **OSATV** 70-80 % **OSATMV** 60-80%		**COHGB:** Co-oximetry; COHb% = 100 x (COHb/THb) % **MTHGB:** Co-oximetry; MetHb% = 100 x (MetHb/THb) % **O2HGB:** Co-oximetry; O2Hb% = 100 x (O2Hb/THb) % **Total HGB:** Co-oximetry; THb = O2Hb + COb + MetHb + HHb **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%)	See Arterial Blood Gas (Full Panel)	**Radiometer ABL800:** O2HGB: 0-100 % MTHGB: 0.0-30.0 % COHGB: 0.0-50.0 % BGHGB: 4.8-23.5 g/dL OSAT: 5-100 % **GEM 5000:** BGHGB: 5.0-20.0 g/dL O2HGB: 0-100 % COHGB: 0.0-75.0 % MTHGB: 0.0-30.0 % sO2: 0-100 %	**Radiometer ABL800:** O2HGB: 0-100 % MTHGB: 0.0-30.0 % COHGB: 0.0-50.0 % BGHGB: 4.8-23.5 g/dL OSAT: 5-100 % **GEM 5000:** BGHGB: 5.0-20.0 g/dL O2HGB: 0-100 % COHGB: 0.0-75.0 % MTHGB: 0.0-30.0 % sO2: 0-100 %
Ionized Calcium (CRRT)	ICACRT		Post filter CRRT. When using Citrate anticoagulant protocol, the preferred targeted range is 1-2 mg/dL.	Potentiometry	Email_ICA CRRT RR Physician Established 11-19-2020	1.00-13.00 mg/dL	1.00-13.00 mg/dL
Ionized Calcium, Serum	ICASST	4.60-5.30 mg/dL		Potentiometry	Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.102)	1.00-13.00 mg/dL	1.00-13.00 mg/dL
Ionized Calcium, Whole Blood	ICA	4.60-5.30 mg/dL		Potentiometry	See Arterial Blood Gas (Full Panel)	1.00-13.00 mg/dL	1.00-13.00 mg/dL
Lactate, Whole Blood	BGLACT	0.5-1.6 mmol/L		Amperometry	See Arterial Blood Gas (Full Panel)	**Radiometer ABL800:** 0.0-30.0 mmol/L **GEM 5000:** 0.3-17.0 mmol/L	**Radiometer ABL800:** 0.0-30.0 mmol/L **GEM 5000:** 0.3-17.0 mmol/L
Lactate, Whole Blood, Serial	0HRLACT 2HRLACT	0.5-1.6 mmol/L		Amperometry		0.3-17.0 mmol/L	0.3-17.0 mmol/L
Methemoglobin	MTHGB	≤1.5 %		Co-oximetry; MetHb% = 100 x (MetHb/THb) %	See Arterial Blood Gas (Full Panel)	0.0-30.0 %	0.0-30.0 %
pH, Pleural Fluid	FPH			Potentiometry		6.80-8.00	6.80-8.00

Potassium, Whole Blood	BGK	0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L			Potentiometry	See Arterial Blood Gas (Full Panel)	**Radiometer ABL800:** 1.0-14.0 mmol/L **GEM 5000:** 1.0-10.0 mmol/L	**Radiometer ABL800:** 1.0-14.0 mmol/L **GEM 5000:** 1.0-10.0 mmol/L
Sodium, Whole Blood	BGNA	0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L			Potentiometry	See Arterial Blood Gas (Full Panel)	**Radiometer ABL 800:** 80-175 mmol/L **GEM 5000:** 100-180 mmol/L	**Radiometer ABL 800:** 80-175 mmol/L **GEM 5000:** 100-180 mmol/L
Total Hemoglobin	BGHGB	6-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL	0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL		Co-oximetry; THb = O2Hb + COb + MetHb + HHb	See Arterial Blood Gas (Full Panel)	5.0-20.0 g/dL	5.0-20.0 g/dL
Venous Blood Gas (Full Panel)	GASALL	**PH** 7.32-7.43 **PCO2** 36-52 mm Hg **HCO3** 22-29 mmol/L **OSAT** 70-80 % **BASE** -3.0-3.0 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **LACT** 0.5-1.6 mmol/L **NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **ICA** 4.60-5.30 mg/dL **BGHGB** 0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL **BGHCT (Calculated) - Radiometer** 0-14 days: 40-57 % 15-30 days: 32-45 % 31-60 days: 28-35 % 61-179 days: 30-37 % 180-2 years: 31-38 % 2-5 years: 31-38 % 6-11 years: 32-40 % 12-17 years: 33-40 % 18+ years: 34-46 % **BGHCT (Calculated) - GEM 5000/7000** 0-15 days: 40-60 % 15-30 days: 32-44 % 30-60 days: 28-34 % 60-180 days: 30-37 % 180-2 years: 31-38 % 2-6 years: 31-38 % 6-12 years: 32-40 % 12-18 years: 32-40 % 18+ years: 34-46 % **O2HGB** 94-98 % **COHGB** ≤1.5 % **MTHGB** ≤1.5 %	**PH** 7.32-7.43 **PCO2** 36-52 mm Hg **HCO3** 22-29 mmol/L **OSAT** 70-80 % **BASE** -3.0-3.0 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **LACT** 0.5-1.6 mmol/L **NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **ICA** 4.60-5.30 mg/dL **BGHGB** 0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL **BGHCT (Calculated) - Radiometer** 0-14 days: 40-57 % 15-30 days: 32-45 % 31-60 days: 28-35 % 61-179 days: 30-37 % 180-2 years: 31-38 % 2-5 years: 31-38 % 6-11 years: 32-40 % 12-17 years: 33-40 % 18+ years: 34-46 % **BGHCT (Calculated) - GEM 5000/7000** 0-15 days: 42-57 % 15-30 days: 30-46 % 30-60 days: 27-38 % 60-180 days: 29-37 % 180-2 years: 30-38 % 2-6 years: 31-38 % 6-12 years: 32-40 % 12-18 years: 33-44 % 18+ years: 40-50 % **O2HGB** 94-98 % **COHGB** ≤1.5 % **MTHGB** ≤1.5 %		**pO2, Glucose, Lactate:** Amperometry **pH, pCO2, K, Na, ICA:** Potentiometry **HCO3 GEM:** Log (HCO_3 (c)) = pH + log(pCO_2) – 7.608 mmol/L **HCT:** 3.0 x tHb **COHGB:** Co-oximetry; COHb% = 100 x (COHb/THb) % **MTHGB:** Co-oximetry; MetHb% = 100 x (MetHb/THb) % **O2HGB:** Co-oximetry; O2Hb% = 100 x (O2Hb/THb) % **Total HGB:** Co-oximetry; THb = O2Hb + COb + MetHb + HHb **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%) **Base excess GEM:** HCO3- - 24.8 + 16.2 x (pH - 7.4)	pH: Clinical Guide to Laboratory Tests 3rd Edition, Tietz, 1995. HCO3 Venous: Clinical Guide to Laboratory Tests 3rd Edition, Tietz, 1995. sO2 Venous: Blood Gas O2Sat: Radiometer Bulletin No: 44 Compendium of reference intervals pO2 Venous: Respirology. 2014 Feb;19(2):168-75, doi:10.11111/resp.122225. Pub 2014 Jan 3. © 2012 Radiometer Medical ApS. All rights reserved. 995-950. 201206B. pCO2 Venous: Respirology. 2014 Feb;19(2):168-75 doi:10.11111/resp.122225. Pub 2014 Jan 3. Base excess: Contemporary Practice in Clinical Chemistry 3rd Edition 2016. Chapter 32. Table 32-1 p450. Glucose: Clinical Guide to Laboratory Tests, 3rd Edition Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999. Lactate: ABL 800 Flex Reference Manual, 2008, verified by GEM Validation Study, 2021. Na: Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.165). Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995. Lower limit adjusted and verified with GEM Validation Study, 2021. K: Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995. Clinical Guide to Laboratory Tests, Tietz, 1995. Upper limit adjusted and verified with GEM Validation Study, 2021. ICA: Blood Gases and Critical Care Testing Physiology, Clinical Interpretations, and Laboratory Applications. 3rd Edition, 2021 (p.102). HCT: Derived from total hemoglobin reference interval. ABL 800 FLEX Reference Manual, 2008. Derived from total hemoglobin reference interval based on GEM calculation of HCT. HGB: OSU Internal Normal Range Study, October 2018. Verified with GEM Validation Study, 2021. O2HGB, COHGB, MTHGB: ABL 800 Flex Reference Manual 2008, verified by GEM Validation Study, 2021. Clinical Guide to Laboratory Tests Third Edition, Tietz, 1995. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics Sixth Edition, 2018.	**Radiometer ABL800:** PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 1-1,030 mg/dL LACT: 0.0-30.0 mmol/L NA: 80-175 mmol/L K: 1.0-14.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB:4.8-23.5 g/dL HCTc: 14-71% O2HGB: 0-100 % COHGB: 0.0-50.0 % MTHGB: 0.0-30.0 % **GEM 5000:** PH: 7.00-7.92 PCO2: 18-125 mm Hg PO2: 35-529 mm Hg HCO3: 0-100 mmol/L sO2: 0-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 16-685 mg/dL LACT: 0.3-17.0 mmol/L NA: 100-180 mmol/L K: 1.0-10.0 mmol/L LACT: 0.3-17.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB: 5.0-20.0 g/dL HCTc: 15-60% O2HGB: 0-100 % COHGB: 0.0-75.0 % MTHGB: 0.0-30.0 %	**Radiometer ABL800:** PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 1-1,030 mg/dL LACT: 0.0-30.0 mmol/L NA: 80-175 mmol/L K: 1.0-14.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB:4.8-23.5 g/dL HCTc: 14-71% O2HGB: 0-100 % COHGB: 0.0-50.0 % MTHGB: 0.0-30.0 % **GEM 5000:** PH: 7.00-7.92 PCO2: 18-125 mm Hg PO2: 35-529 mm Hg HCO3: 0-100 mmol/L sO2: 0-100 % FIO2: 40-100 % BASE: -30.0-30.0 mmol/L GLUC: 16-685 mg/dL LACT: 0.3-17.0 mmol/L NA: 100-180 mmol/L K: 1.0-10.0 mmol/L LACT: 0.3-17.0 mmol/L ICA: 1.00-13.00 mg/dL BGHGB: 5.0-20.0 g/dL HCTc: 15-60% O2HGB: 0-100 % COHGB: 0.0-75.0 % MTHGB: 0.0-30.0 %

Venous Blood Gas	GASV5	**PH** 7.32-7.43 **PCO2** 36-52 mm Hg **HCO3** 22-29 mmol/L **OSAT** 70-80 % **BASE** -3.0-3.0 mmol/L		**pO2:** Amperometry **pH, pCO2:** Potentiometry **Base excess GEM:** HCO3- - 24.8 + 16.2 x (pH - 7.4) **HCO3 GEM:** Log (HCO_3 (c)) = pH + log(pCO_2) – 7.608 mmol/L **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%)	See Venous Blood Gas (Full Panel)	See Venous Blood Gas (Full Panel)	See Venous Blood Gas (Full Panel)
Venous Blood Gas Plus Serial Lactate	GASVL 2HRLACT	**PH** 7.32-7.43 **PCO2** 36-52 mm Hg **HCO3** 22-29 mmol/L **OSAT** 70-80 % **BASE** -3.0-3.0 mmol/L **LACT** 0.5-1.6 mmol/L		**pO2, Lactate:** Amperometry **pH, pCO2:** Potentiometry **Base excess GEM:** HCO3- - 24.8 + 16.2 x (pH - 7.4) **HCO3 GEM:** Log (HCO_3 (c)) = pH + log(pCO_2) – 7.608 mmol/L **sO2:** Co-oximetry; sO2 = 100 x O2Hb%/(O2Hb% + HHb%)	See Venous Blood Gas (Full Panel)	See Venous Blood Gas (Full Panel)	See Venous Blood Gas (Full Panel)
Venous Blood Gas, Umbilical Cord	GASCV	**PH** 7.30-7.40 **PCO2** 33-44 mm Hg **PO2** 23-35 mm Hg **HCO3** 16-25 mmol/L **OSAT** 16-83 % **BASE** -2.0-2.0 mmol/L		**pO2:** Amperometry **pH, pCO2:** Potentiometry **Base:** Calculation of the expression that approximates the amount of acid or base required to titrate one liter of blood back to a normal pH of 7.40 **HCO3:** Calculation **sO2:** Cooximetry	pCO2, pH, pO2, HCO3: Clinical Guide to Laboratory Tests, Tietz 3rd Edition, 1995. Base: Email_Cord blood Gas RR Physician Established Base Excess_11-2020. sO2: Brit Journ Obst Gyn 8-2000 Vol 107 pp 987-994 Cord Bld O2 SAT in vigorous infants at birth: What is normal?	PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % BASE: -30.0-30.0 mmol/L	PH: 6.80-8.00 PCO2: 5-100 mm Hg PO2: 0-700 mm Hg HCO3: 0-100 mmol/L OSAT: 5-100 % BASE: -30.0-30.0 mmol/L
1 Hour Post Glucola	GLUG	70-134 mg/dL		Photometric rate with hexokinase	ADA Standards October 2012, Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999	10-800 mg/dL	10-2,400 mg/dL
Acetaminophen Level	ACTM	≤150.0 mcg/mL		Enzyme immunoassay	Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd Edition 2002 Applied Therapeutics, Inc. and Micromedex On OSU Intranet.	10.0-200.0 mcg/mL	10.0-600.0 mcg/mL
Albumin-Adjusted Calcium	AAC	**ALB** 0-30 days: 2.7-4.3 g/dL 31-182 days: 2.9-4.2 g/dL 183-365 days: 3.3-4.8 g/dL 1-19 years: 2.9-4.2 g/dL 19+ years: 3.5-5.0 g/dL **CA** 0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL	**ALB** 0-30 days: 2.6-4.1 g/dL 31-182 days: 2.8-4.6 g/dL 183-365 days: 2.8-4.8 g/dL 1-19 years: 3.2-4.7 g/dL 19+ years: 3.5-5.0 g/dL **CA** 0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL		**ALB** Colorimetric; Bromocresol green **CA** Photometric; arsenazo **AAC** Total calcium mg/dL + 0.8*(4-albumin g/dL)	See individual analytes	See individual analytes	See individual analytes
Albumin	ALB	0-30 days: 2.7-4.3 g/dL 31-182 days: 2.9-4.2 g/dL 183-365 days: 3.3-4.8 g/dL 1-19 years: 2.9-4.2 g/dL 19+ years: 3.5-5.0 g/dL	0-30 days: 2.6-4.1 g/dL 31-182 days: 2.8-4.6 g/dL 183-365 days: 2.8-4.8 g/dL 1-19 years: 3.2-4.7 g/dL 19+ years: 3.5-5.0 g/dL		Colorimetric; Bromocresol green	Tietz 2nd Edition referenced by Beckman Coulter IFU for recumbent adult and verified by OSUWMC Reference Interval Study 2021.	1.5-6.0 g/dL	1.5-18.0 g/dL
Albumin, CSF	CFMALB	10.0-30.0 mg/dL			Turbidimetry	CCLM Vol 54 issue 2 p285-292 Feb 2016.	1.0-45.0 mg/dL	1.0-450.0 mg/dL
Albumin, Fluid	FALB			**Pleural:** Serum- pleural fluid albumin gradients of >1.2 g/dL are consistent with transudates. **Peritoneal:** Serum-ascites albumin gradient (SAAG) of 1.1 g/dL or greater suggests portal hypertension. **Pericardial:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Colorimetric; Bromocresol green	Pleural: Roth, B.J., et.al. Chest, Vol 98, 546-549, 1990. Peritoneal: Runyon, B.A. Ann Intern Med. 1992;117:215-220.	0.5-6.0 g/dL	0.5-6.0 g/dL
Alcohol (Ethanol), Blood	ETOH	<10 mg/dL		10-50 mg/dL - effects of alcohol may or may not be apparent 30-120 mg/dL - mild euphoria and/or impairment 180-300 mg/dL - disorientation, confusion, dizziness 350-500 mg/dL - unconsciousness, coma, circulation and respiration impairment, possible death > 450 mg/dL- possible death due to respiration impairment Concentrations of blood alcohol causing impairment and/or intoxication may vary by person.	Enzymatic using alcohol dehydrogenase		10-600 mg/dL	10-600 mg/dL
Alk Phosphatase	ALP	0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L 16-18 years: 47-119 U/L 19+ years: 32-126 U/L	0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L 16-18 years: 52-171 U/L 19+ years: 32-126 U/L		Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4.	OSUWMC Reference Range Study effective 12.11.2013; Verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999 :Synchron Performance Verification Manual A22219	5-1,500 U/L	5-15,000 U/L

ALP ALT AST	ENZ3	**ALP** 0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L 16-18 years: 47-119 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L **AST** 0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L 16-18 years: 0-31 U/L 19+ years: 10-39 U/L	**ALP** 0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L 16-18 years: 52-171 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31-365 days: 8-35 U/L 1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L **AST** 0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L 16-18 years: 0-40 U/L 19+ years: 10-39 U/L		**ALP** Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4. **ALT** Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **AST** Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate.	See individual analytes	See individual analytes	See individual analytes
ALP ALT AST LD	ENZ4	**ALP** 0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L 16-18 years: 47-119 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L **AST** 0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L 16-18 years: 0-31 U/L 19+ years: 10-39 U/L **LD** 0-30 days: 145-765 U/L 31-365 days: 190-420 U/L 1-3 years: 165-395 U/L 4-6 years: 135-345 U/L 7-9 years: 140-280 U/L 10-12 years: 120-260 U/L 13-15 years: 100-275 U/L 16-18 years: 105-230 U/L 19+ years: 100-190 U/L	**ALP** 0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L 16-18 years: 52-171 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31-365 days: 8-35 U/L 1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L **AST** 0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L 16-18 years: 0-40 U/L 19+ years: 10-39 U/L **LD** 0-30 days: 125-735 U/L 31-365 days: 170-450 U/L 1-3 years: 155-345 U/L 4-6 years: 155-345 U/L 7-9 years: 145-300 U/L 10-12 years: 120-325 U/L 13-15 years: 120-290 U/L 16-18 years: 105-235 U/L 19+ years: 100-190 U/L		**ALP** Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4. **ALT** Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **AST** Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **LD** Photometric rate	See individual analytes	See individual analytes	See individual analytes
		ALP 0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L 16-18 years: 47-119 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L **AST** 0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L	**ALP** 0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L 16-18 years: 52-171 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31-365 days: 8-35 U/L 1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L **AST** 0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L		**ALP** Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4. **ALT** Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **AST** Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-			

ALP ALT AST LD GGT BILI	ENZ4GB	16-18 years: 0-31 U/L 19+ years: 10-39 U/L **LD** 0-30 days: 145-765 U/L 31-365 days: 190-420 U/L 1-3 years: 165-395 U/L 4-6 years: 135-345 U/L 7-9 years: 140-280 U/L 10-12 years: 120-260 U/L 13-15 years: 100-275 U/L 16-18 years: 105-230 U/L 19+ years: 100-190 U/L **GGT** 0-182 days: 15-132 U/L 183-365 days: 8-39 U/L 1-12 years: 8-22 U/L 13-18 years: 8-24 U/L 19+ years: 8-64 U/L **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **DBIL** All: <0.3 mg/dL	16-18 years: 0-40 U/L 19+ years: 10-39 U/L **LD** 0-30 days: 125-735 U/L 31-365 days: 170-450 U/L 1-3 years: 155-345 U/L 4-6 years: 155-345 U/L 7-9 years: 145-300 U/L 10-12 years: 120-325 U/L 13-15 years: 120-290 U/L 16-18 years: 105-235 U/L 19+ years: 100-190 U/L **GGT** 0-182 days: 12-122 U/L 183-365 days: 8-39 U/L 1-12 years: 8-22 U/L 13-18 years: 8-42 U/L 19+ years: 8-64 U/L **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **DBIL** All: <0.3 mg/dL		phosphate. **LD** Photometric rate **GGT** Photometric rate **DBIL** Photometric with diazonium salt, 3,5-dichloroaniline (DPD). **TBIL** Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators.	See individual analytes	See individual analytes	See individual analytes
Alpha 1 Antitrypsin	A1AT	84-218 mg/dL			Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	30-500 mg/dL	30-5,000 mg/dL
ALT	ALT	0-30 days: 8-25 U/L 31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L	0-30 days: 8-25 U/L 31-365 days: 8-35 U/L 1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L		Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate.	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999 (Lower end of reference range modified to agree with the linear limits.)	3-500 U/L	3-25,000 U/L
Ammonia	NH3	6-47 µmol/L			Photometric	Package insert	10-600 µmol/L	10-3,000 µmol/L
Ammonia, Arterial	NH3A	6-47 µmol/L			Photometric	Package insert	10-600 µmol/L	10-3,000 µmol/L
AMY LIPA	AMY/LIPA	**AMY**			Photometric rate	See individual analytes	See individual analytes	See individual analytes
Amylase	AMY	0-30 days: 0-6 U/L 31-182 days: 1-17 U/L			Photometric rate	Prior study verified by OSUWMC Reference Interval Study 2021.	10-2,000 U/L	10-10,000 U/L
Amylase, Body Fluid	FAMY			**Pleural:** Pleural fluid rich in amylase (fluid amylase to serum/plasma amylase ratio > 1) is associated with acute and chronic pancreatitis, esophageal leakage, malignancy, cirrhosis, or pneumonia. **Pancreatic cyst:** Very low pancreatic cyst fluid amylase concentrations (< 250 U/L) exclude a pseudocyst in the majority of cases. **Peritoneal, Drainage, PFUN:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Photometric rate	Pleural: State of the art. The pleura Sahn SA Am Rev Respir Dis. 1988;138(1):184. Pancreatic cyst: Elta GH, et al. Am J Gasroenterol. 208;113:464-479.	10-2,000 U/L	10-10,000 U/L
Amylase, Urine Random	UAMYR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Photometric rate	Prior study verified by OSUWMC Reference Interval Study 2021.	10-1,500 U/L	10-75,000 U/L
Amylase, 24 Hour Urine	UAMY	0-400 U/24 hrs			Photometric rate	Prior study verified by OSUWMC Reference Interval Study 2021.		
Angiotensin Converting Enzyme	ACE	19-123 U/L			Furylacroloyl-Phenylalanyl-Glycylglycine	Calculated reference range based on correlation study with Mayo Clinic	14-145 U/L	14-1,450 U/L
Anti Streptolysin O	ASO	<250 IU/mL			Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	100-1,000 IU/mL	100-10,000 IU/mL
AST	AST	0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L 16-18 years: 0-31 U/L 19+ years: 10-39 U/L	0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L 16-18 years: 0-40 U/L 19+ years: 10-39 U/L		Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate.	Verified by OSUWMC Reference Interval Study 2021.	3-1,000 U/L	3-50,000 U/L
Basic Metabolic Panel		**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **GLUC** Photometric rate with hexokinase **BUN** Photometric rate **CREA** Kinetic Jaffe	See individual analytes	See individual analytes	See individual analytes

	BMP	**BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **CA** 0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **OSMO CALC** 278-305 mOsm/kg **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2	**BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **CA** 0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **OSMO CALC** 278-305 mOsm/kg **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2		**CA** Photometric, arsenazo **ANION GAP** (Na + K) – (Cl + CO2) **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex **OSMO CALC** (1.86 (Na +K) + 1.15 (Glucose/18) + (Urea/2.8) + 14 where Na and K are in mmol/L; Glucose and Urea are in mg/dL	See individual analytes	See individual analytes	See individual analytes
Beta hCG, Qual, Blood	SPREG			Negative	Lateral-flow test using a monoclonal antibody specific to the beta subunit of hCG.	Package insert		Negative, Positive
Beta hCG, Quant, Blood	QHCGB			Non-pregnant: <10 mIU/mL Postmenopause:<10 mIU/mL Male: <10 mIU/mL FEMALE GESTATIONAL AGE 2-4 Weeks: 39.1-8,388 mIU/mL 5-6 Weeks: 861-88,769 mIU/mL 6-8 Weeks: 8,636-218,085 mIU/mL 8-10 Weeks: 18,700-244,467 mIU/mL 10-12 Weeks: 23,143-181,899 mIU/mL 13-27 Weeks: 6,303-97,171 mIU/mL 24-40 Weeks: 4,360-74,883 mIU/mL Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.	Two-site sandwich immunoassay chemiluminescent.	Advia Centaur tHCG Package Insert 10634917_EN Rev. F, 2011-04	2.6-1,000.0 mIU/mL	2.6-128,000,000.0 mIU/mL
Beta-Hydroxybutyrate, Serum	BHBB	<0.27 mmol/L			Photometric	Stanbio Package Insert and verified by OSUWMC Reference Interval Study 2021.	0.10-8.00 mmol/L	0.10-24.00 mmol/L
Bicarbonate, Fluid	FCO2			**Stool:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation. **PFUN:** Measurement of secretin stimulated electrolytes and enzymes in pancreatic fluid may correlate with the degree of pancreas function. Peak bicarbonate values > 75 mmol/L for screening (time 15 minutes) and >80 mmol/L for confirmatory (time 60 minutes) tests suggest normal pancreas function.	Photometric		5-45 mmol/L	5-90 mmol/L
Bilirubin - Baby	BILB	**DBIL** <0.3 mg/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL			**DBIL** Photometric with diazonium salt, 3,5-dichloroaniline (DPD). **TBIL** Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators.	See individual analytes	See individual analytes	See individual analytes
Bilirubin Direct	DBIL	<0.3 mg/dL			Photometric with diazonium salt, 3,5-dichloroaniline (DPD).	Clinical Guide to Laboratory Tests, Tietz 1995, verified by OSUWMC Reference Interval Study 2021.	>10.0 mg/dL	0.1-20.0 mg/dL
Bilirubin Total	TBIL	0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL			Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators.	Clinical Guide to Laboratory Tests, Tietz 1995, verified by OSUWMC Reference Interval Study 2021.	0.1-30.0 mg/dL	0.1-90.0 mg/dL
Bilirubin, Total and Direct	TDBIL	**DBIL** <0.3 mg/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL			**DBIL** Photometric with diazonium salt, 3,5-dichloroaniline (DPD). **TBIL** Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators.	See individual analytes	See individual analytes	See individual analytes
Bilirubin, Total, Fluid	FBILT			**Peritoneal:** Peritoneal bilirubin concentrations greater than that of serum/plasma may suggest bile within the abdomen. **Drainage:** Drain fluid bilirubin concentration-to-serum/plasma bilirubin concentration ratios exceeding 5 indicates bile leakage.	Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators.	Peritoneal: Runyon BA J Clin Gastroenterol. 1987;9(5):543. Drain: Darwin. Gastrointestinal Endosc. 2010 Jan;71(1):99-104.	0.1-30.0 mg/dL	0.1-90.0 mg/dL

BMP without Glucose	BMPNG	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **CA** 0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **CA** 0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **BUN** Photometric rate **CREA** Kinetic Jaffe **CA** Photometric, arsenazo **ANION GAP** (Na + K) – (Cl + CO2) **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex	See individual analytes	See individual analytes	See individual analytes
B-Type Natriuretic Peptide (Brain)	BNP	0-100 pg/mL			Two site sandwich immunoassay using direct chemiluminescent technology which uses constant amounts of two monoclonal antibodies.	Atellica IM BNP Package Insert 11202199_EN Rev. 05-2020-11	2-4,500 pg/mL	2-4,500 pg/mL
BUN	BUN	7-25 mg/dL			Photometric rate	Beckman Coulter IFU for serum verified by OSUWMC Reference Interval Study 2021.	2-130 mg/dL	2-650 mg/dL
BUN CREA	BCR	**BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL	**BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL		**BUN** Photometric rate **CREA** Kinetic Jaffe	See individual analytes	See individual analytes	See individual analytes
C Reactive Protein	CRP	<10.00 mg/L			Measurement of the rate of decrease in light intensity transmitted (increase in absorbance) through particles suspended in solution is the result of complexes formed during the immunological reaction between the CRP of the patient serum and rabbit anti-CRP-antibodies coated on latex particles.	Clinical Guide to Laboratory Tests, Tietz, 2005; Verified by OSUWMC Reference Interval Study 2021.	0.20-80.00 mg/L	0.20-480.00 mg/L
C Reactive Protein for Cardiac Risk	CRP	<2.00 mg/dL			Measurement of the rate of decrease in light intensity transmitted (increase in absorbance) through particles suspended in solution is the result of complexes formed during the immunological reaction between the CRP of the patient serum and rabbit anti-CRP-antibodies coated on latex particles.	Clinical Guide to Laboratory Tests, Tietz, 2005; Verified by OSUWMC Reference Interval Study 2021.	0.20-80.00 mg/L	0.20-480.00 mg/L
C3 Complement	C3	87-200 mg/dL			Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	15-500 mg/dL	15-1,500 mg/dL
C3, C4	COMP	**C3** 87-200 mg/dL **C4** 8-52 mg/dL			Turbidimetry	See individual analytes	See individual analytes	See individual analytes
C4 Complement	C4	8-52 mg/dL			Turbidimetry	Historic Reference Range. Verified by OSUWMC Reference Interval Study 2021.	8-150 mg/dL	8-450 mg/dL
CA 125	CA125	≤30 U/mL			Two-site sandwich immunoassay using direct chemiluminometric technology.	Advia Centaur CA 125II Package Insert 128516 Rev. H, 2009-02	3-600 U/mL	3-360,000 U/mL
CA 15-3N	CA153	0.0-32.4 U/mL	0.0-32.4 U/mL (use not defined)		Two-site sandwich immunoassay chemiluminescent.	Atellica IM CA 15-3 Package Insert 11206285_EN Rev. 04, 2020-03	3.0-200.0 U/mL	3.0-200,000.0 U/mL
CA 19-9	CA199	≤37.00 U/mL			Two-site sandwich immunoassay using direct chemiluminometric technology.	Clinical Guide to Laboratory Tests, Tietz, 1995; see Source link for additional Reference Range information	15.00-700.00 U/mL	15.00-33,600,000.00 U/mL
Calcium	CA	0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL	0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL		Photometric; arsenazo	Established by OSUWMC Reference Interval Study 2013, verified by OSUWMC Reference Interval study 2021.	4.0-18.0 mg/dL	4.0-18.0 mg/dL
Calcium, Urine 24HR	UCA	100.0-300.0 mg/24 hrs			Photometric; arsenazo			
Calcium/Creat Ratio, Random Urine	CALCR	0-209 days: <0.86 Ca mg/Crea mg 210-569 days: <0.60 Ca mg/Crea mg 570 days-2 years: <0.42 Ca mg/Crea mg 3+ years: <0.22 Ca mg/Crea mg			**CALCIUM** Photometric; arsenazo **CREA** Kinetic Jaffe	See individual analytes	See individual analytes	See individual analytes
Carbamazepine Total Level	CARB	Therapeutic Range: 4.0-12.0 mcg/mL			Competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change.	Applied Clinical Pharmacokinetics, 2001 Micromedex, OSU Intranet	2.0-20.0 mcg/mL	2.0-100.0 mcg/mL
CEA	CEA	≤5.0 ng/mL			Two-site Sandwich Immunoassay Chemiluminescent	Clinical Guide to Laboratory Tests, Tietz, 1995. See source link for additional Reference Range information.	2.0-100.0 ng/mL	2.0-8,000,000.0 ng/mL
Ceruloplasmin	CERP	20-60 mg/dL			Turbidimetry	Verified by OSUWMC Reference Interval Study 2021.	6-200 mg/dL	6-4,000 mg/dL

Chem 6 (Lytes, BUN, CREA)	CHM6	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **BUN** Photometric rate **CREA** Kinetic Jaffe **ANION GAP** (Na + K) – (Cl + CO2) **BUN/CREA RATIO** BUN/Creatinine **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex	See individual analytes	See individual analytes	See individual analytes
Chem 7 (LYTES, BUN, CREA, GLUC)	CHM7	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **ANION GAP** 7-17 mmol/L **OSMO (CALC)** 278-305 mOsm/kg **eGFR** ≥60 mL/min/1.73m2	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **ANION GAP** 7-17 mmol/L **OSMO (CALC)** 278-305 mOsm/kg **eGFR** ≥60 mL/min/1.73m2		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **BUN** Photometric rate **CREA** Kinetic Jaffe **GLUC** Photometric rate with hexokinase **BUN/CREA RATIO** BUN/Creatinine **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex	See individual analytes	See individual analytes	See individual analytes
Chloride	CL	0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L			Indirect ion-selective electrode	Established by OSUWMC Reference Interval Study 2013, verified by OSUWMC Reference Interval study 2021.	50-200 mmol/L	50-200 mmol/L
Chloride, 24 HR Urine	UCL	110-250 mmol/24 hrs			Indirect ion-selective electrode	Clinical Guide to Laboratory Tests, Tietz, 1995		
Chloride, Random Urine	UCLR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Indirect ion-selective electrode		15-400 mmol/L	15-400 mmol/L
Cholesterol, Body Fluid	FCHOL			**Pleural:** Pleural fluid cholesterol concentrations > 200 mg/dL are associated with pseudochylous effusions. **Peritoneal:** Peritoneal fluid cholesterol concentrations greater than 32-70 mg/dL may suggest malignant ascites.	Enzymatic colorimetric	Pleural: Hooper C, et al. Thorax. 2010 Aug;65:Suppl2:ii4-17. McGrath, et al. Int J Clin Pract. 2009 Nov;63(11):1653-9. Peritoneal: Block, et al. Crit Rev Clin Lab Sci. 2013;50:107-124.	25-700 mg/dL	25-700 mg/dL
Cholesterol Total	CHOL	0-30 days: 62-155 mg/dL 31-182 days: 62-141 mg/dL 183-365 days: 76-216 mg/dL 1-3 years: 108-193 mg/dL 4-6 years: 106-193 mg/dL 7-9 years: 104-210 mg/dL 10-12 years: 105-218 mg/dL 13-15 years: 108-205 mg/dL 16-18 years: 92-234 mg/dL 19+ years: <200 mg/dL	0-30 days: 54-151 mg/dL 31-182 days: 81-147mg/dL 183-365 days: 76-179 mg/dL 1-3 years: 85-182 mg/dL 4-6 years: 110-217 mg/dL 7-9 years: 110-211 mg/dL 10-12 years: 105-223 mg/dL 13-15 years: 91-204 mg/dL 16-18 years: 82-192 mg/dL 19+ years: <200 mg/dL		Enzymatic colorimetric	National Cholesterol Education Project (NCEP) Adult Treatment Protocol (ATP- III) (Circulation, 2002;106:3143-3421)	25-700 mg/dL	25-2,100 mg/dL

Cholesterol/Triglyceride	CHTRG	**CHOL** 0-30 days: 62-155 mg/dL 31-182 days: 62-141 mg/dL 183-365 days: 76-216 mg/dL 1-3 years: 108-193 mg/dL 4-6 years: 106-193 mg/dL 7-9 years: 104-210 mg/dL 10-12 years: 105-218 mg/dL 13-15 years: 108-205 mg/dL 16-18 years: 92-234 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 39-140 mg/dL 12-13 years: 37-130 mg/dL 14-15 years: 38-135 mg/dL 16-19 years: 37-140 mg/dL 20+ years: <150 mg/dL	**CHOL** 0-30 days: 54-151 mg/dL 31-182 days: 81-147mg/dL 183-365 days: 76-179 mg/dL 1-3 years: 85-182 mg/dL 4-6 years: 110-217 mg/dL 7-9 years: 110-211 mg/dL 10-12 years: 105-223 mg/dL 13-15 years: 91-204 mg/dL 16-18 years: 82-192 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 24-137 mg/dL 12-13 years: 24-145 mg/dL 14-15 years: 34-165 mg/dL 16-19 years: 34-140 mg/dL 20+ years: <150 mg/dL		Enzymatic colorimetric	See individual analytes	See individual analytes	See individual analytes
CK	CK	0-30 days: 2-134 U/L 31-182 days: 2-146 U/L 183-365 days: 18-138 U/L 1-3 years: 2-134 U/L 4-6 years: 8-147 U/L 7-9 years: 26-145 U/L 10-12 years: 6-137 U/L 13-15 years: 2-143 U/L 16-18 years: 13-144 U/L 19+ years: 30-184 U/L	0-30 days: 2-183 U/L 31-182 days: 2-129 U/L 183-365 days: 2-143 U/L 1-3 years: 2-163 U/L 4-6 years: 18-158 U/L 7-9 years: 2-177 U/L 10-12 years: 6-217 U/L 13-15 years: 2-251 U/L 16-18 years: 2-238 U/L 19+ years: 30-220 U/L		Photometric rate	Established by OSUWMC Reference Interval Study 2013, verified by OSUWMC Reference Interval study 2021.	10-2,000 U/L	10-200,000 U/L
Clozapine Level	CLOZ	350-1,000 ng/mL			Turbidimetric immunoassay.	Estabilished by OSUWMC Reference Interval Study 2023.		68-1,500 ng/mL
CMPN without Glucose		**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **CA** 0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2 **ALB** 0-30 days: 2.7-4.3 g/dL 31-182 days: 2.9-4.2 g/dL 183-365 days: 3.3-4.8 g/dL 1-19 years: 2.9-4.2 g/dL 19+ years: 3.5-5.0 g/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **ALP** 0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L 16-18 years: 47-119 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **CA** 0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **ANION GAP** 7-17 mmol/L **eGFR** 0-4 days: 1.000-39.000 uIU/mL **ALB** 0-30 days: 2.6-4.1 g/dL 31-182 days: 2.8-4.6 g/dL 183-365 days: 2.8-4.8 g/dL 1-19 years: 3.2-4.7 g/dL 19+ years: 3.5-5.0 g/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **ALP** 0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L 16-18 years: 52-171 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31-365 days: 8-35 U/L		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **BUN** Photometric rate **CREA** Kinetic Jaffe **CA** Photometric, arsenazo **ANION GAP** (Na + K) – (Cl + CO2) **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex **TBIL** Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators. **ALP** Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4. **ALT** Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **AST** Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **TP** Colorimetric with cupric ions in an alkaline solution.	See individual analytes	See individual analytes	See individual analytes

		31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L **AST** 0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L 16-18 years: 0-31 U/L 19+ years: 10-39 U/L **TP** 0-30 days: 4.2-6.2 g/dL 31-182 days: 4.4-6.6 g/dL 183-365 days: 5.6-7.9 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL	1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L **AST** 0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L 16-18 years: 0-40 U/L 19+ years: 10-39 U/L **TP** 0-30 days: 4.1-6.3 g/dL 31-182 days: 4.7-6.7 g/dL 183-365 days: 5.5-7.0 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL				
CO2 Total	CMPNG CO2	0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L			Photometric	Beckman Coulter IFU verified by OSUWMC Reference Interval Study 2021.	5-45 mmol/L	5-45 mmol/L
Comprehensive Metabolic Panel		**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **CA** 0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **OSMO** 278-305 mOsm/kg **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2 **ALB** 0-30 days: 2.7-4.3 g/dL 31-182 days: 2.9-4.2 g/dL 183-365 days: 3.3-4.8 g/dL 1-19 years: 2.9-4.2 g/dL 19+ years: 3.5-5.0 g/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **ALP** 0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L 16-18 years: 47-119 U/L 19+ years: 32-126 U/L	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **CA** 0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **OSMO** 278-305 mOsm/kg **ANION GAP** 7-17 mmol/L **eGFR** 0-4 days: 1.000-39.000 uIU/mL **ALB** 0-30 days: 2.6-4.1 g/dL 31-182 days: 2.8-4.6 g/dL 183-365 days: 2.8-4.8 g/dL 1-19 years: 3.2-4.7 g/dL 19+ years: 3.5-5.0 g/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **ALP** 0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L 16-18 years: 52-171 U/L 19+ years: 32-126 U/L		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **GLUC** Photometric rate with hexokinase **BUN** Photometric rate **CREA** Kinetic Jaffe **CA** Photometric, arsenazo **ANION GAP** (Na + K) – (Cl + CO2) **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex **OSMO CALC** (1.86 (Na +K) + 1.15 (Glucose/18) + (Urea/2.8) + 14 where Na and K are in mmol/L; Glucose and Urea are in mg/dL. **TBIL** Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators. **ALP** Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4. **ALT** Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **AST** Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **TP** Colorimetric with cupric ions in an alkaline solution.	See individual analytes	See individual analytes	See individual analytes

	CMP	**ALT** 0-30 days: 8-25 U/L 31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L **AST** 0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L 16-18 years: 0-31 U/L 19+ years: 10-39 U/L **TP** 0-30 days: 4.2-6.2 g/dL 31-182 days: 4.4-6.6 g/dL 183-365 days: 5.6-7.9 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL	**ALT** 0-30 days: 8-25 U/L 31-365 days: 8-35 U/L 1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L **AST** 0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L 16-18 years: 0-40 U/L 19+ years: 10-39 U/L **TP** 0-30 days: 4.1-6.3 g/dL 31-182 days: 4.7-6.7 g/dL 183-365 days: 5.5-7.0 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL					
Cortisol	CORT	3.09-22.40 mcg/dL			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Cortisol Package Insert 11200393_EN Rev. 03-2020-03	0.50-75.00 mcg/dL	0.50-2,400.00 mcg/dL
Cortisol (DST) Overnight	CORTDX	<1.80 mcg/dL			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Cortisol Package Insert 11200393_EN Rev. 03-2020-04	0.50-75.00 mcg/dL	0.50-2,400.00 mcg/dL
Cortisol, Baseline	CORTB	3.09-22.40 mcg/dL			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Cortisol Package Insert 11200393_EN Rev. 03-2020-05	0.50-75.00 mcg/dL	0.50-2,400.00 mcg/dL
Cortisol, 30 Minute	CORT30	≥18.00 mcg/dL			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Cortisol Package Insert 11200393_EN Rev. 03-2020-06	0.50-75.00 mcg/dL	0.50-2,400.00 mcg/dL
Cortisol, 60 Minute	CORT60	≥18.00 mcg/dL			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Cortisol Package Insert 11200393_EN Rev. 03-2020-07	0.50-75.00 mcg/dL	0.50-2,400.00 mcg/dL
Creatinine Body Fluid	FLCREA			**Peritoneal and drainage:** Fluid creatinine concentrations that are greater than serum/plasma creatinine concentrations may imply intraperitoneal leakage of urine outside of the urinary tract. **Pleural:** Pleural fluid creatinine to serum/plasma creatinine concentration ratio > 1 suggests urinothorax.	Kinetic Jaffe	Manahan KJ, et al. Obstet Gynecol. 1999 May;93(5 Pt 1):780-2 Pleural: Toubes, et al. J Thorac Dis. 2017;9(5):1209:1218.	0.20-25.00 mg/dL	0.20-25.00 mg/dL
Creatinine Serum	CREA	**CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **eGFR** ≥60 mL/min/1.73m2	**CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.50 mg/dL **eGFR** ≥60 mL/min/1.73m2		Kinetic Jaffe	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999.	CREA: 0.20-25.00 mg/dL eGFR: ≤90 mL/min/1.73m2	CREA: 0.20-25.00 mg/dL eGFR: ≤90 mL/min/1.73m2
Creatinine, 8 HR Urine	8UCR				Kinetic Jaffe		1.00-300.00 mg/dL	1.00-900.00 mg/dL
Creatinine, 24 HR Urine	UCRE	0-2 years: 0.70-2.00 g/24 hrs 3-8 years: 0.11-0.68 g/24 hrs 9-12 years: 0.17-1.41 g/24 hrs 13-17 years: 0.29-1.87 g/24 hrs 18+ years: 0.60-1.80 g/24 hrs	0-2 years: 0.70-2.00 g/24 hrs 3-8 years: 0.11-0.68 g/24 hrs 9-12 years: 0.17-1.41 g/24 hrs 13-17 years: 0.29-1.87 g/24 hrs 18+ years: 0.80-2.00 g/24 hrs		Kinetic Jaffe	NKDEP traceable :Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999		
Creatinine, Random Urine	UCRER			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Kinetic Jaffe		1.00-300.00 mg/dL	1.00-900.00 mg/dL
Cystatin C and Creatinine with estimated GFR	CYSC	**CYSC** 0.51-1.05 mg/L **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **eGFR** ≥60 mL/min/1.73m2	**CYSC** 0.51-1.05 mg/L **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.50 mg/dL **eGFR** ≥60 mL/min/1.73m2		**CYSC** Turbidometric **CREA** Kinetic Jaffe CKD-EPI 2021 Calculation. eGFRcr-cys = 135 x min(Scr/κ, 1)α x max(Scr/κ, 1)-0.544 x min(Scys/0.8, 1)-0.323 x max(Scys/0.8, 1)-0.778 x 0.9961Age x 0.963 [if female] where κ = 0.7 (females) or 0.9 (males) a = -0.219 (female) or -0.144 (male) Scr = serum creatinine in mg/dL Scys = serum cystatin C in mg/L Age (years) The "min (Scr/κ, 1)" factor indicates the minimum of Scr/κ or 1.0, "max(Scr/κ, 1)" indicates the maximum of Scr/κ or 1.0, "min(Scys/0.8, 1)" indicates the minimum of Scys/0.8 or 1.0, and "max(Scys/0.8, 1)" indicates the maximum of Scys/0.8 or 1.0.		CREA: 0.20-25.00 mg/dL CYSC: 0.40-8.00 mg/L	CREA: 0.20-25.00 mg/dL CYSC: 0.40-32.00 mg/L
Digoxin Level	DIG	Therapeutic Range: 0.5-1.0 ng/mL			Enzyme Immunoassay	Applied Clinical Pharmacokinetics, Bauer, 2001	0.3-5.0 ng/mL	0.3-10.0 ng/mL
Estradiol, Enhanced	EE2B			**Male:** 19+ years: <11.8-39.8 **Menstruating Females:** Follicular phase: 19.5-144.2 Midcycle peak: 63.9-356.7 Luteal phase: 55.8-214.2 **Post-menopausal:** <11.8-32.2 This test is not recommended for patients receiving Fulvestrant (Faslodex) due to possible false elevations. EE2 levels vary widely throughout the menstrual cycle.	Competitive assay format. The endogenous estradiol contained in a sample is released from its binding proteins by a releasing agent. Then, a sheep monoclonal anti-estradiol antibody labeled with acridinium ester is added to bind available estradiol. Finally, an estradiol derivative capture solid phase is added to the reaction to compete with estradiol for the binding of the acridinium-labeled antibody. After washing, acid and base are dispensed to initiate the chemiluminescent reaction.	Advia Centaur, Enhanced Estradiol (eE2) Package Insert 10491467 Rev. C, 2010-09; Pediatric Reference Ranges, Soldin, 1999	11.8-3,000.0 pg/mL	11.8-150,000.0 pg/mL
EUS Pancreatic Lab (Fluid CEA, AMY)	FCEAR			**CEA:** Fluid CEA values >192 ng/mL may indicate mucinous cystic lesions of the pancreas. Results <192 ng/mL require clinical correlations with patient history and other imaging modalities. This chemiluminescent test was developed and its performance characteristics determined by the Critical Care Laboratory at The Ohio State University Wexner Medical Center. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. **AMY:** Very low pancreatic cyst fluid amylase concentrations (< 250 U/L) exclude a pseudocyst in the majority of cases.	**AMY** Photometric rate **CEA** Two-site Sandwich Immunoassay Chemiluminescent	See individual analytes	See individual analytes	See individual analytes
Ferritin	FERR	0-365 days: 5.7-421.0 ng/mL 1-12 years: 12.8-88.7 ng/mL 13-18 years: 6.8-75.6 ng/mL 19+ years: 7.3-270.7 ng/mL	0-365 days: 5.7-421.0 ng/mL 1-12 years: 12.8-88.7 ng/mL 13-18 years: 10.9-135.0 ng/mL 19+ years: 10.5-307.3 ng/mL		Two-site Sandwich Immunoassay Chemiluminescent.	Siemens Atellica IM Reference Interval Verification Study 2023 Siemens Atellica IM Reference Interval Verification Study Summary (Amendment)	0.9-1,650.0 ng/mL	0.9-1,650,000.0 ng/mL

Folate, Serum	FOLSB	0-1 years: 6.30-22.70 ng/mL 2-3 years: 1.70-15.70 ng/mL 4-6 years: 2.70-14.10 ng/mL 7-9 years: 2.40-13.40 ng/mL 10-12 years: 1.00-10.20 ng/mL 13-18 years: 1.20-7.20 ng/mL 19+ years: >5.38 ng/mL	0-1 years: 7.20-22.40 ng/mL 2-3 years: 2.50-15.00 ng/mL 4-6 years: 0.50-13.00 ng/mL 7-9 years: 2.30-11.90 ng/mL 10-12 years: 1.50-10.80 ng/mL 13-18 years: 1.20-8.80 ng/mL 19+ years: >5.38 ng/mL		Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Folate Package Insert 11200602_EN Rev. 04-2020-11; Pediatric Reference Ranges, Soldin, 1999	0.56-24.00 ng/mL	0.56-960.00 ng/mL
FSH	FSH	0-365 days: 1.9-22.9 mIU/mL 1-8 years: 1.1-9.5 mIU/mL 9-11 years: 1.2-9.2 mIU/mL 12-18 years: 1.9-11.2 mIU/mL	0-365 days: 0.8-5.2 mIU/mL 1-8 years: 0.8-2.5 mIU/mL 9-11 years: 1.0-4.2 mIU/mL 12-18 years: 2.3-10.2 mIU/mL	19+ Male: <18.1 mIU/mL 19+ years Female: Follicular: 2.5-10.2 mIU/mL Midcycle: 3.4-33.4 mIU/mL Luteal: 1.5-9.1 mIU/mL Pregnant: <0.3 mIU/mL Post Menopausal: 23.0-116.3 mIU/mL	Two-site sandwich immunoassay using direct chemiluminometric technology.	Atellica IM FSH Package Insert 11200384_EN Rev. 06-2020-09	0.3-200.0 mIU/mL	0.3-6,400.0 mIU/mL
GGT	GGT	0-182 days: 15-132 U/L 183-365 days: 8-39 U/L 1-12 years: 8-22 U/L 13-18 years: 8-24 U/L 19+ years: 8-64 U/L	0-182 days: 12-122 U/L 183-365 days: 8-39 U/L 1-12 years: 8-22 U/L 13-18 years: 8-42 U/L 19+ years: 8-64 U/L		Photometric rate	Beckman Coulter IFU verified by OSUWMC Reference Interval Study 2021 (lower end modified). Pediatric Reference Ranges, Soldin, 1999 (Lower end of reference range modified to agree with the linear limits).	3-1,200 U/L	3-6,000 U/L
Gestational 3HR Glucose Tolerance Test	GTF GT1H GT2H GT3H	**GTF** 70-94 mg/dL **GT1H** 70-179 mg/dL **GT2H** 70-154 mg/dL **GT3H** 70-139 mg/dL		The upper limits of the reference intervals for each fasting, 1 hour, 2 hour, and 3 hour samples are based on the Carpenter-Coustan criteria. According to the ADA practice recommendations, the diagnosis of GDM is made when at least 2 of the four plasma glucose levels meet or exceed the Carpenter-Coustan criteria, although The American College of Obstetricians and Gynecologists notes that some clinicians choose to use just one elevated value.	Photometric rate with hexokinase		10-800 mg/dL	10-2,400 mg/dL
Glucose	GLUC	0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL		The reference interval provided is for plasma glucose measurements from samples collected after an 8 hour fast (no caloric intake).	Photometric rate with hexokinase	ADA Standards October 2012, Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999.	10-800 mg/dL	10-2,400 mg/dL
Glucose Body Fluid	FGLUC			**Amniotic:** Amniotic fluid glucose concentrations < 10 mg/dL are consistent with intra-amniotic inflammation in patients with prelabor rupture of membranes. **Peritoneal:** Peritoneal glucose concentrations >50 mg/dL (2.8 mmol/L) are consistent with spontaneous bacterial peritonitis and concentrations below this are consistent with secondary bacterial peritonitis due to gut perforation. **Pericardial:** Pericardial fluid glucose to serum/plasma glucose ratios are 1.0 in presumed 'normal' patients. **Pancreatic Body Cyst:** Pancreatic Cyst Glucose measurements of ≤ 50 mg/dL are suggestive of a mucinous lesion. **Pleural:** Pleural fluid glucose concentrations are equivalent to serum/plasma glucose concentrations in the absence of pleural pathology. Pleural fluid glucose concentrations < 60 mg/dL may indicate parapneumonic or malignant effusion. Other less common effusions associated with low glucose concentrations include hemothorax, tuberculosis, rheumatoid pleuritis, Churg-Strauss syndrome, paragoniniasis, and lupus pleuritis. **Synovial:** Synovial fluid glucose concentrations lower than glucose in serum/plasma are associated with infection.	Photometric rate with hexokinase	Amniotic: Gonzalez-Bosquet, et al. J Matern Fetal Med. Jul-Aug 1999;8(4):155-8. Pancreatic cyst: Carr, et al. Surgery. 2018 Mar;163(3):600-605. Peritoneal: Runyon BA, Hoefs JC Hepatology. 1985;5(2):257. Pericardial: Ben-Horin S, et al. Am J Med 2005;118:636-40. Pleural: Toubes, et al. J Thorac Dis. 2017;9(5):1209:1218. Light, RW. N Engl J Med. 2002 Jun 20;346(25):1971-1977 Synovial: Margaretten, et al. JAMA. 2007;297(13):1478-1488.	10-800 mg/dL	10-800 mg/dL
Glucose CSF	GLUCSF	40-70 mg/dL			Photometric rate with hexokinase	Clinical Guide to Laboratory Tests, Tietz, 1995	10-800 mg/dL	10-800 mg/dL
Glucose Fasting	GLUF	0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL			Photometric rate with hexokinase	ADA Standards October 2012, Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999.	10-800 mg/dL	10-2,400 mg/dL
Haptoglobin	HAPTO	44-215 mg/dL			Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	30-400 mg/dL	30-1,200 mg/dL
hCG, Qualitative, Urine	UHCG			Negative	Lateral-flow test using a monoclonal antibody specific to the beta subunit of hCG.	Package insert		Negative, Positive
hCG, Quant (Tumor Marker)	HCGTM	<10.0 mIU/mL			Two-site sandwich immunoassay chemiluminescent.	Advia Centaur tHCG Package Insert 10634917_EN Rev. F, 2011-04.	2.6-1,000.0 mIU/mL	2.6-128,000,000.0 mIU/mL
HDL Cholesterol	HDL	0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL			Enzymatic colorimetric	National Cholesterol Education Project (NCEP) Adult Treatment Protocol (ATP- III) (Circulation, 2002;106:3143-3421)	3-200 mg/dL	3-200 mg/dL
		ALB 0-30 days: 2.7-4.3 g/dL 31-182 days: 2.9-4.2 g/dL 183-365 days: 3.3-4.8 g/dL 1-19 years: 2.9-4.2 g/dL 19+ years: 3.5-5.0 g/dL **DBIL** <0.3 mg/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **ALP** 0-30 days: 48-406 U/L 31-365 days: 124-341 U/L 1-3 years: 108-317 U/L 4-6 years: 96-297 U/L 7-9 years: 69-325 U/L 10-12 years: 51-332 U/L 13-15 years: 50-162 U/L	**ALB** 0-30 days: 2.6-4.1 g/dL 31-182 days: 2.8-4.6 g/dL 183-365 days: 2.8-4.8 g/dL 1-19 years: 3.2-4.7 g/dL 19+ years: 3.5-5.0 g/dL **DBIL** <0.3 mg/dL **TBIL** 0-1 day: 1.4-8.7 mg/dL 1-2 days: 3.4-11.5 mg/dL 3-4 days: 1.5-12.0 mg/dL 5-365 days: 0.3-1.2 mg/dL 1+ years: <1.5 mg/dL **ALP** 0-30 days: 75-316 U/L 31-365 days: 82-383 U/L 1-3 years: 104-345 U/L 4-6 years: 93-309 U/L 7-9 years: 86-315 U/L 10-12 years: 42-362 U/L 13-15 years: 74-390 U/L		**ALB** Colorimetric; Bromocresol green. **DBIL** Photometric with diazonium salt, 3,5-dichloroaniline (DPD). **TBIL** Photometric with 3,5-dichlorophenyldiazonium tetrafluoroborate (DPD), and caffeine and a surfactant as accelerators. **ALP**			

Hepatic Function Panel	HFP	16-18 years: 47-119 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31 days-4 years: 8-30 U/L 4-6 years: 8-25 U/L 7-9 years: 8-25 U/L 10-17 years: 8-20 U/L 18+ years: 9-48 U/L **AST** 0-30 days: 0-49 U/L 31-365 days: 0-80 U/L 1-3 years: 0-70 U/L 4-6 years: 0-60 U/L 7-9 years: 0-42 U/L 10-12 years: 0-38 U/L 13-15 years: 0-33 U/L 16-18 years: 0-31 U/L 19+ years: 10-39 U/L **TP** 0-30 days: 4.2-6.2 g/dL 31-182 days: 4.4-6.6 g/dL 183-365 days: 5.6-7.9 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL	16-18 years: 52-171 U/L 19+ years: 32-126 U/L **ALT** 0-30 days: 8-25 U/L 31-365 days: 8-35 U/L 1-3 years: 8-30 U/L 4-6 years: 8-20 U/L 7-9 years: 8-25 U/L 10-17 years: 8-30 U/L 18+ years: 10-52 U/L **AST** 0-30 days: 0-52 U/L 31-365 days: 0-66 U/L 1-3 years: 0-57 U/L 4-6 years: 0-49 U/L 7-9 years: 0-43 U/L 10-12 years: 0-39 U/L 13-15 years: 0-40 U/L 16-18 years: 0-40 U/L 19+ years: 10-39 U/L **TP** 0-30 days: 4.1-6.3 g/dL 31-182 days: 4.7-6.7 g/dL 183-365 days: 5.5-7.0 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL		Photometric rate with p-nitro-phenylphosphate (pNPP) in the presence of 2-amino-2-methyl-1-propanol (AMP) at pH 10.4. **ALT** Photometric rate with alanine to α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **AST** Photometric rate with aspartate and α-oxoglutarate to form pyruvate and glutamate. This assay does not contain pyridoxyl-5-phosphate. **TP** Colorimetric with cupric ions in an alkaline solution.	See individual analytes	See individual analytes	See individual analytes
High Sensitivity Troponin I - Single Order	HSTI-1X	<34 ng/L	<53 ng/L		Three-site sandwich immunoassay using direct chemiluminometric technology.	Atellica IM TnIH Package Insert 11200498_EN Rev. 06, 2019-06.	3-25,000 ng/L	3-2,000,000 ng/L
High Sensitivity Troponin I x2	HSTIInitial HSTI1Hr	<34 ng/L	<53 ng/L		Three-site sandwich immunoassay using direct chemiluminometric technology.	Atellica IM TnIH Package Insert 11200498_EN Rev. 06, 2019-06.	3-25,000 ng/L	3-2,000,000 ng/L
Homocysteine	HOMCYS	3.7-13.9 µmol/L			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Homocysteine Package Insert 10995362_EN Rev. 04-2021-03	0.5-65.0 µmol/L	0.5-130.0 µmol/L
IgA	IGA	0-30 days: 0-10 mg/dL 31-182 days: ≤42 mg/dL 183-365 days: 6-68 mg/dL 1-3 years: 15-111 mg/dL 4-6 years: 33-166 mg/dL 7-9 years: 28-180 mg/dL 10-12 years: 55-193 mg/dL 13-15 years: 62-241 mg/dL 16-18 years: 69-262 mg/dL 19-59 years: 66-433 mg/dL 60+ years: 90-410 mg/dL	0-30 days: ≤11 mg/dL 31-182 days: ≤40 mg/dL 183-365 days: 1-82 mg/dL 1-3 years: 9-137 mg/dL 4-6 years: 44-187 mg/dL 7-9 years: 58-204 mg/dL 10-12 years: 46-218 mg/dL 13-15 years: 29-251 mg/dL 16-18 years: 68-259 mg/dL 19-59 years: 66-433 mg/dL 60+ years: 90-410 mg/dL		Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	10-700 mg/dL	10-14,000 mg/dL
IgG	IGG	0-30 days: 162-872 mg/dL 31-182 days: 311-664 mg/dL 183-365 days: 325-647 mg/dL 1-3 years: 451-1,202 mg/dL 4-6 years: 560-1,319 mg/dL 7-9 years: 485-1,473 mg/dL 10-12 years: 586-1,609 mg/dL 13-15 years: 749-1,640 mg/dL 16-18 years: 804-1,817 mg/dL 19-59 years: 600-1,714 mg/dL 60+ years: 600-1,560 mg/dL	0-30 days: 197-833 mg/dL 31-182 days: 140-533 mg/dL 183-365 days: 130-823 mg/dL 1-3 years: 413-1,112 mg/dL 4-6 years: 468-1,328 mg/dL 7-9 years: 582-1,441 mg/dL 10-12 years: 685-1,620 mg/dL 13-15 years: 590-1,600 mg/dL 16-18 years: 522-1,703 mg/dL 19-59 years: 600-1,714 mg/dL 60+ years: 600-1,560 mg/dL		Turbidimetry	OSUWMC Immunoglobulin Reference Range Study; Verified by OSUWMC Reference Interval Study 2021.	75-3,000 mg/dL	75-60,000 mg/dL
IgM	IGMB	0-29 days: 1-57 mg/dL 30-182 days: <128 mg/dL 183-365 days: <131 mg/dL 1-3 years: 35-184 mg/dL 4-6 years: 42-184 mg/dL 7-9 years: 30-165 mg/dL 10-12 years: 42-211 mg/dL 13-15 years: 34-225 mg/dL 16-18 years: 45-224 mg/dL 19-59 years: 45-281 mg/dL 60+ years: 30-360 mg/dL	0-29 days: 0-65 mg/dL 30-182 days: 6-84 mg/dL 183-365 days: 15-117 mg/dL 1-3 years: 30-146 mg/dL 4-6 years: 31-151 mg/dL 7-9 years: 21-140 mg/dL 10-12 years: 27-151 mg/dL 13-15 years: 26-184 mg/dL 16-18 years: 28-179 mg/dL 19-59 years: 45-281 mg/dL 60+ years: 30-360 mg/dL		Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	20-500 mg/dL	20-50,000 mg/dL
Immunoglobulins IgG IgA IgM	QIMM	**IGA** 0-30 days: 0-10 mg/dL 31-182 days: ≤42 mg/dL 183-365 days: 6-68 mg/dL 1-3 years: 15-111 mg/dL 4-6 years: 33-166 mg/dL 7-9 years: 28-180 mg/dL 10-12 years: 55-193 mg/dL 13-15 years: 62-241 mg/dL 16-18 years: 69-262 mg/dL 19-59 years: 66-433 mg/dL 60+ years: 90-410 mg/dL **IGG** 0-30 days: 162-872 mg/dL 31-182 days: 311-664 mg/dL 183-365 days: 325-647 mg/dL 1-3 years: 451-1,202 mg/dL 4-6 years: 560-1,319 mg/dL 7-9 years: 485-1,473 mg/dL 10-12 years: 586-1,609 mg/dL 13-15 years: 749-1,640 mg/dL 16-18 years: 804-1,817 mg/dL 19-59 years: 600-1,714 mg/dL 60+ years: 600-1,560 mg/dL **IGM** 0-29 days: 1-57 mg/dL 30-182 days: <128 mg/dL 183-365 days: <131 mg/dL 1-3 years: 35-184 mg/dL 4-6 years: 42-184 mg/dL 7-9 years: 30-165 mg/dL 10-12 years: 42-211 mg/dL 13-15 years: 34-225 mg/dL 16-18 years: 45-224 mg/dL 19-59 years: 45-281 mg/dL 60+ years: 30-360 mg/dL	**IGA** 0-30 days: ≤11 mg/dL 31-182 days: ≤40 mg/dL 183-365 days: 1-82 mg/dL 1-3 years: 9-137 mg/dL 4-6 years: 44-187 mg/dL 7-9 years: 58-204 mg/dL 10-12 years: 46-218 mg/dL 13-15 years: 29-251 mg/dL 16-18 years: 68-259 mg/dL 19-59 years: 66-433 mg/dL 60+ years: 90-410 mg/dL **IGG** 0-30 days: 197-833 mg/dL 31-182 days: 140-533 mg/dL 183-365 days: 130-823 mg/dL 1-3 years: 413-1,112 mg/dL 4-6 years: 468-1,328 mg/dL 7-9 years: 582-1,441 mg/dL 10-12 years: 685-1,620 mg/dL 13-15 years: 590-1,600 mg/dL 16-18 years: 522-1,703 mg/dL 19-59 years: 600-1,714 mg/dL 60+ years: 600-1,560 mg/dL **IGM** 0-29 days: 0-65 mg/dL 30-182 days: 6-84 mg/dL 183-365 days: 15-117 mg/dL 1-3 years: 30-146 mg/dL 4-6 years: 31-151 mg/dL 7-9 years: 21-140 mg/dL 10-12 years: 27-151 mg/dL 13-15 years: 26-184 mg/dL 16-18 years: 28-179 mg/dL 19-59 years: 45-281 mg/dL 60+ years: 30-360 mg/dL		Turbidimetry	See individual analytes	See individual analytes	See individual analytes
Iron	IRON	0-30 days: 29-127 mcg/dL 31-365 days: 25-126 mcg/dL 1-3 years: 25-101 mcg/dL 4-6 years: 28-93 mcg/dL 7-9 years: 30-104 mcg/dL 10-12 years: 32-104 mcg/dL 13-15 years: 30-109 mcg/dL 16-18 years: 33-102 mcg/dL 19+ years: 40-174 mcg/dL	0-30 days: 32-112 mcg/dL 31-365 days: 27-109 mcg/dL 1-3 years: 29-91 mcg/dL 4-6 years: 25-115 mcg/dL 7-9 years: 27-96 mcg/dL 10-12 years: 28-112 mcg/dL 13-15 years: 26-110 mcg/dL 16-18 years: 27-138 mcg/dL 19+ years: 40-174 mcg/dL		Colorimetric	Established by OSUWMC Reference Interval Study 2013, verified by OSUWMC Reference Interval study 2021.	10-1,000 mcg/dL	10-2,000 mcg/dL

Iron/Iron Binding/Transferrin	IRBC	**IRON** 0-30 days: 29-127 mcg/dL 31-365 days: 25-126 mcg/dL 1-3 years: 25-101 mcg/dL 4-6 years: 28-93 mcg/dL 7-9 years: 30-104 mcg/dL 10-12 years: 32-104 mcg/dL 13-15 years: 30-109 mcg/dL 16-18 years: 33-102 mcg/dL 19+ years: 40-174 mcg/dL **TRAN** 200-400 mg/dL **TIBC** 0-30 days: 94-236 mcg/dL 31-182 days: 89-311 mcg/dL 183-365 days: 138-365 mcg/dL 1-3 years: 184-377 mcg/dL 4-6 years: 162-352 mcg/dL 7-9 years: 167-336 mcg/dL 10-12 years: 198-383 mcg/dL 13-15 years: 169-358 mcg/dL 16-18 years: 194-372 mcg/dL 19+ years: 250-425 mcg/dL **IRON SATURATION** 20-55%	**IRON** 0-30 days: 32-112 mcg/dL 31-365 days: 27-109 mcg/dL 1-3 years: 29-91 mcg/dL 4-6 years: 25-115 mcg/dL 7-9 years: 27-96 mcg/dL 10-12 years: 28-112 mcg/dL 13-15 years: 26-110 mcg/dL 16-18 years: 27-138 mcg/dL 19+ years: 40-174 mcg/dL **TRAN** 200-400 mg/dL **TIBC** 0-30 days: 94-232 mcg/dL 31-182 days: 116-322 mcg/dL 183-365 days: 176-384 mcg/dL 1-3 years: 204-382 mcg/dL 4-6 years: 180-390 mcg/dL 7-9 years: 183-369 mcg/dL 10-12 years: 173-356 mcg/dL 13-15 years: 193-377 mcg/dL 16-18 years: 174-351 mcg/dL 19+ years: 250-425 mcg/dL **IRON SATURATION** 20-55%		**IRON** Colormetric **TRAN** In the procedure, the measurement of the decrease in light transmitted (increase in absorbance) through particles suspended in solution as a result of complexes formed during the antigen-antibody reaction, is the basis of this assay. **IRON SATURATION** (Iron/TIBC)*100	See individual analytes	See individual analytes	See individual analytes
Lactate Dehydrogenase	LDH	0-30 days: 145-765 U/L 31-365 days: 190-420 U/L 1-3 years: 165-395 U/L 4-6 years: 135-345 U/L 7-9 years: 140-280 U/L 10-12 years: 120-260 U/L 13-15 years: 100-275 U/L 16-18 years: 105-230 U/L 19+ years: 100-190 U/L	0-30 days: 125-735 U/L 31-365 days: 170-450 U/L 1-3 years: 155-345 U/L 4-6 years: 155-345 U/L 7-9 years: 145-300 U/L 10-12 years: 120-325 U/L 13-15 years: 120-290 U/L 16-18 years: 105-235 U/L 19+ years: 100-190 U/L		Photometric rate	Clinical Guide to Laboratory Tests, Tietz, 1995; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999.	25-1,200 U/L	25-60,000 U/L
Lactate Dehydrogenase Body Fluid	FLLD			**Pleural:** A Pleural fluid LDH to serum/plasma LDH ratio > 0.6 or a pleural fluid LDH concentration > two-thirds the upper limit of the serum/plasma LDH reference interval suggest an exudate. **Pericardial:** Pericardial fluid LDH to serum/plasma LDH ratio > 0.6 or > 300 U/L suggests an exudate. **Peritoneal/Ascites:** Peritoneal fluid LDH to serum/plasma LDH ratio > 0.6 is consistent with an exudate. **CSF:** Elevated LDH in CSF specimens may indicate a non-specific immune process. CSF LDH measurements above 40 U/L may be associated with Jakob-Creutzfeldt Disease, Bacterial Meningitis, Neurosyphilis, or tumors of the central nervous system. Contamination of red blood cells can falsely increase LDH measurements. **Amniotic Fluid:** The reference range has not been established for this fluid type. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Photometric rate	CSF: Clinical Utility of Biochemical Analysis of Cerebrospinal Fluid Clinical Chemistry 1995 Watson MA. Pericardial and peritoneal: Burgess. Clinical Chemical Acta 343 (2004) 61–84. Pleural Light, RW. N Engl J Med. 2002 Jun 20;346(25):1971-1977.	25-1,200 U/L	25-30,000 U/L
Lactate, Blood	LACT	0.5-1.6 mmol/L 0.5-2.2 mmol/L			Enzymatic colorimetric		RADIOMETER: 0.0-30.0 mmol/L DXC: 0.2-10.0 mmol/L	RADIOMETER: 0.0-30.0 mmol/L DXC: 0.2-30.0 mmol/L
Lactate, CSF	CSLACT	<2.8 mmol/L			Enzymatic colorimetric	Beckman Coulter literature which cites Clinical Guide to Laboratory Tests, Tietz, 1995	0.2-10.0 mmol/L	0.2-30.0 mmol/L
Lactate, Fluid	FLACT			The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Enzymatic colorimetric		0.2-10.0 mmol/L	0.2-30.0 mmol/L
LDL, Direct Measure	LDL	<100 mg/dL			Enzymatic colorimetric	National Cholesterol Education Project (NCEP) Adult Treatment Protocol (ATP- III) (Circulation, 2002;106:3143-3421)	7-400 mg/dL	7-400 mg/dL
LH	LH	0-365 days: 0.01-1.00 mIU/mL 1-10 years: 0.00-0.10 mIU/mL 11-13 years: 0.37-6.23 mIU/mL 14-18 years: 0.37-17.30 mIU/mL	0-365 days: <3.24 mIU/mL 1-10 years: 0.00-0.10 mIU/mL 11-13 years: 0.08-2.58 mIU/mL 14-18 years: 0.97-6.37 mIU/mL	Male: 19-70 years: 1.5-9.3 mIU/mL >70 years: 3.1-4.6 mIU/mL 19+ years Female: Follicular phase: 1.9-12.5 mIU/mL Midcycle peak: 8.7-76.3 mIU/mL Luteal phase: 0.5-16.9 mIU/mL Pregnant: <0.1-1.5 mIU/mL Postmenopausal: 15.9-54.0 mIU/mL Contraceptives: 0.7-5.6 mIU/mL	Two-site sandwich immunoassay chemiluminescent	Atellica IM LH Package Insert 11200385_EN Rev. 04-2020-06; Pediatric Reference Ranges, Soldin, 1999	0.07-200.00 mIU/mL	0.07-6,400.00 mIU/mL
Lipase	LIPA	0-30 days: 6-55 U/L 31-182 days: 4-29 U/L 183-365 days: 4-23 U/L 1-3 years: 4-31 U/L			Photometric rate	Beckman Coulter Chemistry Information Sheet, 9/2020; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, 1999.	6-600 U/L	6-6,000 U/L
Lipid Panel w Calculated LDL		**CHOL** 0-30 days: 62-155 mg/dL 31-182 days: 62-141 mg/dL 183-365 days: 76-216 mg/dL 1-3 years: 108-193 mg/dL 4-6 years: 106-193 mg/dL 7-9 years: 104-210 mg/dL 10-12 years: 105-218 mg/dL 13-15 years: 108-205 mg/dL 16-18 years: 92-234 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 39-140 mg/dL 12-13 years: 37-130 mg/dL 14-15 years: 38-135 mg/dL 16-19 years: 37-140 mg/dL	**CHOL** 0-30 days: 54-151 mg/dL 31-182 days: 81-147mg/dL 183-365 days: 76-179 mg/dL 1-3 years: 85-182 mg/dL 4-6 years: 110-217 mg/dL 7-9 years: 110-211 mg/dL 10-12 years: 105-223 mg/dL 13-15 years: 91-204 mg/dL 16-18 years: 82-192 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 24-137 mg/dL 12-13 years: 24-145 mg/dL 14-15 years: 34-165 mg/dL 16-19 years: 34-140 mg/dL		**CHOL** Enzymatic colorimetric **TRIG** Enzymatic colorimetric	See individual analytes	See individual analytes	See individual analytes

[illegible]	HDLT	20+ years: <150 mg/dL **HDL** 0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL **LDL CALC** 0-59 days: <130 mg/dL 60-365 days: 32-117 mg/dL 1-2 years: 38-140 mg/dL 2+ years: 0-99 mg/dL **TOT CHOL/HDL** <4.5 **NON HDL** <130 mg/dL.	20+ years: <150 mg/dL **HDL** 0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL **LDL CALC** 0-59 days: <130 mg/dL 60-365 days: 32-117 mg/dL 1-2 years: 38-140 mg/dL 2+ years: 0-99 mg/dL **TOT CHOL/HDL** <4.5 **NON HDL** <130 mg/dL		**HDL** Enzymatic colorimetric **LDL CALC** T Cholesterol – HDL – (Trig/5)	[illegible]	[illegible]	[illegible]
Lipid Panel with Reflex to Measured LDL	LIPID	**CHOL** 0-30 days: 62-155 mg/dL 31-182 days: 62-141 mg/dL 183-365 days: 76-216 mg/dL 1-3 years: 108-193 mg/dL 4-6 years: 106-193 mg/dL 7-9 years: 104-210 mg/dL 10-12 years: 105-218 mg/dL 13-15 years: 108-205 mg/dL 16-18 years: 92-234 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 39-140 mg/dL 12-13 years: 37-130 mg/dL 14-15 years: 38-135 mg/dL 16-19 years: 37-140 mg/dL 20+ years: <150 mg/dL **HDL** 0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL **LDL CALC** 0-59 days: <130 mg/dL 60-365 days: 32-117 mg/dL 1-2 years: 38-140 mg/dL 2+ years: 0-99 mg/dL **TOT CHOL/HDL** <4.5 **NON HDL** <130 mg/dL.	**CHOL** 0-30 days: 54-151 mg/dL 31-182 days: 81-147mg/dL 183-365 days: 76-179 mg/dL 1-3 years: 85-182 mg/dL 4-6 years: 110-217 mg/dL 7-9 years: 110-211 mg/dL 10-12 years: 105-223 mg/dL 13-15 years: 91-204 mg/dL 16-18 years: 82-192 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 24-137 mg/dL 12-13 years: 24-145 mg/dL 14-15 years: 34-165 mg/dL 16-19 years: 34-140 mg/dL 20+ years: <150 mg/dL **HDL** 0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL **LDL CALC** 0-59 days: <130 mg/dL 60-365 days: 32-117 mg/dL 1-2 years: 38-140 mg/dL 2+ years: 0-99 mg/dL **TOT CHOL/HDL** <4.5 **NON HDL** <130 mg/dL.		**CHOL** Enzymatic colorimetric **TRIG** Enzymatic colorimetric **HDL** Enzymatic colorimetric **LDL CALC** T Cholesterol – HDL – (Trig/5) **LDL DIRECT** Enzymatic colorimetric	See individual analytes	See individual analytes	See individual analytes
Lipids w Direct Measure LDL	HDLTB	**CHOL** 0-30 days: 62-155 mg/dL 31-182 days: 62-141 mg/dL 183-365 days: 76-216 mg/dL 1-3 years: 108-193 mg/dL 4-6 years: 106-193 mg/dL 7-9 years: 104-210 mg/dL 10-12 years: 105-218 mg/dL 13-15 years: 108-205 mg/dL 16-18 years: 92-234 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 39-140 mg/dL 12-13 years: 37-130 mg/dL 14-15 years: 38-135 mg/dL 16-19 years: 37-140 mg/dL 20+ years: <150 mg/dL **HDL** 0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL **LDL DIRECT** <100 mg/dL **TOT CHOL/HDL** <4.5 **NON HDL** <130 mg/dL.	**CHOL** 0-30 days: 54-151 mg/dL 31-182 days: 81-147mg/dL 183-365 days: 76-179 mg/dL 1-3 years: 85-182 mg/dL 4-6 years: 110-217 mg/dL 7-9 years: 110-211 mg/dL 10-12 years: 105-223 mg/dL 13-15 years: 91-204 mg/dL 16-18 years: 82-192 mg/dL 19+ years: <200 mg/dL **TRIG** 0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 24-137 mg/dL 12-13 years: 24-145 mg/dL 14-15 years: 34-165 mg/dL 16-19 years: 34-140 mg/dL 20+ years: <150 mg/dL **HDL** 0-9 years: 35-82 mg/dL 10-13 years: 36-84 mg/dL 14-19 years: 35-65 mg/dL 20+ years: ≥40 mg/dL **LDL DIRECT** <100 mg/dL **TOT CHOL/HDL** <4.5 **NON HDL** <130 mg/dL.		**CHOL** Enzymatic colorimetric **TRIG** Enzymatic colorimetric **HDL** Enzymatic colorimetric **LDL DIRECT** Enzymatic colorimetric	See individual analytes	See individual analytes	See individual analytes
Lithium Level	LI	Therapeutic Range: 0-59 years: 0.60-1.20 mmol/L 60+ years: 0.40-0.80 mmol/L			A spectrophotometric method which can be readily adapted to automated clinical chemistry analyzers. Lithium present in the sample reacts with a substituted porphyrin compound at an alkaline pH, resulting in a change in absorbance which is directly proportional to the concentration of Lithium in the sample.	Applied Clinical Pharmacokinetics, Bauer, 2001; Clinical Pharmacokinetics, Eilers, 1995;29:442-50 Bipolar Disord. 2019 Mar;21(2):117-123. Bipolar Disord. 2019 May;21(3):190-191.	0.10-5.00 mmol/L	0.10-5.00 mmol/L
Lytes (Na, K, Cl) - Urine - Random	ULYTR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	**NA/K/CL** Indirect ion-selective electrode	See individual analytes	See individual analytes	See individual analytes
Lytes (Na, K, Cl) - Urine 24HR	ULYT	**UNA** 40-220 mmol/24 hrs **U/K** 25-125 mmol/24 hrs **U/CL** 110-250 mmol/24 hrs			**NA/K/CL** Indirect ion-selective electrode	See individual analytes		

Lytes (Na, K, Cl) Plus CO2	LYTES	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **ANION GAP** 7-17 mmol/L			**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric	See individual analytes	See individual analytes	See individual analytes
Lytes (Na, K, Cl, Creat), Urine, Random	ULYTR UCRER			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	**NA/K/CL** Indirect ion-selective electrode **CREA** Kinetic Jaffe	See individual analytes	See individual analytes	See individual analytes
Magnesium	MG	0-30 days: 1.7-2.5 mg/dL 31-365 days: 1.9-2.4 mg/dL 1-3 years: 1.7-2.4 mg/dL 4-6 years: 1.7-2.2 mg/dL 7-9 years: 1.6-2.3 mg/dL 10-12 years: 1.6-2.2 mg/dL 13-15 years: 1.6-2.3 mg/dL 16-18 years: 1.5-2.2 mg/dL 19+ years: 1.6-2.6 mg/dL	0-30 days: 1.7-2.4 mg/dL 31-365 days: 1.6-2.5 mg/dL 1-3 years: 1.7-2.4 mg/dL 4-6 years: 1.7-2.4 mg/dL 7-9 years: 1.7-2.3 mg/dL 10-12 years: 1.6-2.2 mg/dL 13-15 years: 1.6-2.3 mg/dL 16-18 years: 1.5-2.2 mg/dL 19+ years: 1.6-2.6 mg/dL		Colorimetric with xylidyl blue	Clinical Guide to Laboratory Tests, Tietz, 1995; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999.	0.5-8.0 mg/dL	0.5-24.0 mg/dL
Magnesium, 24HR Urine	UMG	72.9-121.5 mg/24 hrs			Colorimetric with xylidyl blue	Clinical Guide to Laboratory Tests, Tietz, 1995		
Magnesium, Urine, Random	UMGR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Colorimetric with xylidyl blue		0.5-10.0 mg/dL	0.5-100.0 mg/dL
Mechanical Support Hemolysis	HAPTO LDRFX	**HAPTO** 44-215 mg/dL **LDRFX** 0-30 days: 145-765 U/L 31-365 days: 190-420 U/L 1-3 years: 165-395 U/L 4-6 years: 135-345 U/L 7-9 years: 140-280 U/L 10-12 years: 120-260 U/L 13-15 years: 100-275 U/L 16-18 years: 105-230 U/L 19+ years: 100-190 U/L	**HAPTO** 44-215 mg/dL **LDRFX** 0-30 days: 125-735 U/L 31-365 days: 170-450 U/L 1-3 years: 155-345 U/L 4-6 years: 155-345 U/L 7-9 years: 145-300 U/L 10-12 years: 120-325 U/L 13-15 years: 120-290 U/L 16-18 years: 105-235 U/L 19+ years: 100-190 U/L			See individual analytes	See individual analytes	See individual analytes
Methotrexate Level	MTXU			Due to the many different MTX protocols utilized and the many individual differences in the way this drug is handled, please contact the primary attending physician.	Homogeneous enzyme immunoassay	OSU Pharmacy	0.04-1.20 µmol/L	0.04-1,200.00 µmol/L
Microalbumin, 24HR Urine	MALB24	≤30.0 mg/24 hrs			Turbidometric	Package insert		
Microalbumin, Random Urine	MALBRB	**RATIO**			Turbidometric	See individual analytes	See individual analytes	See individual analytes
Mononucleosis Screen	MONO			Negative	Color immunochromatographic dipstick technology with bovine erythrocyte extract coated on the membrane. In the test procedure serum is mixed with the Diluent. Then the Test Strip is placed in the mixture and the mixture migrates along the membrane.	Sure Vue Signature Mono Package Insert		Negative, Positive
Non-Gestational 2HR Glucose Tolerance Test	GTF G2T	**GTF** 70-125 mg/dL **G2T** 70-199 mg/dL		According to the American Diabetes Association's clinical practice recommendations, the diagnosis of diabetes mellitus can be made if either the fasting plasma glucose or the 2hr post-glucose samples meet or exceed 126 mg/dL or 200 mg/dL, respectively. The recommendations also note that in the absence of unequivocal hyperglycemia, the diagnosis requires two abnormal test results from the same sample or in two separate test samples. The ADA criteria for prediabetes is a fasting plasma glucose of 100-125 mg/dL or 2hr post-glucose sample of 140-199 mg/dL.	Photometric rate with hexokinase		10-800 mg/dL	10-2,400 mg/dL
Osmolality	OSMO	278-305 mOsm/kg			Freezing point depression	OSU, In House Reference Range Validation, 2017	50-2,000 mOsm/kg	50-2,000 mOsm/kg
Osmolality, Stool	FOSMO	275-300 mOsm/kg			Freezing point depression	Advanced Instruments Model A2O. June 2014.	50-2,000 mOsm/kg	50-2,000 mOsm/kg
Osmolality, 24 HR Urine	UOSM	300-900 mOsm/kg			Freezing point depression	Clinical Guidelines for Laboratory Tests, Tietz, 1995	50-2,000 mOsm/kg	50-2,000 mOsm/kg
Osmolality, Urine	UOSM	300-900 mOsm/kg			Freezing point depression	Clinical Guidelines for Laboratory Tests, Tietz, 1995	50-2,000 mOsm/kg	50-2,000 mOsm/kg
Pancreatic Fluid CEA	FCEA			Fluid CEA values >192 ng/mL may indicate mucinous cystic lesions of the pancreas. Results <192 ng/mL require clinical correlations with patient history and other imaging modalities.		Clinical Guide to Laboratory Tests, Tietz, 1995; see Source link for additional Reference Range information	2.0-100.0 ng/mL	2.0-10,000.0 ng/mL
Pancreatic Function Test	PFUNZ PFUN15 PFUN30 PFUN45 PFUN60			Bicarbonate > 80 mmol/L is considered a normal result.	**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **AMY** Photometric **LIIPA** Photometric	See individual analytes	See individual analytes	See individual analytes
Phenobarbital Level, Random	PHNOR	Therapeutic Range: 15.0-40.0 mcg/mL			The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001	5.0-80.0 mcg/mL	5.0-240.0 mcg/mL
Phenobarbital Level, Trough (Pre Drug Level)	PHNO	Therapeutic Range: 15.0-40.0 mcg/mL			The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001	5.0-80.0 mcg/mL	5.0-240.0 mcg/mL

Phenytoin Total Level	PTN	Therapeutic Range: 10.0-20.0 mcg/mL			The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001	2.5-40.0 mcg/mL	2.5-200.0 mcg/mL
Phosphate, Inorganic	IP	0-30 days: 4.3-7.7 mg/dL 31-365 days: 3.7-6.5 mg/dL 1-3 years: 3.4-6.0 mg/dL 4-6 years: 3.2-5.5 mg/dL 7-9 years: 3.1-5.5 mg/dL 10-12 years: 3.3-5.3 mg/dL 13-15 years: 2.8-4.8 mg/dL 16-18 years: 2.5-4.8 mg/dL 19+ years: 2.2-4.6 mg/dL	0-30 days: 3.9-6.9 mg/dL 31-365 days: 3.5-6.6 mg/dL 1-3 years: 3.1-6.0 mg/dL 4-6 years: 3.3-5.6 mg/dL 7-9 years: 3.0-5.4 mg/dL 10-12 years: 3.2-5.7 mg/dL 13-15 years: 2.9-5.1 mg/dL 16-18 years: 2.7-4.9 mg/dL 19+ years: 2.2-4.6 mg/dL		Photometric	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999.	1.0-20.0 mg/dL	1.0-60.0 mg/dL
Phosphorus, Random, Urine	UIPR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Photometric		10.0-200.0 mg/dL	10.0-1,000.0 mg/dL
Phosphorus, 24HR	UIP	0.4-1.3 g/24 hrs			Photometric	Clinical Guide to Laboratory Tests, Tietz, 1995		
Potassium	K	0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L			Indirect ion-selective electrode	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999.	1.0-10.0 mmol/L	1.0-10.0 mmol/L
Potassium Body Fluid	FK			**Stool:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Indirect ion-selective electrode		2.0-200.0 mmol/L	2.0-200.0 mmol/L
Potassium 24 HR Urine	UK	25-125 mmol/24 hrs			Indirect ion-selective electrode	Clinical Guide to Laboratory Tests, Tietz, 1995		
Potassium, Random Urine	UKR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Indirect ion-selective electrode	Clinical Guide to Laboratory Tests, Tietz, 1995	2.0-200.0 mmol/L	2.0-200.0 mmol/L
Prealbumin	PALB	17-34 mg/dL			Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	3-80 mg/dL	3-1,600 mg/dL
Procalcitonin	PROCAL	<0.50 ng/mL			Two-site sandwich immunoassay chemiluminescent.	Atellica IM Procalcitonin 11200767_EN Rev. 03, 2019-06	0.04-50.00 ng/mL	0.04-2,000.00 ng/mL
Progesterone	PROG			Male: 0.28-1.22 ng/mL Female: Follicular phase: 0-1.40 ng/mL Luteal phase: 3.34-25.56 ng/mL Malfuteal phase: 4.44-28.03 ng/mL Postmenopausal: 0-0.73 ng/mL	Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Progesterone Package Insert 11200386_EN Rev. 04-2020-06	0.21-60.00 ng/mL	0.21-3,000.00 ng/mL
Prolactin	PROL			Male: 2.1-17.7 ng/mL Female: Nonpregnant: 2.8-29.2 ng/mL Pregnant: 9.7-208.5 ng/mL Postmenopausal: 1.8-20.3 ng/mL <2 years: 3.3-14.7 ng/mL 2-5 years: 1.0-12.8 ng/mL 6-10 years: 1.2-11.4 ng/mL 11-17 years: 1.4-14.3 ng/mL	Two-site sandwich immunoassay chemiluminescent.	Advia Centaur Prolactin Package Insert 111746 Rev. N, 2008-09; Pediatric Reference Intervals, 5th ed Soldin, 2005	0.3-200.0 ng/mL	0.3-800,000.0 ng/mL
Protein & Glucose, CSF	CFPG CFP	**GLUCSF** 40-70 mg/dL. **CFP** 0-3 days: 40-120 mg/dL 4-30 days: 20-80 mg/dL 31+ days: 15-45 mg/dL			**GLUCSF** Photometric rate with hexokinase **CFP** Colorimetric with Pyrogallol red	See individual analytes	See individual analytes	See individual analytes
Protein Total	TP	0-30 days: 4.2-6.2 g/dL 31-182 days: 4.4-6.6 g/dL 183-365 days: 5.6-7.9 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL	0-30 days: 4.1-6.3 g/dL 31-182 days: 4.7-6.7 g/dL 183-365 days: 5.5-7.0 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL		Colorimetric with cupric ions in an alkaline solution	Clinical Guide to Laboratory Tests, Tietz, 1995; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999	3.0-12.0 g/dL	3.0-24.0 g/dL
Protein, CSF	CFP	0-3 days: 40-120 mg/dL 4-30 days: 20-80 mg/dL			Colorimetric with Pyrogallol red	Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999	4-200 mg/dL	4-5,000 mg/dL
Protein, Fluid	FLP			**Pleural:** Pleural fluid protein to serum/plasma protein ratio > 0.5 are consistent with exudates. **Pericardial:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation. **Peritoneal/Ascites:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Colorimetric with cupric ions in an alkaline solution	4th Edition of Tietz	0.5-12.0 g/dL	0.5-24.0 g/dL
Protein, 24 HR Urine	UPRO	40-225 mg/24 hrs			Colorimetric with Pyrogallol red	Clinical Guide to Laboratory Tests, Tietz, 1995		
Protein, Random Urine	UPROR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Colorimetric with Pyrogallol red		4-200 mg/dL	4-5,000 mg/dL
PSA - Diagnostic/Tumor Marker	PSATM	≤4.00 ng/mL			Two-site sandwich immunoassay chemiluminescent.	Atellica IM PSA Package Insert 10997799_EN Rev. 03-2019-09.	0.04-100.00 ng/mL	0.04-6,400,000.00 ng/mL
PSA, Reflex to Free and Total PSA	PSAR	≤4.00 ng/mL				Atellica IM PSA Package Insert 10997799_EN Rev. 03-2019-09.	0.04-100.00 ng/mL	0.04-6,400,000.00 ng/mL
PSA, Screening	PSA	≤4.00 ng/mL			Two-site sandwich immunoassay chemiluminescent.	Atellica IM PSA Package Insert 10997799_EN Rev. 03-2019-09.	0.04-100.00 ng/mL	0.04-6,400,000.00 ng/mL

Renal Panel	RENAL	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-0.90 mg/dL 31-365 days: 0.40-0.60 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.50-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.70-1.10 mg/dL 16-18 years: 0.80-1.20 mg/dL 19+ years: 0.50-1.20 mg/dL **CA** 0-30 days: 8.4-10.6 mg/dL 31-365 days: 8.9-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **OSMO** 278-305 mOsm/kg **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2 **ALB** 0-30 days: 2.7-4.3 g/dL 31-182 days: 2.9-4.2 g/dL 183-365 days: 3.3-4.8 g/dL 1-19 years: 2.9-4.2 g/dL 19+ years: 3.5-5.0 g/dL **IP** 0-30 days: 4.3-7.7 mg/dL 31-365 days: 3.7-6.5 mg/dL 1-3 years: 3.4-6.0 mg/dL 4-6 years: 3.2-5.5 mg/dL 7-9 years: 3.1-5.5 mg/dL 10-12 years: 3.3-5.3 mg/dL 13-15 years: 2.8-4.8 mg/dL 16-18 years: 2.5-4.8 mg/dL 19+ years: 2.2-4.6 mg/dL	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+ years: 98-108 mmol/L **CO2** 0-2 years: 13-29 mmol/L 3+ years: 21-31 mmol/L **GLUC** 0-30 days: 55-115 mg/dL 31-182 days: 57-117 mg/dL 183-365 days: 70-126 mg/dL 1+ years: 70-99 mg/dL **BUN** 7-25 mg/dL **CREA** 0-30 days: 0.50-1.20 mg/dL 31-365 days: 0.40-0.70 mg/dL 1-3 years: 0.40-0.70 mg/dL 4-6 years: 0.50-0.80 mg/dL 7-9 years: 0.60-0.90 mg/dL 10-12 years: 0.60-1.00 mg/dL 13-15 years: 0.60-1.20 mg/dL 16-18 years: 0.80-1.40 mg/dL 19+ years: 0.70-1.30 mg/dL **CA** 0-30 days: 8.5-10.6 mg/dL 31-365 days: 8.7-10.5 mg/dL 1+ years: 8.6-10.5 mg/dL **OSMO** 278-305 mOsm/kg **ANION GAP** 7-17 mmol/L **eGFR** ≥60 mL/min/1.73m2 **ALB** 0-30 days: 2.6-4.1 g/dL 31-182 days: 2.8-4.6 g/dL 183-365 days: 2.8-4.8 g/dL 1-19 years: 3.2-4.7 g/dL 19+ years: 3.5-5.0 g/dL **IP** 0-30 days: 3.9-6.9 mg/dL 31-365 days: 3.5-6.6 mg/dL 1-3 years: 3.1-6.0 mg/dL 4-6 years: 3.3-5.6 mg/dL 7-9 years: 3.0-5.4 mg/dL 10-12 years: 3.2-5.7 mg/dL 13-15 years: 2.9-5.1 mg/dL 16-18 years: 2.7-4.9 mg/dL 19+ years: 2.2-4.6 mg/dL		**NA/K/CL** Indirect ion-selective electrode **CO2** Photometric **GLUC** Photometric rate with hexokinase **BUN** Photometric rate **CREA** Kinetic Jaffe **CA** Photometric, arsenazo **BC RATIO** BUN/Serum Creatinine **ANION GAP** (Na + K) – (Cl + CO2) **eGFR** CKD-EPI 2021 refit using creatinine, age, and sex **OSMO CALC** (1.86 (Na +K) + 1.15 (Glucose/18) + (Urea/2.8) + 14 where Na and K are in mmol/L; Glucose and Urea are in mg/dL. **ALB** Colorimetric; Bromocresol green **IP** Colorimetric	See individual analytes	See individual analytes	See individual analytes
Rheumatoid Factor	RF	≤14 IU/mL		Turbidimetry	Package Insert. Verified by OSUWMC Reference Interval Study 2021.	10-120 IU/mL	10-3,000 IU/mL
Salicylate Level	SALI	Therapeutic Range: 20.0-30.0 mg/dL		Serum is mixed with Reagent 1, which contains antibodies to salicylic acid and the coenzyme nicotinamide adenine dinucleotide (NAD). Subsequently, Reagent 2, which contains salicylic acid labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH), is added. Salicylic acid in the sample and salicylic acid-labeled G6PDH compete for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the salicylic acid concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd Edition 2002 Applied Therapeutics, Inc. and Micromedex. On OSU Intranet	5.0-80.0 mg/dL	5.0-240.0 mg/dL
Sodium	NA	0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L			Verified by OSUWMC Reference Interval Study 2021.	50-200 mmol/L	50-200 mmol/L
Sodium Body Fluid	FNA			**Stool:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.			50-200 mmol/L	50-200 mmol/L
Sodium, Potassium, Chloride	NA,K,CL	**NA** 0-6 days: 133-146 mmol/L 7-30 days: 134-144 mmol/L 31-182 days: 134-142 mmol/L 183-365 days: 133-142 mmol/L 1+ years: 135-145 mmol/L **K** 0-7 days: 3.2-5.5 mmol/L 8-30 days: 3.4-6.0 mmol/L 31-182 days: 3.5-5.6 mmol/L 183-365 days: 3.5-6.1 mmol/L 1-17 years: 3.3-4.6 mmol/L 18+ years: 3.5-5.0 mmol/L **CL** 0-365 days: 98-113 mmol/L 1-17 years: 102-112 mmol/L 18+: 98-108 mmol/L			Indirect ion-selective electrode	See individual analytes	See individual analytes	See individual analytes
Sodium, 24 HR Urine	UNA	40-220 mmol/24 hrs			Indirect ion-selective electrode	Clinical Guide to Laboratory Tests, Tietz, 1995		

Sodium, Random Urine	UNAR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Indirect ion-selective electrode		10-400 mmol/L	10-400 mmol/L
T3 Free	FT3	0-3 days: 1.4-5.4 pg/mL 4-29 days: 1.5-5.0 pg/mL 30-365 days: 2.5-6.5 pg/mL 1-5 years: 3.0-6.0 pg/mL 6-10 years: 2.7-6.2 pg/mL 11-15 years: 2.6-5.7 pg/mL 16-18 years: 2.8-5.2 pg/mL 19+ years: 2.3-4.2 pg/mL	0-3 days: 1.4-4.8 pg/mL 4-29 days: 1.4-5.5 pg/mL 30-365 days: 2.0-6.9 pg/mL 1-5 years: 2.4-6.7 pg/mL 6-10 years: 2.9-6.0 pg/mL 11-15 years: 3.1-5.9 pg/mL 16-18 years: 3.1-5.7 pg/mL 19+ years: 2.3-4.2 pg/mL		Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Free T3 Package Insert 10995347_EN Rev. 03-2020-06	0.2-20.0 pg/mL	0.2-20.0 pg/mL
T3 Total (Triiodothyronine)	T3RIA	0-29 days: 0.48-1.77 ng/mL 30-365 days: 0.73-2.21 ng/mL 1-5 years: 1.26-2.16 ng/mL 6-10 years: 1.10-1.95 ng/mL 11-15 years: 1.04-1.84 ng/mL 16-18 years: 1.01-1.51 ng/mL 19+ years: 0.60-1.81 ng/mL	0-29 days: 0.51-1.84 ng/mL 30-365 days: 1.03-2.29 ng/mL 1-5 years: 0.93-2.13 ng/mL 6-10 years: 1.04-1.98 ng/mL 11-15 years: 0.88-1.76 ng/mL 16-18 years: 0.86-1.78 ng/mL 19+ years: 0.60-1.81 ng/mL		Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Total T3 Package Insert 10995424_EN Rev. 03-2020-06	0.10-8.00 ng/mL	0.10-80.00 ng/mL
T4	T4	0-29 days: 3.4-11.8 mcg/dL 30-365 days: 4.7-11.8 mcg/dL 1-5 years: 6.0-11.3 mcg/dL 6-10 years: 5.2-9.7 mcg/dL 11-15 years: 4.9-9.0 mcg/dL 16-18 years: 5.1-9.0 mcg/dL 19+ years: 4.5-10.9 mcg/dL	0-29 days: 3.4-12.6 mcg/dL 30-365 days: 5.4-14.1 mcg/dL 1-5 years: 5.3-10.2 mcg/dL 6-10 years: 5.3-9.5 mcg/dL 11-15 years: 4.6-9.2 mcg/dL 16-18 years: 4.9-8.1 mcg/dL 19+ years: 4.5-10.9 mcg/dL		Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Total T4 Package Insert 10995425_EN Rev. 03-2020-069; Pediatric Reference Ranges, Soldin, 1999	0.4-30.0 mcg/dL	0.4-300.0 mcg/dL
T4 Free	FT4	0-18 years: 1.04-1.64 ng/dL 19+ years: 0.89-1.76 ng/dL			Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Free T4 Package Insert 10995348_EN Rev. 06-2020-11; Pediatric Reference Ranges, Soldin, 1999	0.10-12.00 ng/dL	0.10-12.00 ng/dL
Testosterone	TESTOS	0-6 months: 20-80 ng/dL 6 months to 9 years: ≤20 ng/dL 10-11 years: ≤44 ng/dL 12-16 years: ≤75 ng/dL 17-18 years: 20-75 ng/dL 19+ years: 8-60 ng/dL	0-6 months: 75-400 ng/dL 6 months to 9 years: ≤20 ng/dL 10-11 years: ≤130 ng/dL 12-13 years: ≤800 ng/dL 14-15 years: ≤1,200 ng/dL 15-16 years: 100-1,200 ng/dL 17-18 years: 300-1,200 ng/dL 19+ years: 240-950 ng/dL		Competitive immunoassay using direct chemiluminescent technology.	Siemens Atellica IM Reference Interval Verification Study 2023	7-1,500 ng/dL	7-3,000 ng/dL
Testosterone Total and Free, Includes SHBG	TESTOS SHGB	**TESTOS** 0-6 months: 20-80 ng/dL 6 months to 9 years: ≤20 ng/dL 10-11 years: ≤44 ng/dL 12-16 years: ≤75 ng/dL 17-18 years: 20-75 ng/dL 19+ years: 8-60 ng/dL **SHGB** 18.00-144.00 nmol/L **FREE TESTOS** 0-365 days: ≤0.25 ng/dL 1-6 years: <0.13 ng/dL 7-8 years: ≤0.23 ng/dL 8-9 years: ≤0.34 ng/dL 9-10 years: ≤0.46 ng/dL 10-11 years: ≤0.59 ng/dL 11-12 years: ≤0.72 ng/dL 12-13 years: ≤0.84 ng/dL 13-14 years: ≤0.96 ng/dL 14-15 years: ≤1.06 ng/dL 15-18 years: ≤1.09 ng/dL 19+ years: 0.00-1.08 ng/dL	**TESTOS** 0-6 months: 75-400 ng/dL 6 months to 9 years: ≤20 ng/dL 10-11 years: ≤130 ng/dL 12-13 years: ≤800 ng/dL 14-15 years: ≤1,200 ng/dL 15-16 years: 100-1,200 ng/dL 17-18 years: 300-1,200 ng/dL 19+ years: 240-950 ng/dL **SHGB** 10.00-57.00 nmol/L **FREE TESTOS** 0-365 days: 0.20-3.10 ng/dL 1-8 years: <0.13 ng/dL 9-10 years: ≤0.45 ng/dL 10-11 years: ≤1.26 ng/dL 11-12 years: ≤5.52 ng/dL 12-13 years: ≤9.28 ng/dL 13-14 years: ≤12.60 ng/dL 14-15 years: 0.48-15.30 ng/dL 15-16 years: 1.62-17.70 ng/dL 16-17 years: 2.93-19.50 ng/dL 17-18 years: 4.28-20.90 ng/dL 18-19 years: 5.40-21.80 ng/dL 19+ years: 2.29-20.70 ng/dL			See individual analytes	See individual analytes	See individual analytes
Theophylline Level	THEO	Therapeutic Range: 5.0-20.0 mcg/mL			Based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001	2.5-40.0 mcg/mL	2.5-200.0 mcg/mL
Tobramycin Level, Extended Interval	TOBREI	Peak: 10.0 - 15.0 mcg/mL, Trough: <1.0 mcg/mL			This assay is based on competition for antibody binding sites between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Antimicrobial Stewardship Program, 2013	0.6-10.0 mcg/mL	0.6-50.0 mcg/mL
Tobramycin Level, Peak (Post Drug Level)	TOBRPK	Therapeutic Range: 10.0-15.0 mcg/mL			This assay is based on competition for antibody binding sites between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Antimicrobial Stewardship Program, 2013	0.6-10.0 mcg/mL	0.6-50.0 mcg/mL
Tobramycin Level, Random	TOBR	Peak: 10.0 - 15.0 mcg/mL, Trough: <1.0 mcg/mL			This assay is based on competition for antibody binding sites between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Antimicrobial Stewardship Program, 2013	0.6-10.0 mcg/mL	0.6-50.0 mcg/mL
Tobramycin Level, Trough (Pre Drug Level)	TOBTR	Therapeutic Range: <1.0 mcg/mL			This assay is based on competition for antibody binding sites between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Enzyme activity decreases upon binding to the antibody, so the drug concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Antimicrobial Stewardship Program, 2013	0.6-10.0 mcg/mL	0.6-50.0 mcg/mL

Transferrin/Iron Binding	TRANB	**TRAN** 200-400 mg/dL **TIBC** 0-30 days: 94-236 mcg/dL 31-182 days: 89-311 mcg/dL 183-365 days: 138-365 mcg/dL 1-3 years: 184-377 mcg/dL 4-6 years: 162-352 mcg/dL 7-9 years: 167-336 mcg/dL 10-12 years: 198-383 mcg/dL 13-15 years: 169-358 mcg/dL 16-18 years: 194-372 mcg/dL 19+ years: 250-425 mcg/dL	**TRAN** 200-400 mg/dL **TIBC** 0-30 days: 94-232 mcg/dL 31-182 days: 116-322 mcg/dL 183-365 days: 176-384 mcg/dL 1-3 years: 204-382 mcg/dL 4-6 years: 180-390 mcg/dL 7-9 years: 183-369 mcg/dL 10-12 years: 173-356 mcg/dL 13-15 years: 193-377 mcg/dL 16-18 years: 174-351 mcg/dL 19+ years: 250-425 mcg/dL			Clinical Guide to Laboratory Tests, Tietz, 1995; Pediatric Reference Ranges, Soldin, 1999	See individual analytes	See individual analytes
Triglyceride	TRIG	0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 39-140 mg/dL 12-13 years: 37-130 mg/dL 14-15 years: 38-135 mg/dL 16-19 years: 37-140 mg/dL 20+ years: <150 mg/dL	0-3 years: 27-125 mg/dL 4-6 years: 32-116 mg/dL 7-9 years: 28-129 mg/dL 10-11 years: 24-137 mg/dL 12-13 years: 24-145 mg/dL 14-15 years: 34-165 mg/dL 16-19 years: 34-140 mg/dL 20+ years: <150 mg/dL		Enzymatic colorimetric	National Cholesterol Education Project (NCEP) Adult Treatment Protocol (ATP- III) (Circulation, 2002;106:3143-3421)	10-1,000 mg/dL	10-10,000 mg/dL
Triglyceride Body Fluid	FTRIG			**Pleural:** Pleural triglycerides <50 mg/dL excludes a chylothorax. Pleural triglycerides >110mg/dL supports a diagnosis of a chylothorax. **Peritoneal/Ascites:** Peritoneal fluid triglyceride values greater than 110 mg/dL have been suggested for diagnosis of chylous ascites. Measurement may also be useful in distinguishing cirrhotic versus malignant origins. **Drainage:** The reference range has not been established for this fluid specimen. The fluid results should be compared with the concentration in serum/plasma or integrated into the clinical context for interpretation.	Enzymatic colorimetric	Pleural: Staats BA, et al. Mayo Clin Proc. 1980;55(11):700. Peritoneal: Jüngst D, et al. Hepatology. 1986;6(2):239.	10-1,000 mg/dL	10-10,000 mg/dL
TSH	TSH	0-18 years: 0.652-4.409 uIU/mL 19+ years: 0.550-4.780 uIU/mL			The Atellica IM TSH3-UL assay is a third-generation assay that employs anti-FITC monoclonal antibody covalently bound to paramagnetic particles, an FITC-labeled anti-TSH capture mouse monoclonal antibody, and a tracer consisting of a proprietary acridinium ester and an anti-TSH mouse monoclonal antibody conjugated to bovine serum albumin (BSA) for chemiluminescent detection.	Atellica IM TSH3-UL Package Insert 11202198_EN Rev. 04-2021-03.	0.008-150.000 uIU/mL	0.008-150.000 uIU/mL
TSH w/ FT4 Reflex	TSHQR	0-18 years: 0.652-4.409 uIU/mL 19+ years: 0.550-4.780 uIU/mL			The Atellica IM TSH3-UL assay is a third-generation assay that employs anti-FITC monoclonal antibody covalently bound to paramagnetic particles, an FITC-labeled anti-TSH capture mouse monoclonal antibody, and a tracer consisting of a proprietary acridinium ester and an anti-TSH mouse monoclonal antibody conjugated to bovine serum albumin (BSA) for chemiluminescent detection.	See individual analytes	See individual analytes	See individual analytes
Urea Nitrogen, 24 HR Urine	UREA	10.0-20.0 g/24 hrs			Photometric rate	Clinical Guide to Laboratory Tests, Tietz, 1995		
Uric Acid	URIC	0-30 days: 1.0-4.6 mg/dL 31-365 days: 1.1-5.4 mg/dL 1-3 years: 1.8-5.0 mg/dL 4-6 years: 2.0-5.1 mg/dL 7-9 years: 1.8-5.5 mg/dL 10-12 years: 2.5-5.9 mg/dL 13-15 years: 2.2-6.4 mg/dL 16-18 years: 2.4-6.6 mg/dL 19+ years: 2.8-6.0 mg/dL	0-30 days: 1.2-3.9 mg/dL 31-365 days: 1.2-5.6 mg/dL 1-3 years: 2.1-5.6 mg/dL 4-6 years: 1.8-5.5 mg/dL 7-9 years: 1.8-5.4 mg/dL 10-12 years: 2.2-5.8 mg/dL 13-15 years: 3.1-7.0 mg/dL 16-18 years: 2.1-7.6 mg/dL 19+ years: 3.5-7.0 mg/dL		Enzymatic colorimetric	OSUWMC Reference Range Study effective 12.11.2013; verified by OSUWMC Reference Interval Study 2021. Pediatric Reference Ranges, Soldin, 1999.	1.5-30.0 mg/dL	1.5-60.0 mg/dL
Uric Acid (Special Handling)	URICSH	0-30 days: 1.0-4.6 mg/dL 31-365 days: 1.1-5.4 mg/dL 1-3 years: 1.8-5.0 mg/dL 4-6 years: 2.0-5.1 mg/dL 7-9 years: 1.8-5.5 mg/dL 10-12 years: 2.5-5.9 mg/dL 13-15 years: 2.2-6.4 mg/dL 16-18 years: 2.4-6.6 mg/dL 19+ years: 2.8-6.0 mg/dL	0-30 days: 1.2-3.9 mg/dL 31-365 days: 1.2-5.6 mg/dL 1-3 years: 2.1-5.6 mg/dL 4-6 years: 1.8-5.5 mg/dL 7-9 years: 1.8-5.4 mg/dL 10-12 years: 2.2-5.8 mg/dL 13-15 years: 3.1-7.0 mg/dL 16-18 years: 2.1-7.6 mg/dL 19+ years: 3.5-7.0 mg/dL		Enzymatic colorimetric	OSUWMC Reference Range Study effective 12.11.2013; Pediatric Reference Ranges, Soldin, 1999.	1.5-30.0 mg/dL	1.5-60.0 mg/dL
Uric Acid, 24HR	URIC	0.3-0.8 g/24 hrs			Enzymatic colorimetric	Clinical Guide to Laboratory Tests, Tietz, 1995		
Uric Acid, Random, Urine	URICR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Enzymatic colorimetric		1.0-100.0 mg/dL	1.0-300.0 mg/dL
Urine Protein/Creat Ratio, Random	UPCR				**UCRE** Kinetic Jaffe **UPRO** Colorimetric with Pyrogallol red	See individual analytes	See individual analytes	See individual analytes
Urine Protein/Creat Ratio, 24HR	UPCR24	**UCRE** 0-2 years: 0.70-2.00 g/24 hrs 3-8 years: 0.11-0.68 g/24 hrs 9-12 years: 0.17-1.41 g/24 hrs 13-17 years: 0.29-1.87 g/24 hrs 18+ years: 0.60-1.80 g/24 hrs **UPRO** 40-225 mg/24 hrs	**UCRE** 0-2 years: 0.70-2.00 g/24 hrs 3-8 years: 0.11-0.68 g/24 hrs 9-12 years: 0.17-1.41 g/24 hrs 13-17 years: 0.29-1.87 g/24 hrs 18+ years: 0.80-2.00 g/24 hrs **UPRO** 40-225 mg/24 hrs		**UCRE** Kinetic Jaffe **UPRO** Colorimetric with Pyrogallol red	See individual analytes	See individual analytes	See individual analytes
Urine Urea Nitrogen - Random	UREAR			The reference range has not been established for random urine specimens. The test result should be integrated into the clinical context for interpretation.	Photometric rate	Clinical Guide to Laboratory Tests, Tietz, 1995	20-1,300 mg/dL	20-13,000 mg/dL
Vancomycin Level, Continuous Infusion	VANCI	20.0-25.0 mcg/mL			Serum or plasma is mixed with Reagent 1, which contains vancomycin labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Subsequently, Reagent 2, which contains antibodies to vancomycin and the coenzyme nicotinamide adenine dinucleotide (NAD), is added. Vancomycin in the sample and vancomycin-labeled G6PDH compete for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the vancomycin concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting in an absorbance change that is measured spectrophotometrically.	American Journal of Health-System Pharmacy, Volume 77, Issue 11, 1 June 2020, Pages 835-864	2.0-50.0 mcg/mL	□ 2.0-250.0 mcg/mL
Vancomycin Level, Random	VANCO	Peak: 20.0-40.0 mcg/mL Trough: 10.0-20.0 mcg/mL			Serum or plasma is mixed with Reagent 1, which contains vancomycin labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Subsequently, Reagent 2, which contains antibodies to vancomycin and the coenzyme nicotinamide adenine dinucleotide (NAD), is added. Vancomycin in the sample and vancomycin-labeled G6PDH compete for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the vancomycin concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001 Clinical Pharmacotherapy, 1995; 15:85-91	2.0-50.0 mcg/mL	2.0-250.0 mcg/mL

Vancomycin Level, Trough (Pre Drug Level)	VANCTR	Therapeutic Range: 10.0-20.0 mcg/mL		Serum or plasma is mixed with Reagent 1, which contains vancomycin labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Subsequently, Reagent 2, which contains antibodies to vancomycin and the coenzyme nicotinamide adenine dinucleotide (NAD), is added. Vancomycin in the sample and vancomycin-labeled G6PDH compete for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the vancomycin concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001 Clinical Pharmacotherapy, 1995; 15:85-91	2.0-50.0 mcg/mL	2.0-250.0 mcg/mL
Vancomycin, Peak (Post Drug Level)	VANCPK	Therapeutic Range: 20.0-40.0 mcg/mL		Serum or plasma is mixed with Reagent 1, which contains vancomycin labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH). Subsequently, Reagent 2, which contains antibodies to vancomycin and the coenzyme nicotinamide adenine dinucleotide (NAD), is added. Vancomycin in the sample and vancomycin-labeled G6PDH compete for antibody binding sites. Enzyme activity decreases upon binding to the antibody, so the vancomycin concentration in the sample can be measured in terms of enzyme activity. Active enzyme converts oxidized NAD to NADH, resulting in an absorbance change that is measured spectrophotometrically.	Applied Clinical Pharmacokinetics, 2001 Clinical Pharmacotherapy, 1995; 15:85-91	2.0-50.0 mcg/mL	2.0-250.0 mcg/mL
Vitamin B12	B12B	0-4 years: ≥213 pg/mL 5-9 years: 343-1,184 pg/mL 10-14 years: 298-955 pg/mL		Competitive immunoassay using direct chemiluminescent technology.	Atellica IM Vitamin B12 Package Insert 10995437_EN Rev. 02-2019-08; Pediatric Reference Ranges, Soldin, 1999	45-2,000 pg/mL	45-20,000 pg/mL
Acanthocytes	PACANTH			Manual			
Bone Marrow, Biasic (ASP, BX, FE)	BMASP			Manual			
CBC, EDIF, Platelet	CBC.EDIFF	See HEM3 and INPT209		The Sysmex XN performs hematology analysis according to the hydrodynamic focusing (DC detection), flow cytometry method (semiconductor laser), and sodium lauryl sulfate (SLS)-hemoglobin method.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Interval*s. 7th ed., AACC Press, 2011.	See HEM3 and INPT209	See HEM3 and INPT209
CBC, Platelets		**WBC** 0-14 days: 8.16-14.56 K/uL 15-30 days: 8.36-14.42 K/uL 31-60 days: 7.05-14.68 K/uL 61-179 days: 6.00-13.25 K/uL 180 days-2 years: 6.48-13.02 K/uL 2-5 years: 4.86-13.18 K/uL 6-11 years: 4.27-11.40 K/uL 12-17 years: 4.19-9.43 K/uL 18+ years: 3.99-11.19 K/uL **RBC** 0-14 days: 4.12-5.74 M/uL 15-30 days: 3.32-4.80 M/uL 31-60 days: 2.93-3.87 M/uL 61-179 days: 3.45-4.75 M/uL 180 days-2 years: 3.97-5.01 M/uL 2-5 years: 3.84-4.92 M/uL 6-11 years: 3.90-4.96 M/uL 12-17 years: 3.93-4.90 M/uL 18+ years: 3.91-5.04 M/uL **HGB** 0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180 days-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL **HCT** 0-14 days: 39.6-57.2 % 15-30 days: 32.0-44.5 % 31-60 days: 27.7-35.1 % 61-179 days: 29.5-37.1 % 180 days-2 years: 30.9-37.9 % 2-5 years: 31.2-37.8 % 6-11 years: 32.4-39.5 % 12-17 years: 33.4-40.4 % 18+ years: 34.9-44.3 % **MCV** 0-14 days: 92.7-106.4 fL 15-30 days: 90.1-103.0 fL 31-60 days: 83.4-96.4 fL 61-179 days: 74.8-88.3 fL 180 days-2 years: 71.3-82.6 fL 2-5 years: 72.3-85.0 fL 6-11 years: 75.9-87.6 fL 12-17 years: 76.9-90.6 fL 18+ years: 79.6-97.7 fL	**WBC** 0-14 days: 8.04-15.40 K/uL 15-30 days: 7.80-15.91 K/uL 31-60 days: 8.14-14.99 K/uL 61-179 days: 6.51-13.32 K/uL 180 days-2 years: 5.98-13.51 K/uL 2-5 years: 5.14-13.38 K/uL 6-11 years: 4.31-11.00 K/uL 12-17 years: 3.84-9.84 K/uL 18+ years: 3.73-10.10 K/uL **RBC** 0-14 days: 4.10-5.55 M/uL 15-30 days: 3.16-4.63 M/uL 31-60 days: 3.02-4.22 M/uL 61-179 days: 3.43-4.80 M/uL 180 days-2 years: 4.03-5.07 M/uL 2-5 years: 3.89-4.97 M/uL 6-11 years: 3.96-5.03 M/uL 12-17 years: 4.03-5.29 M/uL 18+ years: 4.38-5.83 M/uL **HGB** 0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180 days-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL **HCT** 0-14 days: 39.8-53.6 % 15-30 days: 30.5-45.0 % 31-60 days: 26.8-37.5 % 61-179 days: 28.6-37.2 % 180 days-2 years: 30.8-37.8 % 2-5 years: 31.0-37.7 % 6-11 years: 32.2-39.8 % 12-17 years: 33.9-43.5 % 18+ years: 39.6-48.8 % **MCV** 0-14 days: 91.3-103.1 fL 15-30 days: 89.4-99.7 fL 31-60 days: 84.3-94.2 fL 61-179 days: 74.1-87.5 fL 180 days-2 years: 69.5-81.7 fL 2-5 years: 71.3-84.0 fL 6-11 years: 74.4-86.1 fL 12-17 years: 76.7-89.2 fL 18+ years: 79.0-94.5 fL	The Sysmex XN performs hematology analysis according to the hydrodynamic focusing (DC detection), flow cytometry method	OSU Internal Normal Range Study, October 2018	WBC: 0.30-440.00 K/uL RBC: 0.05-8.60 M/uL HGB: See individual analyte	WBC: 0.30 K/uL-dilute to endpoint RBC: 0.05 M/uL-dilute to endpoint HGB: See individual analyte

[redacted]	CBCP	**MCH** 0-14 days: 31.1-35.9 pg 15-30 days: 30.4-35.3 pg 31-60 days: 28.0-32.5 pg 61-179 days: 24.4-29.5 pg 180 days-2 years: 23.2-27.5 pg 2-5 years: 23.7-28.6 pg 6-11 years: 24.8-29.5 pg 12-17 years: 24.8-30.2 pg 18+ years: 25.9-33.9 pg **MCHC** 0-14 days: 33.4-35.4 g/dL 15-30 days: 33.2-35.0 g/dL 31-60 days: 32.5-34.9 g/dL 61-179 days: 32.1-34.4 g/dL 180 days-2 years: 31.9-34.2 g/dL 2-5 years: 31.8-34.6 g/dL 6-11 years: 31.8-34.6 g/dL 12-17 years: 31.5-34.2 g/dL 18+ years: 31.4-35.9 g/dL **RDW** 0-14 days: 14.6-17.3 % 15-30 days: 14.4-16.2 % 31-60 days: 13.6-15.8 % 61-179 days: 12.2-14.3 % 180 days-2 years: 12.7-15.1 % 2-5 years: 12.4-14.9 % 6-11 years: 12.2-14.4 % 12-17 years: 12.3-14.6 % 18+ years: 10.8-14.9 % **PLT** 0-14 days: 144-449 K/uL 15-30 days: 279-571 K/uL 31-60 days: 331-597 K/uL 61-179 days: 247-580 K/uL 180 days-2 years: 214-459 K/uL 2-5 years: 189-394 K/uL 6-11 years: 199-367 K/uL 12-17 years: 194-345 K/uL 18+ years: 150-393 K/uL **MPV** 0-14 days: 10.4-12.0 fL 15-30 days: 10.0-12.2 fL 31-60 days: 9.4-11.1 fL 61-179 days: 9.0-10.9 fL 180 days-2 years: 8.8-10.6 fL 2-5 years: 8.9-11.0 fL 6-11 years: 9.3-11.3 fL 12-17 years: 9.6-11.7 fL 18+ years: 8.5-12.2 fL	**MCH** 0-14 days: 31.3-35.6 pg 15-30 days: 29.9-34.1 pg 31-60 days: 27.8-32.0 pg 61-179 days: 24.4-28.9 pg 180 days-2 years: 22.7-27.2 pg 2-5 years: 23.7-28.3 pg 6-11 years: 24.9-29.2 pg 12-17 years: 25.2-30.2 pg 18+ years: 26.1-33.3 pg **MCHC** 0-14 days: 33.0-35.7 g/dL 15-30 days: 32.7-35.1 g/dL 31-60 days: 32.3-34.8 g/dL 61-179 days: 31.9-34.4 g/dL 180 days-2 years: 31.6-34.4 g/dL 2-5 years: 32.0-34.7 g/dL 6-11 years: 32.2-34.9 g/dL 12-17 years: 31.8-34.8 g/dL 18+ years: 31.9-36.5 g/dL **RDW** 0-14 days: 14.8-17.0 % 15-30 days: 14.3-16.8 % 31-60 days: 13.8-16.1 % 61-179 days: 12.4-15.3 % 180 days-2 years: 12.9-15.6 % 2-5 years: 12.5-14.9 % 6-11 years: 12.3-14.1 % 12-17 years: 12.4-14.5 % 18+ years: 10.9-14.3 % **PLT** 0-14 days: 218-419 K/uL 15-30 days: 248-586 K/uL 31-60 days: 229-562 K/uL 61-179 days: 244-529 K/uL 180 days-2 years: 206-445 K/uL 2-5 years: 202-403 K/uL 6-11 years: 206-369 K/uL 12-17 years: 175-332 K/uL 18+ years: 146-337 K/uL **MPV** 0-14 days: 10.2-11.9 fL 15-30 days: 10.1-12.1 fL 31-60 days: 9.2-10.8 fL 61-179 days: 8.9-10.6 fL 180 days-2 years: 8.7-10.5 fL 2-5 years: 9.0-10.9 fL 6-11 years: 9.2-11.4 fL 12-17 years: 9.6-11.8 fL 18+ years: 8.7-12.3 fL		(semiconductor laser), and sodium lauryl sulfate (SLS)-hemoglobin method.	Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	HCT: See individual analyte PLT: See individual analyte	HCT: See individual analyte PLT: See individual analyte
Clumped Platelet, Citrated Draw	CITPLT	0-14 days: 144-449 K/uL 15-30 days: 279-571 K/uL 31-60 days: 331-597 K/uL 61-179 days: 247-580 K/uL 180 days-2 years: 214-459 K/uL 2-5 years: 189-394 K/uL 6-11 years: 199-367 K/uL 12-17 years: 194-345 K/uL 18+ years: 150-393 K/uL	0-14 days: 218-419 K/uL 15-30 days: 248-586 K/uL 31-60 days: 229-562 K/uL 61-179 days: 244-529 K/uL 180 days-2 years: 206-445 K/uL 2-5 years: 202-403 K/uL 6-11 years: 206-369 K/uL 12-17 years: 175-332 K/uL 18+ years: 146-337 K/uL		Electronic resistance detection and flow cytometry.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	5-5,000 K/uL	≥5 K/uL
Electronic Diff		**NRBC** 0-3 days: 0.1-8.3 /100 WBC 4 days – 17 years: ≤0.0 /100 WBC 18+ years: ≤0.2 /100 WBC **SEG+BANDABS** 0-14 days: 1.73-6.75 K/uL 15-30 days: 1.23-4.80 K/uL 31-60 days: 1.00-4.68 K/uL 61-179 days: 1.04-7.20 K/uL 180 days-2 years: 1.27-7.18 K/uL 2-5 years: 1.60-8.29 K/uL 6-11 years: 1.64-7.87 K/uL 12-17 years: 1.82-7.47 K/uL 18+ years: 1.64-7.28 K/uL **LYMPHABS** 0-14 days: 1.75-8.00 K/uL 15-30 days: 2.42-8.20 K/uL 31-60 days: 2.29-9.14 K/uL 61-179 days: 2.14-8.99 K/uL 180 days-2 years: 1.52-8.09 K/uL 2-5 years: 1.25-5.77 K/uL 6-11 years: 1.16-4.28 K/uL 12-17 years: 1.16-3.33 K/uL 18+ years: 1.16-3.51 K/uL **MONOABS** 0-14 days: 0.57-1.72 K/uL 15-30 days: 0.42-1.21 K/uL 31-60 days: 0.28-1.21 K/uL 61-179 days: 0.24-1.17 K/uL 180 days-2 years: 0.26-1.08 K/uL 2-5 years: 0.24-0.92 K/uL 6-11 years: 0.19-0.81 K/uL 12-17 years: 0.19-0.72 K/uL 18+ years: 0.22-0.87 K/uL **EOSABS** 0-14 days: 0.09-0.64 K/uL 15-30 days: 0.06-0.75 K/uL 31-60 days: 0.04-0.63 K/uL 61-179 days: 0.02-0.74 K/uL 180 days-2 years: 0.02-0.58 K/uL 2-5 years: 0.03-0.46 K/uL 6-11 years: 0.03-0.47 K/uL 12-17 years: 0.02-0.32 K/uL 18+ years: 0.00-0.42 K/uL	**NRBC** 0-3 days: 0.1-8.3 /100 WBC 4 days – 17 years: ≤0.0 /100 WBC 18+ years: ≤0.2 /100 WBC **SEG+BANDABS** 0-14 days: 1.60-6.06 K/uL 15-30 days: 1.18-5.45 K/uL 31-60 days: 0.83-4.23 K/uL 61-179 days: 0.97-5.45 K/uL 180 days-2 years: 1.19-7.21 K/uL 2-5 years: 1.54-7.92 K/uL 6-11 years: 1.63-7.55 K/uL 12-17 years: 1.54-7.04 K/uL 18+ years: 1.57-6.19 K/uL **LYMPHABS** 0-14 days: 2.07-7.53 K/uL 15-30 days: 2.11-8.38 K/uL 31-60 days: 2.47-7.95 K/uL 61-179 days: 2.45-8.89 K/uL 180 days-2 years: 1.56-7.83 K/uL 2-5 years: 1.13-5.52 K/uL 6-11 years: 0.97-3.96 K/uL 12-17 years: 0.97-3.26 K/uL 18+ years: 0.83-3.57 K/uL **MONOABS** 0-14 days: 0.52-1.77 K/uL 15-30 days: 0.28-1.38 K/uL 31-60 days: 0.28-1.05 K/uL 61-179 days: 0.28-1.07 K/uL 180 days-2 years: 0.25-1.15 K/uL 2-5 years: 0.19-0.94 K/uL 6-11 years: 0.19-0.85 K/uL 12-17 years: 0.18-0.78 K/uL 18+ years: 0.24-0.93 K/uL **EOSABS** 0-14 days: 0.12-0.66 K/uL 15-30 days: 0.08-0.80 K/uL 31-60 days: 0.05-0.57 K/uL 61-179 days: 0.03-0.61 K/uL 180 days-2 years: 0.02-0.82 K/uL 2-5 years: 0.03-0.53 K/uL 6-11 years: 0.03-0.52 K/uL 12-17 years: 0.04-0.38 K/uL 18+ years: 0.00-0.48 K/uL		Flow cytometry	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	SEG+BANDS%: 0.0-100.0 % LYMPH%: 0.0-100.0 % MONO%: 0.0-100.0 % EOS%: 0.0-100.0 % BASO%: 0.0-100.0 % IGRE%: 0.0-100.0 % NRBC: 0.0-600.0 /100 WBC SEG+BANDABS: 0.04-440.00 K/uL LYMPHABS: 0.04-440.00 K/uL MONOABS: 0.04-440.00 K/uL EOSABS: 0.04-440.00 K/uL BASOABS: 0.04-440.00 K/uL IGREABS: 0.04-440.00 K/uL	SEG+BANDS%: 0.0-100.0 % LYMPH%: 0.0-100.0 % MONO%: 0.0-100.0 % EOS%: 0.0-100.0 % BASO%: 0.0-100.0 % IGRE%: 0.0-100.0 % NRBC: 0.0-600.0 /100 WBC SEG+BANDABS: ≥440.00 K/uL LYMPHABS: ≥440.00 K/uL MONOABS: ≥440.00 K/uL EOSABS: ≥440.00 K/uL BASOABS: ≥440.00 K/uL IGREABS: ≥440.00 K/uL

	CBC,EDIFF EDIFF	**BASOABS** 0-14 days: 0.02-0.07 K/uL 15-30 days: 0.01-0.06 K/uL 31-60 days: 0.01-0.05 K/uL 61-179 days: 0.01-0.07 K/uL 180 days-2 years: 0.01-0.06 K/uL 2-5 years: 0.01-0.06 K/uL 6-11 years: 0.01-0.05 K/uL 12-17 years: 0.01-0.05 K/uL 18+ years: 0.00-0.15 K/uL **IGREABS** 0-1 days: ≤0.28 K/uL 2-13 days: ≤0.27 K/uL 14-30 days: ≤0.22 K/uL 31-90 days: ≤0.09 K/uL 91-180 days: ≤0.06 K/uL 181 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.08 K/uL	**BASOABS** 0-14 days: 0.02-0.11 K/uL 15-30 days: 0.01-0.07 K/uL 31-60 days: 0.01-0.07 K/uL 61-179 days: 0.01-0.06 K/uL 180 days-2 years: 0.01-0.06 K/uL 2-5 years: 0.01-0.06 K/uL 6-11 years: 0.01-0.06 K/uL 12-17 years: 0.01-0.05 K/uL 18+ years: 0.00-0.09 K/uL **IGREABS** 0-1 days: ≤0.28 K/uL 2-13 days: ≤0.27 K/uL 14-30 days: ≤0.22 K/uL 31-90 days: ≤0.09 K/uL 91-180days: ≤0.06 K/uL 181 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.07 K/uL					
Extended Reticulocyte Panel	EXRETIC IRF RET-HE	**RETIC** 0-3 days: 3.47-5.40 % 4-30 days: 1.06-2.37 % 31-60 days: 2.12-3.47 % 61-179 days: 1.55-2.70 % 180 days-2 years: 0.99-1.82 % 2-5 years: 0.82-1.45 % 6-11 years: 0.98-1.94 % 12-17 years: 0.90-1.49 % 18+ years: 0.74-2.54 % **RETICABS** 0-3 days: 0.1475-0.2164 M/uL 4-30 days: 0.0513-0.1104 M/uL 31-60 days: 0.0518-0.0779 M/uL 61-179 days: 0.0482-0.0882 M/uL 180 days-2 years: 0.0435-0.1111 M/uL 2-5 years: 0.0364-0.0680 M/uL 6-11 years: 0.0424-0.0702 M/uL 12-17 years: 0.0416-0.0651 M/uL 18+ years: 0.0324-0.1142 M/uL **IRETF** 0-3 days: 30.5-35.1 % 4-30 days: 14.5-24.6 % 31-60 days: 19.1-28.9 % 61-179 days: 13.4-23.3 % 180 days-2 years: 11.4-25.8 % 2-5 years: 8.4-21.7 % 6-11 years: 8.9-24.1 % 12-17 years: 9.0-18.7 % 18+ years: 1.1-16.2 % **RETHE** 0-179 days: 29.2-37.5 pg 180 days-2 years: 30.1-35.7 pg 2-5 years: 29.3-37.3 pg 6-11 years: 30.4-39.7 pg 12-17 years: 29.9-38.4 pg 18+ years: 28.8-39.9 pg	**RETIC** 0-3 days: 3.47-5.40 % 4-30 days: 1.06-2.37 % 31-60 days: 2.12-3.47 % 61-179 days: 1.55-2.70 % 180 days-2 years: 0.99-1.82 % 2-5 years: 0.82-1.45 % 6-11 years: 0.98-1.94 % 12-17 years: 0.90-1.49 % 18+ years: 0.68-2.64 % **RETICABS** 0-3 days: 0.1475-0.2164 M/uL 4-30 days: 0.0513-0.1104 M/uL 31-60 days: 0.0518-0.0779 M/uL 61-179 days: 0.0482-0.0882 M/uL 180 days-2 years: 0.0435-0.1111 M/uL 2-5 years: 0.0364-0.0680 M/uL 6-11 years: 0.0424-0.0702 M/uL 12-17 years: 0.0416-0.0651 M/uL 18+ years: 0.0317-0.1377 M/uL **IRETF** 0-3 days: 30.5-35.1 % 4-30 days: 14.5-24.6 % 31-60 days: 19.1-28.9 % 61-179 days: 13.4-23.3 % 180 days-2 years: 11.4-25.8 % 2-5 years: 8.4-21.7 % 6-11 years: 8.9-24.1 % 12-17 years: 9.0-18.7 % 18+ years: 0.2-16.3 % **RETHE** 0-179 days: 27.6-38.7 pg 180 days-2 years: 28.7-35.7 pg 2-5 years: 27.7-37.8 pg 6-11 years: 32.4-37.6 pg 12-17 years: 30.3-40.4 pg 18+ years: 29.9-38.7 pg		Flow cytometry / calculation	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	RETIC: 0.25-30.00% RETICABS: XN: 0.0100-0.7200 XN-L: 0.0100-0.4576 Manual: 0.0100-2.5800 IRETF: 0.0-100.0 %	RETIC: 0.25-30.00 % RETICABS: 0.0100-2.5800 Manual: 0.0100-2.5800* IRETF: 0.0-100.0 % *Instrument may prompt diktion but final result should not exceed 2.5800
		See HEM3 and LAB296 **BLAST%** ≤0.0 % **LYMPHOMA%** ≤0.0 % **HAIRY%** ≤0.0 % **PLASMA%** ≤0.0 % **PROLYMPH%** ≤0.0 % **OTHER%** ≤0.0 % **NRBC** 0.0-0.2 /100 WBC **SEG+BANDABS** 0-14 days: 1.73-6.75 K/uL 15-30 days: 1.23-4.80 K/uL 31-60 days: 1.00-4.68 K/uL 61-179 days: 1.04-7.20 K/uL 180 days-2 years: 1.27-7.18 K/uL 2-5 years: 1.60-8.29 K/uL 6-11 years: 1.64-7.87 K/uL 12-17 years: 1.82-7.47 K/uL 18+ years: 1.64-7.28 K/uL **LYMPHABS** 0-14 days: 1.75-8.00 K/uL 15-30 days: 2.42-8.20 K/uL 31-60 days: 2.29-9.14 K/uL 61-179 days: 2.14-8.99 K/uL 180 days-2 years: 1.52-8.09 K/uL 2-5 years: 1.25-5.77 K/uL 6-11 years: 1.16-4.28 K/uL 12-17 years: 1.16-3.33 K/uL 18+ years: 1.16-3.51 K/uL **MONOABS** 0-14 days: 0.57-1.72 K/uL 15-30 days: 0.42-1.21 K/uL 31-60 days: 0.28-1.21 K/uL 61-179 days: 0.24-1.17 K/uL 180 days-2 years: 0.26-1.08 K/uL 2-5 years: 0.24-0.92 K/uL	See HEM3 and LAB296 **BLAST%** ≤0.0 % **LYMPHOMA%** ≤0.0 % **HAIRY%** ≤0.0 % **PLASMA%** ≤0.0 % **PROLYMPH%** ≤0.0 % **OTHER%** ≤0.0 % **NRBC** 0.0-0.2 /100 WBC **SEG+BANDABS** 0-14 days: 1.60-6.06 K/uL 15-30 days: 1.18-5.45 K/uL 31-60 days: 0.83-4.23 K/uL 61-179 days: 0.97-5.45 K/uL 180 days-2 years: 1.19-7.21 K/uL 2-5 years: 1.54-7.92 K/uL 6-11 years: 1.63-7.55 K/uL 12-17 years: 1.54-7.04 K/uL 18+ years: 1.57-6.19 K/uL **LYMPHABS** 0-14 days: 2.07-7.53 K/uL 15-30 days: 2.11-8.38 K/uL 31-60 days: 2.47-7.95 K/uL 61-179 days: 2.45-8.89 K/uL 180 days-2 years: 1.56-7.83 K/uL 2-5 years: 1.13-5.52 K/uL 6-11 years: 0.97-3.96 K/uL 12-17 years: 0.97-3.26 K/uL 18+ years: 0.83-3.57 K/uL **MONOABS** 0-14 days: 0.52-1.77 K/uL 15-30 days: 0.28-1.38 K/uL 31-60 days: 0.28-1.05 K/uL 61-179 days: 0.28-1.07 K/uL 180 days-2 years: 0.25-1.15 K/uL 2-5 years: 0.19-0.94 K/uL			See HEM3 and LAB296 BAND%: 0.0-100.0 %	See HEM3 and LAB296 BAND%: 0.0-100.0 % SEG%: 0.0-100.0 % LYMPH%: 0.0-100.0 % MONO%: 0.0-100.0 % EOS%: 0.0-100.0 % BASO%: 0.0-100.0 % META%: 0.0-100.0 % MYELO%: 0.0-100.0 %

Fetal (Pre) CBC, DIFF, Retic	CBCMDC	6-11 years: 0.19-0.81 K/uL 12-17 years: 0.19-0.72 K/uL 18+ years: 0.22-0.87 K/uL **EOSABS** 0-14 days: 0.09-0.64 K/uL 15-30 days: 0.06-0.75 K/uL 31-60 days: 0.04-0.63 K/uL 61-179 days: 0.02-0.74 K/uL 180 days-2 years: 0.02-0.58 K/uL 2-5 years: 0.03-0.46 K/uL 6-11 years: 0.03-0.47 K/uL 12-17 years: 0.02-0.32 K/uL 18+ years: 0.00-0.42 K/uL **BASOABS** 0-14 days: 0.02-0.07 K/uL 15-30 days: 0.01-0.06 K/uL 31-60 days: 0.01-0.05 K/uL 61-179 days: 0.01-0.07 K/uL 180 days-2 years: 0.01-0.06 K/uL 2-5 years: 0.01-0.06 K/uL 6-11 years: 0.01-0.05 K/uL 12-17 years: 0.01-0.05 K/uL 18+ years: 0.00-0.15 K/uL **METAABS** 0-1 days: ≤0.28 K/uL 2-12 days: ≤0.27 K/uL 13-29 days: ≤0.22 K/uL 30-89 days: ≤0.09 K/uL 90-179 days: ≤0.06 K/uL 180 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.08 K/uL **MYELOABS** 0-1 days: ≤0.28 K/uL 2-12 days: ≤0.27 K/uL 13-29 days: ≤0.22 K/uL 30-89 days: ≤0.09 K/uL 90-179 days: ≤0.06 K/uL 180 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.08 K/uL **PROMYELOABS** 0-1 days: ≤0.28 K/uL 2-12 days: ≤0.27 K/uL 13-29 days: ≤0.22 K/uL 30-89 days: ≤0.09 K/uL 90-179 days: ≤0.06 K/uL 180 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.08 K/uL **BLASTABS** ≤0.00 K/uL **LYMPHOMAABS** ≤0.00 K/uL **HAIRYABS** ≤0.00 K/uL **PLASMAABS** ≤0.00 K/uL **PROLYMPHABS** ≤0.00 K/uL **OTHERABS**	6-11 years: 0.19-0.85 K/uL 12-17 years: 0.18-0.78 K/uL 18+ years: 0.24-0.93 K/uL **EOSABS** 0-14 days: 0.12-0.66 K/uL 15-30 days: 0.08-0.80 K/uL 31-60 days: 0.05-0.57 K/uL 61-179 days: 0.03-0.61 K/uL 180 days-2 years: 0.02-0.82 K/uL 2-5 years: 0.03-0.53 K/uL 6-11 years: 0.03-0.52 K/uL 12-17 years: 0.04-0.38 K/uL 18+ years: 0.00-0.48 K/uL **BASOABS** 0-14 days: 0.02-0.11 K/uL 15-30 days: 0.01-0.07 K/uL 31-60 days: 0.01-0.07 K/uL 61-179 days: 0.01-0.06 K/uL 180 days-2 years: 0.01-0.06 K/uL 2-5 years: 0.01-0.06 K/uL 6-11 years: 0.01-0.06 K/uL 12-17 years: 0.01-0.05 K/uL 18+ years: 0.00-0.09 K/uL **METAABS** 0-1 days: ≤0.28 K/uL 2-12 days: ≤0.27 K/uL 13-29 days: ≤0.22 K/uL 30-89 days: ≤0.09 K/uL 90-179 days: ≤0.06 K/uL 180 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.07 K/uL **MYELOABS** 0-1 days: ≤0.28 K/uL 2-12 days: ≤0.27 K/uL 13-29 days: ≤0.22 K/uL 30-89 days: ≤0.09 K/uL 90-179 days: ≤0.06 K/uL 180 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.07 K/uL **PROMYELOABS** 0-1 days: ≤0.28 K/uL 2-12 days: ≤0.27 K/uL 13-29 days: ≤0.22 K/uL 30-89 days: ≤0.09 K/uL 90-179 days: ≤0.06 K/uL 180 days-2 years: ≤0.14 K/uL 2-5 years: ≤0.06 K/uL 6-11 years: ≤0.04 K/uL 12-17 years: ≤0.04 K/uL 18+ years: ≤0.07 K/uL **BLASTABS** ≤0.00 K/uL **LYMPHOMAABS** ≤0.00 K/uL **HAIRYABS** ≤0.00 K/uL **PLASMAABS** ≤0.00 K/uL **PROLYMPHABS** ≤0.00 K/uL **OTHERABS**		The Sysmex XN performs hematology analysis according to the hydrodynamic focusing (DC detection), flow cytometry method (semiconductor laser), and sodium lauryl sulfate (SLS)-hemoglobin method.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	SEG%: 0.0-100.0 % LYMPH%: 0.0-100.0 % MONO%: 0.0-100.0 % EOS%: 0.0-100.0 % BASO%: 0.0-100.0 % META%: 0.0-100.0 % MYELO%: 0.0-100.0 % PROMYELO%: 0.0-100.0 % BLAST%: 0.0-100.0 % LYMPHOMA%: 0.0-100.0 % HAIRY%: 0.0-100.0 % PLASMA%: 0.0-100.0 % PROLYMPH%: 0.0-100.0 % OTHER%: 0.0-100.0 % SEG+BANDABS: 0.00-440.00 K/uL LYMPHABS: 0.00-440.00 K/uL MONOABS: 0.00-440.00 K/uL EOSABS: 0.00-440.00 K/uL BASOABS: 0.00-440.00 K/uL METAABS: 0.00-440.00 K/uL MYELOABS: 0.00-440.00 K/uL PROMYELOABS: 0.00-440.00 K/uL BLASTABS: 0.00-440.00 K/uL LYMPHOMAABS: 0.00-440.00 K/uL HAIRYABS: 0.00-440.00 K/uL PLASMAABS: 0.00-440.00 K/uL PROLYMPHABS: 0.00-440.00 K/uL OTHERABS: 0.00-440.00 K/uL	PROMYELO%: 0.0-100.0 % BLAST%: 0.0-100.0 % LYMPHOMA%: 0.0-100.0 % HAIRY%: 0.0-100.0 % PLASMA%: 0.0-100.0 % PROLYMPH%: 0.0-100.0 % OTHER%: 0.0-100.0 % SEG+BANDABS: ≥0.00 L/uL LYMPHABS: ≥0.00 L/uL MONOABS: ≥0.00 L/uL EOSABS: ≥0.00 L/uL BASOABS: ≥0.00 L/uL METAABS: ≥0.00 L/uL MYELOABS: ≥0.00 L/uL PROMYELOABS: ≥0.00 L/uL BLASTABS: ≥0.00 L/uL LYMPHOMAABS: ≥0.00 L/uL HAIRYABS: ≥0.00 L/uL PLASMAABS: ≥0.00 L/uL PROLYMPHABS: ≥0.00 L/uL OTHERABS: ≥0.00 L/uL SCHISTO: 1+, 2+, 3+ POLY: 1+, 2+, 3+ SICKLE: 1+, 2+, 3+ SPHEROCYTES: 1+, 2+, 3+ ACANTHO: Present ECHINO: Present OVALO: Present TARGET: Present TEAR: Present HJBODIES: Present ROULEAUX: Present AGGLUT: Present PLTCLUMP: Present GIANT: Present SATELLITISM: Present
Hematocrit	HCT	0-14 days: 39.6-57.2 % 15-30 days: 32.0-44.5 % 31-60 days: 27.7-35.1 % 61-179 days: 29.5-37.1 % 180 days-2 years: 30.9-37.9 % 2-5 years: 31.2-37.8 % 6-11 years: 32.4-39.5 % 12-17 years: 33.4-40.4 % 18+ years: 34.9-44.3 %	0-14 days: 39.8-53.6 % 15-30 days: 30.5-45.0 % 31-60 days: 26.8-37.5 % 61-179 days: 28.6-37.2 % 180 days-2 years: 30.8-37.8 % 2-5 years: 31.0-37.7 % 6-11 years: 32.2-39.8 % 12-17 years: 33.9-43.5 % 18+ years: 39.6-48.8 %		Cumulative pulse height detection.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	0.1-75.0 %	0.1 %-dilute to endpoint
Hemoglobin	HGB	0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180 days-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL	0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180 days-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL		Photometrically measured.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	0.2-26.0 g/dL	0.2 g/dL-dilute to endpoint
Hemoglobin & Hematocrit	HH	**HGB** 0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180 days-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL **HCT** 0-14 days: 39.6-57.2 % 15-30 days: 32.0-44.5 % 31-60 days: 27.7-35.1 % 61-179 days: 29.5-37.1 % 180 days-2 years: 30.9-37.9 % 2-5 years: 31.2-37.8 % 6-11 years: 32.4-39.5 % 12-17 years: 33.4-40.4 % 18+ years: 34.9-44.3 %	**HGB** 0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180 days-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL **HCT** 0-14 days: 39.8-53.6 % 15-30 days: 30.5-45.0 % 31-60 days: 26.8-37.5 % 61-179 days: 28.6-37.2 % 180 days-2 years: 30.8-37.8 % 2-5 years: 31.0-37.7 % 6-11 years: 32.2-39.8 % 12-17 years: 33.9-43.5 % 18+ years: 39.6-48.8 %		**HGB:** Photometrically measured. **HCT:** Cumulative pulse height detection.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	See individual analytes	See individual analytes

Immature Platelet Fraction	IPFPLT IPF	**IPF** 0-179 days: 1.3-6.8 % 180 days-2 years: 1.4-4.5 % 2-5 years: 1.0-3.6 % 6-11 years: 1.0-4.7 % 12-17 years: 1.4-6.4 % 18+ years: 0.0-8.6 % **PLTCIPF** 0-14 days: 144-449 K/uL 15-30 days: 279-571 K/uL 31-60 days: 331-597 K/uL 61-179 days: 247-580 K/uL 180 days-2 years: 214-459 K/uL 2-5 years: 189-394 K/uL 6-11 years: 199-367 K/uL 12-17 years: 194-345 K/uL 18+ years: 150-393 K/uL	**IPF** 0-179 days: 2.0-6.8 % 180 days-2 years: 1.4-3.8 % 2-5 years: 1.1-3.6 % 6-11 years: 1.0-4.9 % 12-17 years: 1.6-6.1 % 18+ years: 0.0-9.0 % **PLTCIPF** 0-14 days: 218-419 K/uL 15-30 days: 248-586 K/uL 31-60 days: 229-562 K/uL 61-179 days: 244-529 K/uL 180 days-2 years: 206-445 K/uL 2-5 years: 202-403 K/uL 6-11 years: 206-369 K/uL 12-17 years: 175-332 K/uL 18+ years: 146-337 K/uL		Calculation	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	IPF: 0.0-100.0 % PLTCIPF: 5-5,000 K/uL	IPF: 0.0-100.0 % PLTCIPF: 5 K/uL-dilute to endpoint
Malaria Prep	Parasite Screen ID Blood MPB				Giemsa stain			No parasitic organisms seen, including plasmodium organism Positive for Plasmodium species
Platelet Count	PLAT	**PLT** 0-14 days: 144-449 K/uL 15-30 days: 279-571 K/uL 31-60 days: 331-597 K/uL 61-179 days: 247-580 K/uL 180 days-2 years: 214-459 K/uL 2-5 years: 189-394 K/uL 6-11 years: 199-367 K/uL 12-17 years: 194-345 K/uL 18+ years: 150-393 K/uL **MPV** 0-14 days: 10.4-12.0 fL 15-30 days: 10.0-12.2 fL 31-60 days: 9.4-11.1 fL 61-179 days: 9.0-10.9 fL 180 days-2 years: 8.8-10.6 fL 2-5 years: 8.9-11.0 fL 6-11 years: 9.3-11.3 fL 12-17 years: 9.6-11.7 fL 18+ years: 8.5-12.2 fL	**PLT** 0-14 days: 218-419 K/uL 15-30 days: 248-586 K/uL 31-60 days: 229-562 K/uL 61-179 days: 244-529 K/uL 180 days-2 years: 206-445 K/uL 2-5 years: 202-403 K/uL 6-11 years: 206-369 K/uL 12-17 years: 175-332 K/uL 18+ years: 146-337 K/uL **MPV** 0-14 days: 10.2-11.9 fL 15-30 days: 10.1-12.1 fL 31-60 days: 9.2-10.8 fL 61-179 days: 8.9-10.6 fL 180 days-2 years: 8.7-10.5 fL 2-5 years: 9.0-10.9 fL 6-11 years: 9.2-11.4 fL 12-17 years: 9.6-11.8 fL 18+ years: 8.7-12.3 fL		Electronic resistance detection and flow cytometry.	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	5-5,000 K/uL	5 K/uL-dilute to endpoint
Reticulocytes	RETIC	**RETIC** 0-3 days: 3.47-5.40 % 4-30 days: 1.06-2.37 % 31-60 days: 2.12-3.47 % 61-179 days: 1.55-2.70 % 180 days-2 years: 0.99-1.82 % 2-5 years: 0.82-1.45 % 6-11 years: 0.98-1.94 % 12-17 years: 0.90-1.49 % 18+ years: 0.74-2.54 % **RETICABS** 0-3 days: 0.1475-0.2164 M/uL 4-30 days: 0.0513-0.1104 M/uL 31-60 days: 0.0518-0.0779 M/uL 61-179 days: 0.0482-0.0882 M/uL 180 days-2 years: 0.0435-0.1111 M/uL 2-5 years: 0.0364-0.0680 M/uL 6-11 years: 0.0424-0.0702 M/uL 12-17 years: 0.0416-0.0651 M/uL 18+ years: 0.0324-0.1142 M/uL	**RETIC** 0-3 days: 3.47-5.40 % 4-30 days: 1.06-2.37 % 31-60 days: 2.12-3.47 % 61-179 days: 1.55-2.70 % 180 days-2 years: 0.99-1.82 % 2-5 years: 0.82-1.45 % 6-11 years: 0.98-1.94 % 12-17 years: 0.90-1.49 % 18+ years: 0.68-2.64 % **RETICABS** 0-3 days: 0.1475-0.2164 M/uL 4-30 days: 0.0513-0.1104 M/uL 31-60 days: 0.0518-0.0779 M/uL 61-179 days: 0.0482-0.0882 M/uL 180 days-2 years: 0.0435-0.1111 M/uL 2-5 years: 0.0364-0.0680 M/uL 6-11 years: 0.0424-0.0702 M/uL 12-17 years: 0.0416-0.0651 M/uL 18+ years: 0.0317-0.1377 M/uL		Flow cytometry	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	RETIC: 0.25-30.00% RETICABS: XN: 0.0100-0.7200 XN-L: 0.0100-0.4576 Manual: 0.0100-2.5800	RETIC: 0.25-30.00 % RETICABS: 0.0100-2.5800 Manual: 0.0100-2.5800* *Instrument may prompt dilution but final result should not exceed 2.5800
Schistocytes	PSCHISTO				Manual			
Sedimentation Rate, Automated	ESR	0-49 years: <20 mm/hr 50-84 years: <30 mm/hr 85+ years: <42 mm/hr	0-49 years: <15 mm/hr 50-84 years: <20 mm/hr 85+ years: <30 mm/hr		Westergren	McPherson, R.A., & Pinkus, M.R, (2017). *Henry's Clinical Diagnosis and Management by Laboratory Methods* (23rd ed.). St. Louis, MO: Elsevier Inc. pg. 532	1-140 mm/hr	1-140 mm/hr
White Blood Count	WBC	0-14 days: 8.16-14.56 K/uL 15-30 days: 8.36-14.42 K/uL 31-60 days: 7.05-14.68 K/uL 61-179 days: 6.00-13.25 K/uL 180 days-2 years: 6.48-13.02 K/uL 2-5 years: 4.86-13.18 K/uL 6-11 years: 4.27-11.40 K/uL 12-17 years: 4.19-9.43 K/uL 18+ years: 3.99-11.19 K/uL	0-14 days: 8.04-15.40 K/uL 15-30 days: 7.80-15.91 K/uL 31-60 days: 8.14-14.99 K/uL 61-179 days: 6.51-13.32 K/uL 180 days-2 years: 5.98-13.51 K/uL 2-5 years: 5.14-13.38 K/uL 6-11 years: 4.31-11.00 K/uL 12-17 years: 3.84-9.84 K/uL 18+ years: 3.73-10.10 K/uL		Flow cytometry	OSU Internal Normal Range Study, October 2018 Soldin, Steven J. *Pediatric Reference Intervals* . 7th ed., AACC Press, 2011.	0.30-440.00 K/uL	0.30 K/uL-dilute to endpoint
Body Fluid Cell Count	FCNT				Hemocytometer counts and Iris instrument.		TNC: 3-2,500 /uL RBC: 3-50,000 /uL	TNC: ≥3 /uL RBC: ≥3 /uL
Body Fluid Cell Count with Diff	FCNT FPDIFF Body fluid differential	**SFBLAST** 0% **SFMALIG** 0% **SFLYMPHOM** 0%			Hemocytometer counts, Iris instrument and manual differential.		TNC: 3-2,500 /uL RBC: 3-50,000 /uL FSEG: 0-100 % FLYM: 0-100 % FMOMAC: 0-100 % FMESO: 0-100 % FEOS: 0-100 % FBASO: 0-100 % FPLAS: 0-100 % FMALIG: 0-100 % FBLAS: 0-100 % FLPHOM: 0-100 % FSYNLC: 0-100 % FNRBC: 0-100 % FOTHR: 0-100 %	TNC: ≥3 /uL RBC: ≥3 /uL FSEG: 0-100 % FLYM: 0-100 % FMOMAC: 0-100 % FMESO: 0-100 % FEOS: 0-100 % FBASO: 0-100 % FPLAS: 0-100 % FMALIG: 0-100 % FBLAS: 0-100 % FLPHOM: 0-100 % FSYNLC: 0-100 % FNRBC: 0-100 % FOTHR: 0-100 %

Cell Count & Diff, CSF	CSFLC CSFDIF Spinal fluid cell count and body fluid differential	**SFWBC** 0-365 days: <31 /uL 1-4 years: <21 /uL 5+ years: <6 /uL **SFRBC** <3 /uL **SFSEG** 0-89 days: ≤8 % 90+ days: ≤6 % **SFLYM** 0-89 days: 35-50% 90+ days: 40-80 % **SFMOMA** 0-89 days: 50-90% 90+ days: 15-45 %		Hemocytometer counts, Iris instrument and manual differential.	*Body Fluids* 3rd ed. Kjeldsbreg, Knight 1993	SFWBC: 3-2,500 /uL SFRBC: 3-50,000 /uL SFSEG: 0-100 % SFLYM: 0-100 % SFMOMA: 0-100 % SFEOS: 0-100 % SFBAS: 0-100 % SFPLAS: 0-100 % SFMALIG: 0-100 % SFBLAS: 0-100 % SFLPHOM: 0-100 % SFNRBC: 0-100 % SFOTHR: 0-100 %	SGROS: Amber, Bloody, Brown, Colorless, Green, Orange, Pink, Red, Red-cell tinged, White, Xanthrochromic, Clear, Hazy, Opaque SSUPN: Amber, Bloody, Brown, Colorless, Green, Orange, Pink, Red, Red-cell tinged, White, Xanthrochromic, Clear, Hazy, Opaque SFWBC: ≥3 /uL SFRBC: ≥3 /uL SFSEG: 0-100 % SFLYM: 0-100 % SFMOMA: 0-100 % SFEOS: 0-100% SFBAS: 0-100 % SFPLAS: 0-100 % SFMALIG: 0-100 % SFBLAS: 0-100 % SFLPHOM: 0-100 % SFNRBC: 0-100 % SFOTHR: 0-100 %
Crystals, Fluid	FCRYS		Negative	Unstained synovial fluid slides reviewed by polarized microscopy.			Negative, Positive
CSF Fluid Count Only	CSFLC Spinal fluid cell count	**SFWBC** 0-365 days: <31 /uL 1-4 years: <21 /uL 5+ years: <6 /uL **SFRBC** <3 /uL		Hemocytometer counts and Iris instrument.	*Body Fluids* 3rd ed. Kjeldsbreg, Knight 1993	SFWBC: 3-2,500 /uL SFRBC: 3-50,000 /uL	CSFTUBENUM: CSF Tube 1, CSF Tube 2, CSF Tube 3, CSF Tube 4, No tube number indicated SGROS: Amber, Bloody, Brown, Colorless, Green, Orange, Pink, Red, Red-cell tinged, White, Xanthrochromic, Clear, Hazy, Opaque SSUPN: Amber, Bloody, Brown
Differential, Fluid	FPDIFF	**SFBLAST** 0% **SFMALIG** 0% **SFLYMPHOM** 0%		Microscopic evaluation of body fluid cells is performed by reviewing a Wright-stained body fluid cytospin slide using a brightfield microscope.		FSEG: 0-100 % FLYM: 0-100 % FMOMAC: 0-100 % FMESO: 0-100 % FEOS: 0-100 % FBASO: 0-100 % FPLAS: 0-100 % FMALIG: 0-100 % FBLAS: 0-100 % FLPHOM: 0-100 % FSYNLC: 0-100 % FNRBC: 0-100 % FOTHR: 0-100 %	FSEG: 0-100 % FLYM: 0-100 % FMOMAC: 0-100 % FMESO: 0-100 % FEOS: 0-100 % FBASO: 0-100 % FPLAS: 0-100 % FMALIG: 0-100 % FBLAS: 0-100 % FLPHOM: 0-100 % FSYNLC: 0-100 % FNRBC: 0-100 % FOTHR: 0-100 %
Hematocrit, Fluid	FHCT Fluid HCT Fluid PCV			Manual spun hematocrit.		5.0-60.0 %	5.0-60.0 %
Myoglobin Urine	MYO Urine myoglobin screen		Negative	The peroxidase-like activity of hemoglobin catalyzes the reaction of diisopropylbenzene dihydroperoxide and 3,3',5,5'-tetramethylbenzidine to produce a color from orange to green.	*Urinalysis and Body Fluid*, Ringsrud 1995		UBLD: Negative, Trace, Small, Moderate, Large MYO: Negative, Reflexed to Sendout
Occult Blood, Fecal Immunological	FIOB		Negative	Immunoassay utilizing rabbit polyclonal antibodies to detect presence of hemoglobin in feces.			Negative, Positive
Occult Blood, Gastric	OCBDG Gastrocult		Negative	Developing solution (stabilized mixture of hydrogen peroxide and denatured alcohol) creates a reaction between hemoglobin and guaiac to produce a blue color.			Negative, Positive
Occult Blood, Stool	OCBDF Occult blood Fecal hemoccult		Negative	Developing solution (stabilized mixture of hydrogen peroxide and denatured alcohol) creates a reaction between hemoglobin and guaiac to produce a blue color.			Negative, Positive
pH, Urine	UPH	5.0-7.0		Double indicator principle to cover the range of urinary pH range. Colors range from orange through yellow and green to blue.	*Urinalysis and Body Fluid*, Ringsrud 1995		MMMP: 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, ≥8.5, Unable to analyze due to interfering substance. SSCIC: 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, ≥8.5, Unable to analyze due to interfering substance. Unspecified: 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, ≥9.0, Unable to analyze due to interfering substance.
Specific Gravity, Urine	USG	1.001-1.035		Clinical Lab CCL: Fiber optic refractive index method. Clinical Lab University East: Fiber optic refractive index method. Clinical Lab James: Fiber optic refractive index method. All Performing Labs: pKa change of pretreated polyelectrolyte in relation to ionic concentration.	*Urinalysis and Body Fluid*, Ringsrud 1995	CCL: 1.001-1.045 RRL: 1.001-1.045 JAMES: 1.001-1.045 Unspecified: 1.005-1.030	CCL: 1.001-1.045 RRL: 1.001-1.045 JAMES: 1.001-1.045 Unspecified: 1.005-1.030
Synovasure PJI, Synovial Fluid	SYNOVA Synovasure Alpha Defensin Lateral Flow Test		Negative	Qualitative, visually read immunochromatographic assay for the detection of human host response proteins, Alpha Defensins 1-3, in the synovial fluid of adults with a total joint replacement who are being evaluated for revision surgery.			Negative, Positive
Urinalysis			**COLOR:** Yellow **APPEARANCE:** Clear **GLUCOSE:** Negative **KETONE:** Negative **SPECIFIC GRAVITY:** 1.001-1.035 **BLOOD:** Negative **PH:** 5.0, 5.5, 6.0, 6.5, 7.0 **PROTEIN:** Negative **UROBILINOGEN:** 0.2 E.U./dL, 1.0 E.U./dL **NITRITE:** Negative **LEUKOCYTE ESTERASE:** Negative **RBC:** 0-2 / HPF **WBC:** 0-5 /HPF	**DIPSTICK** Dry pad urine chemistry **SG**	Varies		COLOR: Yellow, Orange, Red, See Comment APPEAR: Clear, Cloudy, Turbid, Unable to analyze due to interfering substance. GLUCOSE: Negative, 100 mg/dL, 250 mg/dL, 500 mg/dL, ≥1000 mg/dL, Unable to analyze due to interfering substance. KETONE: Negative, Trace, 15 mg/dL = Small, 40 mg/dL = Moderate, ≥80 mg/dL = Large, Unable to analyze due to interfering substance. SPECIFIC GRAVITY: See individual analyte BLOOD: Negative, Trace, Small, Moderate, Large, Unable to analyze due to interfering substance. PH: See individual analyte PROTEIN: Negative, Trace, 30 mg/dL, 100 mg/dL, 300 mg/dL, ≥300 mg/dL, Unable to analyze due to interfering substance.

	URIN			**SQUAMOUS:** 0-2/hpf, 3-5/hpf = 1+ **BACTERIA:** Absent **RENAL TUBULAR CELLS:** 0-2/hpf **WBC CASTS:** Absent **WBC/RENAL TUBULAR CASTS:** Absent **RBC CASTS:** Absent **YEAST:** Absent **TRICHOMONAS:** Absent **LEUCINE:** Absent **TYROSINE:** Absent **CYSTINE:** Absent **TRIPLE PHOSPHATE:** Absent	Dry pad urine chemistry or optic refractive index method **URINE MICROSCOPIC** Automatic particle counter and/or manual microscopic			UROBILINOGEN: 0.2 E.U./dL, 1.0 E.U./dL, 2.0 E.U./dL, 4.0 E.U./dL, ≥8.0 E.U./dL, Unable to analyze due to interfering substance. NITRITE: Negative, Positive, Unable to analyze due to interfering substance. LEUKOCYTE ESTERASE: Negative, Trace, Small, Moderate, Large, Unable to analyze due to interfering substance. RBC: 0-2, 3-5, 6-10, 11-25, >25 /HPF WBC: 0-5, 6-10, 11-20, > 20 /HPF SQUAMOUS: 0-2/hpf, 3-5/hpf = 1+, 6-10/hpf = 2+, 11-20/hpf = 3+, >20/hpf = 4+ BACTERIA: Absent, Trace, Present RENAL TUBULAR CELLS: 0-2/hpf, 3-5/hpf = 1+, 6-10/hpf = 2+, 11-20/hpf = 3+, >20/hpf = 4+ AMORPHOUS: <25% = Slight, 26-50% = Moderate, >51% = Heavy HYALINE CASTS: 0-2, 3-5, 6-10, 11-20, >20 /LPF GRANULAR CASTS: 0-2, 3-5, 6-10, 11-
Urinalysis Reflex to Culture	URIN1			**COLOR:** Yellow **APPEARANCE:** Clear **GLUCOSE:** Negative **KETONE:** Negative **SPECIFIC GRAVITY:** 1.001-1.035 **BLOOD:** Negative **PH:** 5.0, 5.5, 6.0, 6.5, 7.0 **PROTEIN:** Negative **UROBILINOGEN:** 0.2 E.U./dL, 1.0 E.U./dL **NITRITE:** Negative **LEUKOCYTE ESTERASE:** Negative **RBC:** 0-2 / HPF **WBC:** 0-5 /HPF **SQUAMOUS:** 0-2/hpf, 3-5/hpf = 1+ **BACTERIA:** Absent **RENAL TUBULAR CELLS:** 0-2/hpf **WBC CASTS:** Absent **WBC/RENAL TUBULAR CASTS:** Absent **RBC CASTS:** Absent **YEAST:** Absent **TRICHOMONAS:** Absent **LEUCINE:** Absent **TYROSINE:** Absent **CYSTINE:** Absent **TRIPLE PHOSPHATE:** Absent	**DIPSTICK** Dry pad urine chemistry **SG** Dry pad urine chemistry or optic refractive index method **URINE MICROSCOPIC** Automatic particle counter and/or manual microscopic	Varies		See LAB347
Urine Dipstick with Reflex to Microscopy	UASR			**COLOR:** Yellow **APPEARANCE:** Clear **GLUCOSE:** Negative **KETONE:** Negative **SPECIFIC GRAVITY:** 1.001-1.035 **BLOOD:** Negative **PH:** 5.0, 5.5, 6.0, 6.5, 7.0 **PROTEIN:** Negative **UROBILINOGEN:** 0.2 E.U./dL, 1.0 E.U./dL **NITRITE:** Negative **LEUKOCYTE ESTERASE:** Negative	**DIPSTICK** Dry pad urine chemistry **SG** Dry pad urine chemistry or optic refractive index method	Varies		See URN11
Urine Dipstick; Reflex Microscopy; Reflex Culture	UASR1			**COLOR:** Yellow **APPEARANCE:** Clear **GLUCOSE:** Negative **KETONE:** Negative **SPECIFIC GRAVITY:** 1.001-1.035 **BLOOD:** Negative **PH:** 5.0, 5.5, 6.0, 6.5, 7.0 **PROTEIN:** Negative **UROBILINOGEN:** 0.2 E.U./dL, 1.0 E.U./dL **NITRITE:** Negative **LEUKOCYTE ESTERASE:** Negative	**DIPSTICK** Dry pad urine chemistry **SG** Dry pad urine chemistry or optic refractive index method	National guidelines and recommendations		See URN11

Urine Screen	UAS Urine dipstick			**COLOR:** Yellow **APPEARANCE:** Clear **GLUCOSE:** Negative **KETONE:** Negative **SPECIFIC GRAVITY:** 1.001-1.035 **BLOOD:** Negative **PH:** 5.0, 5.5, 6.0, 6.5, 7.0 **PROTEIN:** Negative **UROBILINOGEN:** 0.2 E.U./dL, 1.0 E.U./dL **NITRITE:** Negative **LEUKOCYTE ESTERASE:** Negative	**DIPSTICK** Dry pad urine chemistry **SG** Dry pad urine chemistry or optic refractive index method	Varies		COLOR: Yellow, Orange, Red, See Comment APPEAR: Clear, Cloudy, Turbid, Unable to analyze due to interfering substance. GLUCOSE: Negative, 100 mg/dL, 250 mg/dL, 500 mg/dL, ≥1000 mg/dL, Unable to analyze due to interfering substance. KETONE: Negative, Trace, 15 mg/dL = Small, 40 mg/dL = Moderate, ≥80 mg/dL = Large, Unable to analyze due to interfering substance. SPECIFIC GRAVITY: See individual analyte BLOOD: Negative, Trace, Small, Moderate, Large, Unable to analyze due to interfering substance. PH: See individual analyte PROTEIN: Negative, Trace, 30 mg/dL, 100 mg/dL, 300 mg/dL, ≥300 mg/dL, Unable to analyze due to interfering substance. UROBILINOGEN: 0.2 E.U./dL, 1.0 E.U./dL, 2.0 E.U./dL, 4.0 E.U./dL, ≥8.0 E.U./dL, Unable to analyze due to interfering substance. NITRITE: Negative, Positive, Unable to analyze due to interfering substance. LEUKOCYTE ESTERASE: Negative, Trace, Small, Moderate, Large, Unable to analyze due to interfering substance.
Anti Phospholipid Antibody	PLAB Anticardiolipin Antibodies IgG, IgM Antiphospholipid Antibodies IgG, IgM Cardiolipin Antibodies IgG, IgM Phospholipid Antibodies IgG, IgM	**PLABG** 0.0-20.0 CU **PLABM** 0.0-20.0 CU			Chemiluminescent two-step immunoassay.	Inova Quanta-Flash Package Insert	PLABG: 10.0-500.0 CU PLABM: 10.0-200.0 CU	PLABG: 10.0-10,000.0 CU PLABM: 10.0-4,000.0 CU
Anti Xa DOAC (Apixaban)	AXAPIX Eliquis			Therapeutic reference ranges have not been established. At steady state - median (5th-95th percentile) peak and trough levels have been observed in clinical trials: Peak Conc., ng/mL (a) — Trough Conc., ng/mL (b) VTE prevention after total hip replacement 2.5 mg twice daily: 77 (41-146) — 51 (23-109) Stroke and systemic embolism prevention in patients with AF 2.5 mg twice daily: 123 (69-221) — 79 (34-162) 5 mg twice daily: 171 (91-321) — 103 (41-230) Prevention and treatment of DVT and PE 2.5 mg twice daily: 67 (30-153) — 32 (11-90) 5 mg twice daily: 132 (59-302) — 63 (22-77) 10 mg twice daily: 251 (111-572) — 120 (41-335) (a) Defined as samples collected 2-4 hours after dosing (b) Defined as samples collected 10-12 hours after dosing AF-atrial fibrillation, CR-CL-creatinine clearance, DVT-deep vein thrombosis, VTE-venous thromboembolism	Chromogenic measurement at 405nm.	**1.** Package insert: Rivaroxaban: Diagnostica Stago. Revised December 2014 **2.** Mueck W, Stampfuss J, Kubitza D, Becka M: Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical Pharmacokinetics 2014; 53(1):1-16 doi: 10.1007/s40262-013-0100-7 **3.** Bayer Pharma AG. Xarelto (rivaroxaban) Summary of Product Characteristics; 2013. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf **4.** EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-510 **5.** EINSTEIN-PE Investigators, Buller HR, Prins MH, et al: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-1297 **6.** Patel MR, Mahaffey KW, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883891 **7.** Siegal DM, Curnutte JT, Connolly SJ, et al: Andexanet alfa for reversal of factor Xa inhibitor	23-500 ng/mL	23-500 ng/mL
Anti Xa DOAC (Rivaroxaban)	AXRIVA Xarelto			Therapeutic reference ranges have not been established. At steady state - median (5th-95th percentile) peak and trough levels have been observed in clinical trials: Dose — Indication — Peak Conc., ng/mL (a) — Trough Conc. ng/mL (b) 2.5 mg — Acute coronary syndrome — 46 (28-70) — 17 (6-37) twice daily 10 mg — VTE prevention once daily after total hip replacement — 125 (91-196) — 9 (1-38) 15 mg — Stroke prevention once daily in patients with AF (CR-CL 30-49 mL/min) — 229 (178-313) — 57 (18-136) 20 mg — DVT treatment once daily — 270 (189-419) — 26 (6-87) 20 mg — Stroke prevention once daily in patients with AF (CR-CL ≥50 mL/min) — 249 (184-343) — 44 (12-137) (a) Defined as samples collected 2-4 hours after dosing (b) Defined as samples collected 20-28 hours after dosing AF-atrial fibrillation, CR-CL-creatinine clearance, DVT-deep vein thrombosis, VTE-venous thromboembolism	Chromogenic measurement at 405nm.	**1.** Package insert: Rivaroxaban: Diagnostica Stago. Revised December 2014 **2.** Mueck W, Stampfuss J, Kubitza D, Becka M: Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical Pharmacokinetics 2014; 53(1):1-16 doi: 10.1007/s40262-013-0100-7 **3.** Bayer Pharma AG. Xarelto (rivaroxaban) Summary of Product Characteristics; 2013. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf **4.** EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-510 **5.** EINSTEIN-PE Investigators, Buller HR, Prins MH, et al: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-1297 **6.** Patel MR, Mahaffey KW, Garg J, et al: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883891 **7.** Siegal DM, Curnutte JT, Connolly SJ, et al: Andexanet alfa for reversal of factor Xa inhibitor	25-500 ng/mL	25-500 ng/mL
Anti Xa Heparin (Unfractionated)	AXHEP UFH Heparin assay Unfractionated heparin	0.30-0.70 IU/mL			Chromogenic measurement at 405nm.	Chest, vol. 119, issue 1, January 2001, pgs. 64S-75S.	0.10-0.80 IU/mL	0.10-1.60 IU/mL
Anti Xa LMWH (Enoxaparin) Random	AXLMWHR Low molecular weight heparin LMWH Random	0.60-1.00 Anti-Xa IU/mL			Chromogenic measurement at 405nm.	Chest, vol. 119, issue 1, January 2001, pgs. 64S-75S.	0.10-1.60 Anti-Xa IU/mL	0.10-1.60 Anti-Xa IU/mL
Anti Xa LMWH (Enoxaparin), *Exact Time Required* 4 Hr Post	AXLMWHPK Low molecular weight heparin LMWH Peak	0.60-1.00 Anti-Xa IU/mL			Chromogenic measurement at 405nm.	Chest, vol. 119, issue 1, January 2001, pgs. 64S-75S.	0.10-1.60 Anti-Xa IU/mL	0.10-1.60 Anti-Xa IU/mL
Antithrombin III	AT Antithrombin Activity Antithrombin Functional ATIII AT3	0-4 days: 39-87 % 5-29 days: 41-93 % 30-89 days: 48-108 % 90-179 days: 73-121 % 180-365 days: 84-124 % 1-5 years: 82-139 % 6-10 years: 90-131 % 11-16 years: 77-132 % 17+ years: 85-118 %			Chromogenic measurement at 405nm.	OSUWMC Normal Range Study 02/2004; Blood, Vol 80, 1998-2005, Andrew, 1992; Amer. Jour. Ped. Hematol. Oncol, Vol 12, 95-104, Andrew, 1990		9-200 %

Beta-2 Glycoprotein 1 Ab, IgG & IgM	B2GP1 β2GP1 IgG B2GP1 IgG β2GP1 IgM B2GP1 IgM	**B2GP1G** 0.0-20.0 CU **B2GP1M** 0.0-20.0 CU		Chemiluminescent two-step immunoassay.	Inova Quanta-Flash Package Insert Verified in House	B2GP1G: 10.0-500.0 CU B2GP1M: 10.0-200.0 CU	B2GP1G: 10.0-10,000.0 CU B2GP1M: 10.0-4,000.0 CU
D-Dimer, Quantitative	HSDDI High sensitivity D-Dimer	<0.50 mcg/mL FEU		A suspension of latex microparticles, coated by covalent bonding with monoclonal antibodies specific for D-dimer, is mixed with the test plasma whose D-dimer level is to be assayed. Agglutination of the microparticles results via an antigen-antibody reaction, which induces an increase in turbidity of the reaction medium. This increase in turbidity is reflected by an increase in absorbance, the latter being measured photometrically at 540 nm. The increase in absorbance is a function of the D-dimer level present in the test sample.	OSUWMC Normal Range Study (08/2007)	0.27-4.00 mcg/mL FEU	0.27-20.00 mcg/mL FEU
DIC Workup	DIC,DICMIXES Disseminated Intravascular Coagulation Workup Consumptive Coagulopathy Workup	**PT** 11.9-14.2 sec **INR** 0.9-1.1 **PTT** 24.0-34.3 sec **TT** 13.0-20.0 sec **FIB** 220-410 mg/dL **DDIMER** <0.50 mcg/mL FEU		**PT, PTT, Mixing Studies, FIB, TT:** Mechanical Clot Detection **D-Dimer:** Optical measurement at 540 nm	See individual analytes	See individual analytes	See individual analytes
Factor II Activity	FA2 Factor 2 Activity Prothrombin Activity	0-4 days: 26-70 % Activity 5-29 days: 33-93 % Activity 30-89 days: 34-102 % Activity 90-179 days: 45-105 % Activity 180-365 days: 60-116 % Activity 1-5 years: 71-116 % Activity 6-10 years: 67-107 % Activity 11-16 years: 61-104 % Activity 17+ years: 60-150 % Activity		1 stage clotting assay.	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	3-500 % Activity	3-500 % Activity
Factor II Inhibitor	FA2IN Factor 2 Inhibitor Factor II Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor IX Activity	FA9 Factor 9 Activity Hemophilia B Christmas Factor	0-4 days: 15-91 % Activity 5-29 days: 15-91 % Activity 30-89 days: 21-81 % Activity 90-179 days: 21-113 % Activity 180-365 days: 36-136 % Activity 1-5 years: 47-104 % Activity 6-10 years: 63-89 % Activity 11-16 years: 59-122 % Activity 17+ years: 77-147 % Activity	<1%: severe hemophilia 1- <5%: moderate hemophilia 5- <40%: mild hemophilia	1 stage clotting assay.	OSUWMC Normal Range Study 02/2004; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	1-500 % Activity	1-500 % Activity
Factor IX Inhibitor	FA9IN Factor 9 Inhibitor Factor IX Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor V Activity	FA5 Factor 5 Activity Labile Factor Proaccelerin	0-4 days: 34-108 % Activity 5-29 days: 45-145 % Activity 30-89 days: 62-134 % Activity 90-179 days: 48-132 % Activity 180-365 days: 55-127 % Activity 1-5 years: 79-127 % Activity 6-10 years: 63-116 % Activity 11-16 years: 55-99 % Activity 17+ years: 50-150 % Activity		1 stage clotting assay.	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	3-500 % Activity	3-500 % Activity
Factor V Inhibitor	FA5IN Factor 5 Inhibitor Factor V Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor VII Activity	FA7 Factor 7 Activity Stabile Factor Proconvertin	0-4 days: 28-104 % Activity 5-29 days: 35-143 % Activity 30-89 days: 42-138 % Activity 90-179 days: 39-143 % Activity 180-365 days: 47-127 % Activity 1-5 years: 55-116 % Activity 6-10 years: 52-120 % Activity 11-16 years: 58-115 % Activity 17+ years: 65-135 % Activity		1 stage clotting assay.	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	3-1,000 % Activity	3-1,000 % Activity

Factor VII Inhibitor	FA7IN Factor 7 Inhibitor Factor VII Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor VIII Activity	FA8 Factor 8 Activity Factor VIII Clotting Anti-Hemophilic Factor	0-4 days: 50-178 % Activity 5-29 days: 50-154 % Activity 30-89 days: 50-157 % Activity 90-179 days: 50-125 % Activity 180-365 days: 50-109 % Activity 1-5 years: 59-142 % Activity 6-10 years: 58-132 % Activity 11-16 years: 53-131 % Activity 17+ years: 50-200 % Activity	<1%: severe hemophilia 1- <5%: moderate hemophilia 5- <40%: mild hemophilia	1 stage clotting assay.	Clinical Laboratory Reference Values. In: Laposata M. eds. *Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory*. McGraw-Hill Education; 2014; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	1-500 % Activity	1-500 % Activity
Factor VIII Activity, Chromogenic	FA8C Factor 8 Activity Factor VIII Clotting Factor VIII Chromogenic	0-4 days: 50-178 % Activity 5-29 days: 50-154 % Activity 30-89 days: 50-157 % Activity 90-179 days: 50-125 % Activity 180-365 days: 50-109 % Activity 1-5 years: 59-142 % Activity 6-10 years: 58-132 % Activity 11-16 years: 53-131 % Activity 17+ years: 50-200% % Activity	<1%: severe hemophilia 1- <5%: moderate hemophilia 5- <40%: mild hemophilia	Two stage chromogenic assay, measurement at 405nm.	Clinical Laboratory Reference Values. In: Laposata M. eds. *Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory*. McGraw-Hill Education; 2014; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	1-200 % Activity	1-200 % Activity
Factor VIII Inhibitor	FA8IN Factor 8 Inhibitor Factor VIII Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor X Activity	FA10 Factor 10 Activity Stuart-Power Factor	0-4 days: 12-68 % Activity 5-29 days: 19-79 % Activity 30-89 days: 31-87 % Activity 90-179 days: 35-107 % Activity 180-365 days: 38-118 % Activity 1-5 years: 58-116 % Activity 6-10 years: 55-101 % Activity 11-16 years: 50-117 % Activity 17+ years: 60-130 % Activity		1 stage clotting assay.	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	3-500 % Activity	3-500 % Activity
Factor X Inhibitor	FA10IN Factor 10 Inhibitor Factor X Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor XI Activity	FA11 Factor 11 Activity Hemophilia C Plasma Thromboplastin Antecedent (PTA)	0-4 days: 10-66 % Activity 5-29 days: 23-87 % Activity 30-89 days: 27-79 % Activity 90-179 days: 41-97 % Activity 180-365 days: 49-134 % Activity 1-5 years: 56-150 % Activity 6-10 years: 52-120 % Activity 11-16 years: 50-97 % Activity 17+ years: 65-135 % Activity		1 stage clotting assay.	Clinical Guide to Laboratory Tests, Tietz, 1995; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987	1-500 % Activity	1-500 % Activity
Factor XI Inhibitor	FA11IN Factor 11 Inhibitor Factor XI Bethesda Titer Bethesda Titer	0.0 Bethesda units	Negative	Bethesda method using a 1 stage clotting assay.			≥0.0 Bethesda units Negative, Positive
Factor XIII Activity	FA13 Factor 13 Screen Factor 13 Qualitative Factor XIII Qualitative Fibrin Stabilization Factor		Present	Clot solubility.			Absent, Present
Fibrinogen, Clottable	FIB Factor I Activity Fibrinogen Activity Claus Fibrinogen	220-410 mg/dL		Mechanical clot detection of dilute plasma in the presence of excess thrombin.	OSU Lab Normal Range Study (05/2003)	60-900 mg/dL	60-900 mg/dL
Fibrinogen, Obstetrical	FIB Fibrinogen, OB	OB 1st Trimester: 244-510 mg/dL OB 2nd Trimester: 291-538 mg/dL OB 3rd Trimester: 373-619 mg/dL	Fibrinogen levels may be altered by the normal physiologic changes of pregnancy and should be interpreted considering reference ranges specific to gestational age.	Mechanical clot detection of dilute plasma in the presence of excess thrombin.	Reference: Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009; 114:1326.	60-900 mg/dL	60-900 mg/dL
Heparin Platelet Factor 4 (HIT Screen) with Reflex to (SRA)	PF4IGP	PF4 IgG OD: <0.400 % Heparin Inhibition: <50		Enzyme-linked immunosorbent assay (ELISA), IgG.	Immucor LIFECODES® PF4 IgG Assay Package Insert	PF4 IgG OD: 0.000-3.000	PF4 IgG OD: 0.000-3.000

Lupus Anticoagulant	PTLTT PTT-LA,DRVVT LA Screen APS Screen Antiphospholipid Antibody Screen Staclot LA DRVVT	**PT** 11.9-14.2 sec **INR** 0.9-1.1 **TT** 13.0-20.0 sec **PTT-LA** ≤44.7 sec **DRVVT SCREEN RATIO** ≤1.28 **DRVVT NORMALIZED RATIO** ≤1.25 **HEXAGONAL PL NEUTRALIZATION** ≤8.6 sec		**Hexagonal PL Neutralization:** STACLOT-LA: Mechanical clot detection in the presence/absence of hexagonal ring phospholipid **DRVVT:** Mechanical clot detection in the presence of Diluted Russell's Viper Venom **PTT-LA:** Mechanical clot detection in the presence of cephalin and activator **PT, TT, Mixing Studies:** Mechanical clot detection	OSUWMC Normal Range Study	PT: See individual analyte TT: See individual analyte PTT-LA: 20.0-180.0 sec	PT: See individual analyte TT: See individual analyte PTT-LA: 20.0-180.0 sec
Platelet Aggregation	PLATGG Plt. Agg. Plt. Aggregation	Aggregation w/ADP 5 umol/L: 67-92 % Aggregation Aggregation w/ADP 10.0 mmol/L: 73-91 % Aggregation Aggregation w/Arach Acid 0.5 mmol/L: 72-91 % Aggregation Aggregation w/Epinephrine 5 umol/L: 64-105 % Aggregation Aggregation w/Ristocetin 0.5 mg/mL: 0-6 % Aggregation Aggregation w/Ristocetin 1.25 mg/mL: 70-105 % Aggregation Aggregation w/Collagen 2 ug/mL: 80-96 % Aggregation Aggregation w/Collagen 5 ug/mL: 71-92 % Aggregation Aggregation w/TXA 2.0 umol/L: 73-112 % Aggregation ATP Release w/ Collagen 2 ug/mL: 0.26-1.07 nmol ATP Release w/ Collagen 5 ug/mL: 0.49-1.32 nmol ATP Release w/Arach Acid 0.5 mmol/L: 0.37-0.90 nmol ATP Release w/ADP 5 umol/L: 0.28-0.93 nmol ATP Release w/ADP 10 umol/L: 0.44-1.19 nmol ATP Release w/Thrombin 1U: 0.36-0.99 nmol ATP Release w/Epinephrine 5 umol/L: 0.35-0.96 nmol		Born method of turbidimetric aggregation with simultaneous measurement of ATP release by platelet lumi-aggregeometry.	OSUWMC Normal Range Study (02-2023)		
Platelet Function Test	PFST PFA Screen	Collagen / Epi Closure Time: 73-172 sec Collagen / ADP Closure Time: 53-111 sec		Instrument PFA-100 closure time: the time measured from the start of the test until a platelet to close aperture after exposure to agonist.	OSU Normal Range Study (07/2004)	Collagen / Epi Closure Time: 31-300 sec Collagen / ADP Closure Time: 31-300 sec	Collagen / Epi Closure Time: 31-300 sec Collagen / ADP Closure Time: 31-300 sec
Platelet P2Y12 Inhibition Test	P2Y12 Clopidogrel Inhibition Ticagrelor Inhibition	194-418 PRU	Test results are reported in P2Y12 Reaction Units (PRU). The pre-drug Normal Reference Range is 194 - 418 PRU. PRU measures the extent of platelet aggregation in the presence of P2Y12 inhibitor drugs such as clopidogrel (Plavix), prasugrel (Effient), ticlopidine (Ticlid), and ticagrelor (Brilinta).	Whole blood platelet aggregometry based on the ability of activated platelets to bind fibrinogen. Fibrinogen-coated microparticles aggregate in whole blood in proportion to the number of expressed platelet GP IIb/IIIa receptors.	Accriva Diagnostics Verify Now P2Y12 Package Insert VN1009WEU	0-999 PRU	0-999 PRU
Protein C Activity	PROTC Protein C Functional PC Functional PC Activity	0-4 days: 17-53 % Activity 5-29 days: 20-64 % Activity 30-89 days: 21-65 % Activity 90-179 days: 28-80 % Activity 180-365 days: 37-81 % Activity 1-5 years: 56-150 % Activity 6-10 years: 40-92 % Activity 11-16 years: 55-111 % Activity 17+ years: 72-220 % Activity		This clotting assay measures Protein C which is activated in the presence of the specific activator extracted from Agkistrodon c. contortrix venom. The resulting activated protein C inhibits the factors V and VIII, and thus prolongs the APTT of a system in which all the factors are present, constant and in excess (provided by the test system), except for the protein C which is derived from the sample being tested	OSUWMC Normal Range Study; Blood, Vol 80, 1998-2005, Andrew, 1992; Amer. Jour. Ped. Hematol. Oncol, Vol 12, 95-104, Andrew, 1990		10-300 % Activity
Protein S Activity	PROTS Protein S Functional PS Functional PS Activity	0-4 days: 12-60 % Activity 5-29 days: 22-78 % Activity 30-89 days: 33-93 % Activity 90-179 days: 54-118 % Activity 180-365 days: 55-119 % Activity 1-5 years: 53-173 % Activity 6-10 years: 55-155 % Activity 11-16 years: 65-138 % Activity 17+ years: 50-168 % Activity		Clotting assay based on the cofactor activity of protein S which enhances the anticoagulant action of activated protein C. This enhancement is reflected by the prolongation of the clotting time of a system enriched with factor Va which is a physiological substrate for activated protein C.	OSUWMC Normal Range Study; Blood, Vol 80, 1998-2005, Andrew, 1992; Amer. Jour. Ped. Hematol. Oncol, Vol 12, 95-104, Andrew, 1990		10-300 % Activity
Protime - INR	PTI PT/INR Protime/INR	**PT** 11.9-14.2 sec **INR**		**PT:** Mechanical clot detection initiated by Calcium Thromboplastin **INR:** Calculation	OSUWMC Normal Range Study	PT: 7.0-109.0 sec INR: 0.5-15.2	PT: 7.0-109.0 sec INR: 0.5-15.2
PT and PT Mixing Study	PT PT Mixing PT Inhibitor Screen	**PT** 11.9-14.2 sec **INR** 0.9-1.1		**PT:** Mechanical clot detection initiated by Calcium Thromboplastin **INR:** Calculation **PT Mixing Study:** PT performed immediately subsequent to 1:1 mix with normal plasma pool.		PT: 7.0-109.0 sec INR: 0.5-15.2	PT: 7.0-109.0 sec INR: 0.5-15.2
PT, INR, PTT	PTPTT PT/INR PTT Protime/INR Activated Partial Thromboplastin Time	**PT** 11.9-14.2 sec **INR**		**PT, PTT:** Mechanical clot detection **INR:** Calculation	See individual analytes	See individual analytes	See individual analytes
PT INR - Stroke	PTISTR	**PT** 11.9-14.2 sec **INR** 0.9-1.1		**PT, PTT:** Mechanical clot detection **INR:** Calculation	OSUWMC Normal Range Study	PT: 7.0-109.0 sec INR: 0.5-15.2	PT: 7.0-109.0 sec INR: 0.5-15.2
PTT	PTT Partial Thromboplastin Time aPTT Activated Partial Thromboplastin Time	24.0-34.3 sec		Mechanical clot detection initiated by Calcium in the presence of cephalin (platelet substitute) and a particulate activator (silica).	OSUWMC Normal Range Study	20.0-180.0 sec	20.0-180.0 sec
PTT with Mixing Study	PTTMS PTT/Mixing aPTT/Mixing PTT Inhibitor Screen	24.0-34.3 sec		**PTT:** Mechanical clot detection initiated by Calcium in the presence of cephalin (platelet substitute) and a particulate activator (silica). **PTT Mixing Study:** PTT performed immediately subsequent to 1:1 mix with normal plasma pool.		20.0-180.0 sec	20.0-180.0 sec
Ristocetin Cofactor	RCF RCF Activity VonWillebrand Factor Activity	40-200 % Activity		Ability of patient plasma to agglutinate formalin-fixed normal platelets in the presence of ristocetin.	OSUWMC Normal Range Study		13-400 % Activity

ROTEM Main Lab: Heparin Panel	RTMHEP	INTEM CT: 122-208 sec INTEM CFT: 45-110 sec INTEM ALPHA: 70-81 degree INTEM A20: 51-72 mm INTEM MCF: 51-72 mm EXTEM CT: 43-82 sec EXTEM CFT: 48-127 sec EXTEM ALPHA: 65-80 degree EXTEM A20: 50-70 mm EXTEM MCF: 52-70 mm FIBTEM A20: 7-21 mm FIBTEM MCF: 7-21 mm Reference ranges are not available for all ROTEM components unless otherwise noted: Interpretation of ROTEM results must include all available parameters, patient clinical context and current therapy. Interpretation of the HEPTEM results must include clinical correlation between the INTEM and the HEPTEM data. All results should be interpreted carefully based on patient clinical context and current therapy. Interpretation of APTEM results (fibrinolytic activity) must include correlation between the EXTEM and APTEM data. All results should be interpreted carefully based on patient clinical context and current therapy.	Rotem Physician Advice	Rotational Viscoelastic Testing- Rotem Delta: The patented ROTEM technology is based on a fixed cylindrical cup and a permanently oscillating vertical axis. The axis is supported by a high precision ball bearing and oscillates to the left and to the right through an angle of 4.75°.	Normal Range Study 2013		
ROTEM Main Lab: Routine Panel	RTMRTN	INTEM CT: 122-208 sec INTEM CFT: 45-110 sec INTEM ALPHA: 70-81 degree INTEM A20: 51-72 mm INTEM MCF: 51-72 mm INTEM ML: No reference range available; see comment INTEM LI30: No reference range available; see comment EXTEM CT: 43-82 sec EXTEM CFT: 48-127 sec EXTEM ALPHA: 65-80 degree EXTEM A20: 50-70 mm EXTEM MCF: 52-70 mm FIBTEM A20: 7-21 mm FIBTEM MCF: 7-21 mm Reference ranges are not available for all ROTEM components unless otherwise noted: Interpretation of ROTEM results must include all available parameters, patient clinical context and current therapy. Interpretation of APTEM results (fibrinolytic activity) must include correlation between the EXTEM and APTEM data. All results should be interpreted carefully based on patient clinical context and current therapy.	Rotem Physician Advice	Rotational Viscoelastic Testing- Rotem Delta: The patented ROTEM technology is based on a fixed cylindrical cup and a permanently oscillating vertical axis. The axis is supported by a high precision ball bearing and oscillates to the left and to the right through an angle of 4.75°.	Normal Range Study 2013		
ROTEM Main Lab: Trauma Panel	RTMTRA	EXTEM CT: 43-82sec EXTEM CFT: 48-127 sec EXTEM ALPHA: 65-80 degree EXTEM A20: 50-70 mm EXTEM MCF: 52-70 mm FIBTEM A20: 7-21 mm FIBTEM MCF: 7-21 mm Reference ranges are not available for all ROTEM components unless otherwise noted: Interpretation of ROTEM results must include all available parameters, patient clinical context and current therapy. Interpretation of APTEM results (fibrinolytic activity) must include correlation between the EXTEM and APTEM data. All results should be interpreted carefully based on patient clinical context and current therapy.	Rotem Physician Advice	Rotational Viscoelastic Testing- Rotem Delta: The patented ROTEM technology is based on a fixed cylindrical cup and a permanently oscillating vertical axis. The axis is supported by a high precision ball bearing and oscillates to the left and to the right through an angle of 4.75 °.	Normal Range Study 2013		
Thrombin Time	TT	13.0-20.0 sec		Mechanical clot detection of undiluted plasma in the presence of a predetermined quantity of thrombin, resulting in a fibrin clot.	OSUWMC Normal Range Study	10.0-120.0 sec	10.0-120.0 sec
Thrombin Time w/ Mixing Studies	TTMS TTMixing TT with Mixing	13.0-20.0 sec		**TT:** Mechanical clot detection of undiluted plasma in the presence of a predetermined quantity of thrombin, resulting in a fibrin clot. **TT Mixing Study:** Thrombin Time is performed subsequent to a 1:1 mix with normal plasma pool and also in the presence of protamine sulfate (if indicated).	OSUWMC Normal Range Study	10.0-120.0 sec	10.0-120.0 sec
Von Willebrand Battery Agn + Factor VIII	PTT (VW) F8, RCF, VWFAG vWF Antigen and Factor VIII vWF Immunologic and Factor VIII vWF Antigen and Factor 8 vWF Immunoloeic and Factor 8	**PTT** 24.0-34.3 sec **FA8** 0-4 days: 50-178 % Activity 5-29 days: 50-154 % Activity 30-89 days: 50-157 % Activity 90-179 days: 50-125 % Activity 180-365 days: 50-109 % Activity 1-5 years: 59-142 % Activity 6-10 years: 58-132 % Activity 11-16 years: 53-131 % Activity 17+ years: 50-200 % Activity **RCF** 40-200 % Activity **VWFAG** 0-4 days: 50-287 % 5-29 days: 50-254 % 30-89 days: 50-246 % 90-179 days: 50-206 % 180-365 days: 50-197 % 1-5 years: 60-120 % 6-10 years: 44-144 % 11-16 years: 46-153 % 17+ years: 50-180 %		**PTT:** Mechanical clot detection initiated by Calcium in the presence of cephalin (platelet substitute) and a particulate activator (silica). **VWF Ag:** Immuno-turbidimetric method (STA - Liatest VWF:Ag) **Factor VIII:** One Stage Clotting Assay **Ristocetin Cofactor:** Ability of patient plasma to agglutinate formalin-fixed normal platelets in the presence of ristocetin.	See individual analytes	See individual analytes	See individual analytes

Von Willebrand Factor Ag	VWFAG vWF Antigen vWF Immunologic	0-4 days: 50-287 % 5-29 days: 50-254 % 30-89 days: 50-246 % 90-179 days: 50-206 % 180-365 days: 50-197 % 1-5 years: 60-120 % 6-10 years: 44-144 % 11-16 years: 46-153 % 17+ years: 50-180 %		Immuno-turbidimetric method (STA - Liatest VWF:Ag)	OSUWMC Normal Range Study; Blood, Vol 80, 1998-2005, Andrew, 1992; Blood, Vol 70, 165-172, Andrew, 1987		3-400 %
Amikacin Level, Extended Interval	AMIKEI	Peak: 30-60 mcg/mL, Trough: <6 mcg/mL		Homogeneous particle-enhanced turbidimetric immunoassay.	OSU Pharmacy	3.0-50.0 mcg/mL	3.0-150.0 mcg/mL
Amikacin Level, Peak (Post Drug Level)	AMIKPK	Therapeutic Range: 30.0-60.0 mcg/mL		Homogeneous particle-enhanced turbidimetric immunoassay.	OSU Pharmacy	3.0-50.0 mcg/mL	3.0-150.0 mcg/mL
Amikacin Level, Random	AMIKR	Peak: 30-60 mcg/mL, Trough: <6 mcg/mL		Homogeneous particle-enhanced turbidimetric immunoassay.	OSU Pharmacy	3.0-50.0 mcg/mL	3.0-150.0 mcg/mL
Amikacin Level, Trough (Pre Drug Level)	AMIKTR	Therapeutic Range: <6.0 mcg/mL		Homogeneous particle-enhanced turbidimetric immunoassay.	OSU Pharmacy	3.0-50.0 mcg/mL	3.0-150.0 mcg/mL
Amphetamines, Urine, Confirmation	AMPC Adderall Meth Speed	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: Amphetamine: 25 ng/mL Methamphetamine: 25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		CONFIRMATION (Amphetamine/Methamphetamine): 25-5,000 ng/mL	CONFIRMATION: (Amphetamine/Methamphetamine): 25-25,000 ng/mL
Benzodiazepines, Urine, Confirmation	BENZMS	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: 2-Hydroxyethylflurazepam: 50 ng/mL 7-Aminoclonazepam: 10 ng/mL 7-Aminoflunitrazepam: 10 ng/mL Alpha-hydroxyalprazolam: 10 ng/mL Alpha-hydroxymidazolam: 10 ng/mL Alprazolam: 10 ng/mL Diazepam: 10 ng/mL Flurazepam: 10 ng/mL Midazolam: 10 ng/mL Nordiazepam: 10 ng/mL Temazepam: 10 ng/mL Clonazepam: 25 ng/mL Lorazepam: 25 ng/mL Oxazepam: 25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		2-Hydroxyethylflurazepam: 50-1,750 ng/mL 7-Aminoclonazepam: 10-1,000 ng/mL 7-Aminoflunitrazepam: 10-1,300 ng/mL Alpha-hydroxyalprazolam: 10-2,000 ng/mL Alpha-hydroxymidazolam: 10-1,750 ng/mL Alprazolam: 10-2,000 ng/mL Diazepam: 10-2,000 ng/mL Flurazepam: 10-1,000 ng/mL Midazolam: 10-2,000 ng/mL Nordiazepam: 10-2,000 ng/mL Temazepam: 10-2,000 ng/mL Clonazepam: 25-2,000 ng/mL Lorazepam: 25-2,000 ng/mL Oxazepam: 25-2,000 ng/mL	2-Hydroxyethylflurazepam: 50-1,750 ng/mL 7-Aminoclonazepam: 10-1,000 ng/mL 7-Aminoflunitrazepam: 10-1,300 ng/mL Alpha-hydroxyalprazolam: 10-2,000 ng/mL Alpha-hydroxymidazolam: 10-1,750 ng/mL Alprazolam: 10-2,000 ng/mL Diazepam: 10-2,000 ng/mL Flurazepam: 10-1,000 ng/mL Midazolam: 10-2,000 ng/mL Nordiazepam: 10-2,000 ng/mL Temazepam: 10-2,000 ng/mL Clonazepam: 25-2,000 ng/mL Lorazepam: 25-2,000 ng/mL Oxazepam: 25-2,000 ng/mL
Buprenorphine and Norbuprenorphine, Urine, Confirmation	QBUPR Subutex Suboxone Buprenex	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: Buprenorphine: 5.0 ng/mL Norbuprenorphine: 5.0 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		Buprenorphine: 5.0 -5,000.0 ng/mL Norbuprenorphine: 5.0 - 5,000.0 ng/mL	Buprenorphine: 5.0 -25,000.0 ng/mL Norbuprenorphine: 5.0 - 25,000.0 ng/mL
Carboxy THC, Urine Confirmation	THCCON Cannabinoids THC Marijuana Mary Jane	None Detected Cutoff concentrations by gas chromatography-tandem mass spectrometry: 9-Carboxy-11-Nor-Delta-THC: 5.0 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitative. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		5.0-500.0 ng/mL	5.0-500.0 ng/mL
Cocaine, Urine, Confirmation	COCCON Coke Crack	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: Benzoylecgonine: 25 ng/mL Cocaine: 25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitative. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		Benzoylecgonine: 25-5,000 ng/mL Cocaine: 25-5,000 ng/mL	Benzoylecgonine: 25-25,000 ng/mL Cocaine: 25-25,000 ng/mL
Cyclic Citrullinated Peptide Ab	ACCP Anti-CCP	<5.0 U/mL		Chemiluminescent microparticle immunoassay	Abbott	0.5-200.0 U/mL	0.5-1,200.0 U/mL
Cyclosporine Level, 2HR	CSAN2 Sandimmune Neoral Gengraf	Therapeutic Range: 320-960 ng/mL			OSU Pharmacy	30-1,500 ng/mL	30-3,000 ng/mL
Cyclosporine Level, Random	CSANR Sandimmune Neoral Gengraf	**Kidney/Pancreas Transplant:** 0 to 3 months: 800-1000 ng/mL 3 to 12 months: 600-800 ng/mL >12 months: 400-600 ng/mL			OSU Pharmacy	30-1,500 ng/mL	30-3,000 ng/mL
Cyclosporine Level, Trough (Pre Drug Level)	CSANT Sandimmune Neoral Gengraf	**Kidney/Pancreas Transplant:** 0 to 3 months: 800-1000 ng/mL 3 to 12 months: 600-800 ng/mL >12 months: 400-600 ng/mL. **Aplastic anemia and stem cell transplant:** 200-400			OSU Pharmacy	30-1,500 ng/mL	30-3,000 ng/mL
Ethanol (Alcohol), Urine	ALCOU	<10 mg/dL	Detectable ethanol in urine indicates exposure to ethanol within the past 8-12 hours.	Beckman Coulter DxC700AU; Emit* II Plus Ethyl Alcohol Assay		10-600 mg/dL	10-600 mg/dL
Ethylene Glycol, Blood, Screen with Reflex to Confirmation	EGU	Negative Cutoff concentrations by gas chromatography: 10 mg/dL		**Screen:** Beckman Coulter DxC700AU: Catachem DiscretPak Ethylene Glycol Reagent Kit **Confirmation:** Gas Chromatography Flame Ionization Detection (GC-FID)		CONFIRMATION: 10-250 mg/dL	SCREEN: Negative, Presumptive Positive. Confirmation to follow. CONFIRMATION: 10-250 mg/dL
Everolimus, Trough (Pre Drug Level)	EVERTR	**Kidney/Pancreas Transplant:** 0 to 3 months: 7-10 ng/mL 3 to 12 months: 5-8 ng/mL >12 months: 4-8 ng/mL		Particle enhanced turbidimetric immunoassay	OSU Pharmacy	2.0-20.0 ng/mL	2.0-40.0 ng/mL

Fentanyl, Urine, Confirmation	FENTQ	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: Fentanyl: 2.5 ng/mL Norfentanyl: 2.5 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		Fentanyl: 2.5-5,000.0 ng/mL Norfentanyl: 2.5-5,000.0 ng/mL	Fentanyl: 2.5-25,000.0 ng/mL Norfentanyl: 2.5-25,000.0 ng/mL
Gentamicin Level, Extended Infusion	GENTEI Garamycin	Peak: 3-15.0 mcg/mL, Trough: ≤1.0 mcg/mL		Enzyme immunoassay		0.3-10.0 mcg/mL	0.3-20.0 mcg/mL
Gentamicin Level, Peak (Post Drug Level)	GENTPK Garamycin	Therapeutic Range: 3.0-15.0 mcg/mL		Enzyme immunoassay	OSU Pharmacy	0.3-10.0 mcg/mL	0.3-20.0 mcg/mL
Gentamicin Level, Random	GENT Garamycin	Peak: 3-15.0 mcg/mL, Trough: ≤1.0 mcg/mL		Enzyme immunoassay		0.3-10.0 mcg/mL	0.3-20.0 mcg/mL
Gentamicin, Trough (Pre Drug Level)	GENTTR Garamycin	0-365 days: Therapeutic Range: <1.6 mcg/mL 1+ years: Therapeutic Range: ≤1.0 mcg/mL		Enzyme immunoassay	OSU Pharmacy	0.3-10.0 mcg/mL	0.3-20.0 mcg/mL
Lidocaine Level	LIDOU	Therapeutic Range: 1.5-5.0 mcg/mL		Enzyme immunoassay	OSU Pharmacy	0.5-12.0 mcg/mL	0.5-36.0 mcg/mL
Methadone, Urine, Confirmation	METHMS	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: Methadone: 25 ng/mL EDDP Methadone: 25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		Methadone: 25-5,000 ng/mL EDDP Methadone: 25-5,000 ng/mL	Methadone: 25-25,000 ng/mL EDDP Methadone: 25-25,000 ng/mL
Nicotine Screen Urine	NICOTU	None Detected Cutoff concentrations by immunoassay detection: 500 ng/mL	Positive results indicate recent exposure to cigarette smoke.	Beckman Coulter DxC700AU Thermo Scientific DRI® Cotinine Assay			None Detected, Positive, Presumptive Positive. Confirmation to Follow.
Opioids, Urine, Confirmation	OPICON	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: 6-Monoacetylmorphine: 5.0 ng/mL Codeine: 25 ng/mL Hydrocodone: 25 ng/mL Hydromorphone: 25 ng/mL Morphine: 25 ng/mL Tramadol: 25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		6-Monoacetylmorphine: 5.0-5,000.0 ng/mL Codeine: 25-5,000 ng/mL Hydrocodone: 25-5,000 ng/mL Hydromorphone: 25-5,000 ng/mL Morphine: 25-5,000 ng/Ml	6-Monoacetylmorphine: 5.0-25,000.0 ng/mL Codeine: 25-25,000 ng/mL Hydrocodone: 25-25,000 ng/mL Hydromorphone: 25-25,000 ng/mL Morphine: 25-25,000 ng/mL
Oxycodone, Urine, Confirmation	OXYCON	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: Oxycodone: 25 ng/mL Oxymorphone: 25 ng/mL Noroxycodone: 25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		Oxycodone: 25-5,000 ng/mL Oxymorphone: 25-5,000 ng/mL Noroxycodone: 25-5,000 ng/mL	Oxycodone: 25-25,000 ng/mL Oxymorphone: 25-25,000 ng/mL Noroxycodone: 25-25,000 ng/mL
Pentobarbital Level	PENTU	Intracranial Pressure Therapy: 30-40 ug/mL		Gas Chromatography (GC)	OSU Pharmacy	5-50 ug/mL	5-50 ug/mL
Phenytoin Free Level	FPTN Dilantin, Free	Therapeutic Range: 0.6-2.4 mcg/mL		Chemiluminescent microparticle immunoassay	OSU Pharmacy	0.5-40.0 mcg/mL	0.5-40.0 mcg/mL
Sirolimus (Rapamycin) Level, Random	SIROR	Bone Marrow Transplant: 3-12 Kidney/Pancreas Transplant: 0 to 3 months: 7-10; 3 to 12 months: 5-8; >12 months: 4-8		Chemiluminescent microparticle immunoassay	OSU Pharmacy	2.0-30.0 ng/mL	2.0-60.0 ng/mL
Sirolimus (Rapamycin) Level, Trough (Pre Drug Level)	SIROTR	Bone Marrow Transplant: 3-12 Kidney/Pancreas Transplant: 0 to 3 months: 7-10; 3 to 12 months: 5-8; >12 months: 4-8		Chemiluminescent microparticle immunoassay	OSU Pharmacy	2.0-30.0 ng/mL	2.0-60.0 ng/mL
Tacrolimus Level, Trough (Pre Drug Level)	TACRO Prograf	Bone Marrow Transplant: 5-15 Kidney/Pancreas Transplant: 0 to 3 months: 8-10; 3 to 12 months: 6-8; >12 months: 4-6		Chemiluminescent microparticle immunoassay	OSU Pharmacy	2.0-30.0 ng/mL	2.0-60.0 ng/mL
Tacrolimus, Random	TACROR Prograf	Bone Marrow Transplant: 5-15 Kidney/Pancreas Transplant: 0 to 3 months: 8-10; 3 to 12 months: 6-8; >12 months: 4-6		Chemiluminescent microparticle immunoassay	OSU Pharmacy	2.0-30.0 ng/mL	2.0-60.0 ng/mL
Tramadol, Urine	TramU Ultram ConZip	None Detected Cutoff concentrations by liquid chromatography-tandem mass spectrometry: <25 ng/mL	Numeric results (positive) indicate the measured concentration of drug in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitation. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection. Drug concentrations in urine cannot determine the dose, route of administration, or exact time of exposure.	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)		25-5,000 ng/mL	25-25,000 ng/mL
Urine Drug Screen 10	10DRUG	None Detected Cutoff concentrations by immunoassay detection: Amphetamine/Methamphetamine: 500 ng/mL Barbiturates: 200 ng/mL Benzodiazepines: 200 ng/mL Buprenorphine: 5 ng/mL Cannabinoids: 50 ng/mL Cocaine: 150 ng/mL Fentanyl: 1 ng/mL Methadone: 300 ng/mL Opiates: 300 ng/mL Oxycodone: 100 ng/mL	Presumptive positive results indicate the presence of a compound within the specified class of drugs or a structurally related compound in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of detection. The detection of drugs in urine is dependent on several factors such as the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection.	Beckman Coulter DxC700AU: Emit® II Plus Amphetamines Assay, Barbiturates Assay, Benzodiazepine Assay, Buprenorphine Assay, Cannabinoids Assay, Cocaine Metabolite Assay, Methadone Assay, and Opiates Assay. ARK™ Fentanyl II Assay. DRI® Oxycodone Assay.		Negative, Positive, Presumptive Positive. Confirmation to follow.	
Urine Drug Screen 10 with Confirmation	UPMSC	None Detected Cutoff concentrations by immunoassay detection: Amphetamine/Methamphetamine: 500 ng/mL Barbiturates: 200 ng/mL Benzodiazepines: 200 ng/mL Buprenorphine: 5 ng/mL Cannabinoids: 50 ng/mL Cocaine: 150 ng/mL Fentanyl: 1 ng/mL Methadone: 300 ng/mL Opiates: 300 ng/mL Oxycodone: 100 ng/mL	Presumptive positive results indicate the presence of a compound within the specified class of drugs or a structurally related compound in the urine sample. Negative results may reflect the absence of drug or drug present below the assay's limit of quantitative. The detection of drugs in urine is dependent on several factors including the amount of drug ingested, time since exposure, individual metabolism, kidney and liver function, urine concentration, and the assay's limit of detection.	**Screen:** Beckman Coulter DxC700AU: Emit® II Plus Amphetamines Assay, Barbiturates Assay, Benzodiazepine Assay, Buprenorphine Assay, Cannabinoids Assay, Cocaine Metabolite Assay, Methadone Assay, and Opiates Assay. ARK™ Fentanyl II Assay. DRI® Oxycodone Assay. **Confirmation:** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)			See individual reflex tests
Valproic Acid, Free	FVPA Depakote Divalproex Valproate Depakene	Therapeutic Range: 5-35 mcg/mL		Chemiluminescent microparticle immunoassay	OSU Pharmacy	2-150 mcg/mL	

Valproic Acid, Total	VPA Depakote Divalproex Valproate Depakene	Therapeutic Range: 50-120 mcg/mL		Chemiluminescent microparticle immunoassay		4-150 mcg/mL	4-750 mcg/mL
Volatile Alcohol Panel, Blood	VOLABU Alcohol Drug Methanol Ethanol Isopropanol Acetone Ethyl Alcohol Isopropyl Alcohol	**METHANOL** <10 mg/dL **ETHYL ALCOHOL** <10 mg/dL **ACETONE** <10 mg/dL **ISOPROPANOL** <10 mg/dL		Gas Chromatography (GC) Flame Ionization Detection (FID)		METHANOL: 10-400 mg/dL ETHYL ALCOHOL: 10-400 mg/dL ACETONE: 10-400 mg/dL ISOPROPANOL: 10-400 mg/dL	METHANOL: 10-400 mg/dL ETHYL ALCOHOL: 10-400 mg/dL ACETONE: 10-400 mg/dL ISOPROPANOL: 10-400 mg/dL
Adrenal Vein Sampling Pre Stimulation	CORT LAV1 CORT RAV1 CORT IVC1 CORT LAV2 CORT RAV2 CORT IVC2 CORT LAV3 CORT RAV3 CORT IVC3 ALDOLAV1 ALDO RAV1 ALDO IVC1 ALDOLAV2 ALDORAV2 ALDOIVC2 ALDO LAV3 ALDO RAV3 ALDO IVC3	**CORTISOL LEFT AV1** 3.09-22.40 mcg/dL **CORTISOL RIGHT AV1** 3.09-22.40 mcg/dL **CORTISOL IVC1** 3.09-22.40 mcg/dL **CORTISOL LEFT AV2** 3.09-22.40 mcg/dL **CORTISOL RIGHT AV2** 3.09-22.40 mcg/dL **CORTISOL IVC2** 3.09-22.40 mcg/dL **CORTISOL LEFT AV3** 3.09-22.40 mcg/dL **CORTISOL RIGHT AV3** 3.09-22.40 mcg/dL **CORTISOL IVC3** 3.09-22.40 mcg/dL **ALDOSTERONE LEFT AV1** <23.20 ng/dL **ALDOSTERONE RIGHT AV1** <23.20 ng/dL **ALDOSTERONE IVC1** <23.20 ng/dL **ALDOSTERONE LEFT AV2** <23.20 ng/dL **ALDOSTERONE RIGHT AV2** <23.20 ng/dL **ALDOSTERONE IVC2** <23.20 ng/dL **ALDOSTERONE LEFT AV3** <23.20 ng/dL **ALDOSTERONE RIGHT AV3** <23.20 ng/dL **ALDOSTERONE IVC3** <23.20 ng/dL	**Aldosterone Reference Range** Plasma Upright: <35.30 ng/dL Plasma Supine: <23.60 ng/dL Serum Upright: <39.20 ng/dL Serum Supine: <23.20 ng/dL	Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes
Adrenal Vein Sampling Post Stimulation		**ALDOSTERONE 5 MIN LEFT AV** No established reference range **ALDOSTERONE 5 MIN RIGHT AV** <23.20 ng/dL **ALDOSTERONE 5 MIN IVC AV** <23.20 ng/dL **ALDOSTERONE 10 MIN LEFT AV** <23.20 ng/dL **ALDOSTERONE 10 MIN RIGHT AV** <23.20 ng/dL **ALDOSTERONE 10 MIN IVC AV** <23.20 ng/dL **ALDOSTERONE 15 MIN LEFT AV** <23.20 ng/dL **ALDOSTERONE 15 MIN RIGHT AV** <23.20 ng/dL **ALDOSTERONE 15 MIN IVC AV** <23.20 ng/dL		Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes

[illegible]	ALDO LAV 5M ALDO RAV 5M ALDO IVC 5M ALDO LAV 10M ALDO RAV 10M ALDO IVC 10M ALDO LAV 15M ALDO RAV 15M ALDO IVC 15M CORT LAV 5M CORT RAV 5M CORT IVC 5M CORT LAV 10M CORT RAV 10M CORT IVC 10M CORT LAV 15M CORT RAV 15M CORT IVC 15M	**CORTISOL 5 MIN LEFT AV** 3.09-22.40 mcg/dL **CORTISOL 5 MIN RIGHT AV** 3.09-22.40 mcg/dL **CORTISOL 5 MIN IVC AV** 3.09-22.40 mcg/dL **CORTISOL 10 MIN LEFT AV** 3.09-22.40 mcg/dL **CORTISOL 10 MIN RIGHT AV** 3.09-22.40 mcg/dL **CORTISOL 10 MIN IVC AV** 3.09-22.40 mcg/dL **CORTISOL 15 MIN LEFT AV** 3.09-22.40 mcg/dL **CORTISOL 15 MIN RIGHT AV** 3.09-22.40 mcg/dL **CORTISOL 15 MIN IVC AV** 3.09-22.40 mcg/dL		[illegible]	[illegible]	[illegible]	[illegible]
AFP Tumor Marker	AFPTM AFPTMR AFP	<8.1 ng/mL		Two-site sandwich immunoassay chemiluminescent.	Siemens AFP Package Insert 10995310_EN Rev. 03, 2020-02	2.2-1,000.0 ng/mL	2.2-1,000,000.0 ng/mL
Aldosterone	ALDOS ALDNH ALDPRL ALDPRI ALDOPRR ALDPOL ALDPOI LDOPOR		**Reference Range:** Plasma Upright: <35.30 ng/dL Plasma Supine: <23.60 ng/dL Serum Upright: <39.20 ng/dL Serum Supine: <23.20 ng/dL	Chemiluminescent immunoassay.	Package Insert	4.00-100.00 ng/dL	4.00-100,000.00 ng/dL
ANA Multiplex Screen	ANAS		Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive
ANA Multiplex Scrn with Reflex	ANASR		Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive
ANA Screen IFA	ANAB		Negative	Indirect immunofluorescence antibody.	INOVA IFU 2018 Revision 7		SCREEN: Negative, Positive QUANTITATIVE: 1:80, 1:160, 1:320, 1:640, 1:1280, ≥1:2560
ANCA Init Scrn (ANCA, PR3AB, MPO)	ANCA Anti-PR3 MPO		Negative	**ANCA:** Indirect fluorescent antibody. **MPO & PR3:** Multiplex flow immunoassay	INOVA IFU 2019 Revision 3 (ANCA). Instructions for use manual (MPO & PR3)		See individual analytes
Anti Microsomal Antibody	MIAN aTPO	<60.0 IU/mL		Chemiluminescent immunoassay.	Siemens Anti-Thyroid Peroxidase Package Insert 10995280 EN Rev. 02, 2019-07	28.0-1,300.0 IU/mL	28.0-130,000.0 IU/mL
Anti Mitochondrial Antibody	AMA		Negative	Indirect immunofluorescence antibody.	INOVA IFU 2019 Revision 21		SCREEN: Negative, Positive, Indeterminate TITER: 1:20, 1:40, 1:80, 1:160, ≥1:320
Anti Mullerian Hormone	AMH	18-19 years: 0.530-10.580 ng/mL 20-24 years: 1.350-16.460 ng/mL 25-29 years: 0.910-13.520 ng/mL 30-34 years: 0.480-11.000 ng/mL 35-39 years: ≤10.160 ng/mL 40-44 years: ≤7.360 ng/mL 45-49 years: ≤3.300 ng/mL 50+ years: ≤0.900 ng/mL.	18+ years: ≤18.000 ng/mL	One-step sandwich immunoassay.	Siemens Insulin Package Insert 10998438_EN Rev. 01, 2023-06	0.043-24.000 ng/mL	0.043-24.000 ng/mL
Anti Neutrophil Cytoplasmic Antibody	ANCA		Negative	Indirect immunofluorescence antibody.	INOVA IFU 2019 Revision 3		SCREEN: Negative, Positive, Atypical fluorescence present TITER: 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, ≥1:1280
Anti Parietal Antibody	PCA		Negative	Indirect immunofluorescence antibody.	INOVA IFU 2019 Revision 21		SCREEN: Negative, Positive, Indeterminate TITER: 1:20, 1:40, 1:80, 1:160, ≥1:320
Anti Smooth Muscle Antibody	SMA		Negative	Indirect immunofluorescence antibody.	INOVA IFU 2019 Revision 21		SCREEN: Negative, Positive, Indeterminate TITER: 1:20, 1:40, 1:80, 1:160, ≥1:320
Anti-Proteinase 3 Ab	PR3AB Anti-PR3		Negative	Multiplex flow immunoassay.	IFU		Negative, Positive
Anti-Scleroderma Ab (SCL70)	SCL70T		Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive
Beta 2 Microglobulin Serum	B2M	0.80-2.34 mg/L		Turbidimetry	Package insert (Insert Code: INS043.OPT.A, Version: 09th August 2018)	0.30-20.00 mg/L	0.30-40.00 mg/L
Calcitonin	CALCIT CALCT	≤9.53 pg/mL	≤13.38 pg/mL	Two-site sandwich immunoassay chemiluminescent.	Siemens Calcitonin Package Insert RPBL1393R01 EN Rev. 01, 2019-04	5.00-1,800.00 pg/mL	5.00-180,000.00 pg/mL
Centromere B Antibody	CENTB		Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive
Chromatin Antibody	CHROMT		Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive
Chronic Hepatitis Panel (Dialysis, ESRD, AKI)	HBSAGS HEP3BS		**HBSAG:** Negative **HBSAB:** Negative **HBCGM:** Negative **HCAB:** Negative	Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes
CMV IgG Ab	CMVG		Negative	Chemiluminescent immunoassay.	Package Insert		Negative, Positive, Indeterminate
CMV IgM Ab	CMVM		Negative	Chemiluminescent immunoassay.	Package Insert		Negative, Positive, Indeterminate
CMVG, CMVM, EBV, HSVGI2, HSVM	CMVG CMVM EBV HSVGI2 HSVM		**CMVG:** Negative **CMVM:** Negative **EBV:** Negative **HSVGI2:** Negative **HSVM:** Negative	**CMVM & CMVG:** Chemiluminescent immunoassay. **EBV & HSVGI2:** Multiplex flow immunoassay **HSVM:** ELISA manual method	See individual analytes	See individual analytes	See individual analytes
C-Peptide	CPEP CpS	0.81-3.85 ng/mL		Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL
C-Peptide Tolerance (Part of the Insulin Glucose Tolerance Battery): -5 Minutes	CPM5M	0.81-3.85 ng/mL		Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL
C-Peptide Tolerance (Part of the Insulin Glucose Tolerance Battery): 0 Minute	CPZERO	0.81-3.85 ng/mL		Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL
C-Peptide Tolerance (Part of the Insulin Glucose Tolerance Battery): 2 Minutes	CPEP2M	0.81-3.85 ng/mL		Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL
C-Peptide Tolerance (Part of the Insulin Glucose Tolerance Battery): 5 Minutes	CPEP5M	0.81-3.85 ng/mL		Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL

C-Peptide Tolerance (Part of the Insulin Glucose Tolerance Battery): 10 Minutes	CP10M	0.81-3.85 ng/mL			Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL
C-Peptide Tolerance (Part of the Insulin Glucose Tolerance Battery): 30 Minutes	CP30M	0.81-3.85 ng/mL			Two-site sandwich immunoassay chemiluminescent.	Siemens C-Peptide Package Insert 10997742_EN Rev. 03, 2021-06	0.05-25.00 ng/mL	0.05-5,000.00 ng/mL
Cryptococcal Antigen	CRAG			Negative	Lateral flow assay.	Package Insert		SCREEN: Negative, Positive TITER: 1:2, 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, ≥1:2560
Cryptococcus, Antigen CSF	FCRAG			Negative	Lateral flow assay.	Package Insert		SCREEN: Negative, Positive TITER: 1:2, 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, ≥1:2560
DHEA-Sulfate	DHES DHEAS	25.90-460.20 ug/dL	34.50-568.90 ug/dL		Chemiluminescent immunoassay.	Siemens DHEAS Package Insert 11200382_EN	3.00-1,500.00 ug/dL	3.00-3,000.00 ug/dL
dsDNA Antibody	DSDNAB			Negative	Multiplex flow immunoassay.	Package Insert Textbook	QUANTITATIVE: 1-300 IU/mL	QUALITATIVE: Negative, Positive, Indeterminate QUANTITATIVE: 1-30,000 IU/mL
EBV VCA IgG Ab	EBVG			Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive, Indeterminate
EBV VCA IgG and IgM	EBV			**EBVG:** Negative **EBVM:** Negative	Multiplex flow immunoassay.	See individual analytes	See individual analytes	See individual analytes
EBV VCA IgM Ab	EBVM			Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive, Indeterminate
ENA Battery (SSA, SSB, SM, RNP)	ENAB			**RNP:** Negative **SMT:** Negative **SSAF:** Negative **SSBT:** Negative	Multiplex flow immunoassay.	See individual analytes	See individual analytes	See individual analytes
Free Hemoglobin, Plasma	PLASHGB	≤5.0 mg/dL			Photometric	HemoCue Operating Manual	30.0-2,100.0 mg/dL	≥30.0 mg/dL
G6PD, Qualitative	G6PD			Enzyme Activity Present	Visual Fluorescence	Package Insert	Enzyme Activity Absent, Enzyme Activity Present, Enzyme Activity Indeterminate	
Anti-Glomerular Basement Mem Ab	GBMAB			Negative	Multiplex flow immunoassay.	Bio-Rad IFU Vasculitis Revision 665-0516E		Negative, Positive
Growth Hormone	GRHR	≤6.88 ng/mL	≤1.23 ng/mL		Chemiluminescent immunoassay.	Package Insert	0.05-80.00 ng/mL	0.05-1,600.00 ng/mL
Hemoglobin A1C	A1CB	4.7-5.6 %			High-Performance Liquid Chromatography (HPLC)	Textbook	3.5-15.0 %	3.5-15.0 %
Hemoglobin, Fetal	HF	<1.0 %			High-Performance Liquid Chromatography (HPLC)	Package Insert Textbook	1.0-40.0 %	1.0-40.0 %
Hemoglobinopathy Eval	HEPB GCBCH Abnormal HGB Detection HEPB	**HEPB:** **HGBA** ≥95.0% **HGBA2** 2.1-3.3 % **HGBF** <1.0 % **HGBC** ≤0.0% **HGBS** ≤0.0% **HGB OTHER** ≤0.0% **GCBCH:** **RBC** 0-14 days: 4.12-5.74 M/uL 15-30 days: 3.32-4.80 M/uL 31-60 days: 2.93-3.87 M/uL 61-179 days: 3.45-4.75 M/uL 180 days-2 years: 3.97-5.01 M/uL 2-5 years: 3.84-4.92 M/uL 6-11 years: 3.90-4.96 M/uL 12-17 years: 3.93-4.90 M/uL 18+ years: 3.91-5.04 M/uL **HGB** 0-7 days: 13.4-20.0 g/dL 8-14 days: 13.4-20.0 g/dL 15-30 days: 10.8-14.6 g/dL 31-60 days: 9.2-11.4 g/dL 61-179 days: 9.9-12.4 g/dL 180 days-2 years: 10.2-12.7 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.6-13.2 g/dL 12-17 years: 10.8-13.3 g/dL 18+ years: 11.4-15.2 g/dL **MCH** 0-14 days: 31.1-35.9 pg 15-30 days: 30.4-35.3 pg 31-60 days: 28.0-32.5 pg 61-179 days: 24.4-29.5 pg 180 days-2 years: 23.2-27.5 pg 2-5 years: 23.7-28.6 pg 6-11 years: 24.8-29.5 pg 12-17 years: 24.8-30.2 pg 18+ years: 25.9-33.9 pg **MCV** 0-14 days: 92.7-106.4 fL 15-30 days: 90.1-103.0 fL 31-60 days: 83.4-96.4 fL 61-179 days: 74.8-88.3 fL 180 days-2 years: 71.3-82.6 fL 2-5 years: 72.3-85.0 fL 6-11 years: 75.9-87.6 fL 12-17 years: 76.9-90.6 fL 18+ years: 79.6-97.7 fL **RDW** 0-14 days: 14.6-17.3 % 15-30 days: 14.4-16.2 % 31-60 days: 13.6-15.8 % 61-179 days: 12.2-14.3 % 180 days-2 years: 12.7-15.1 % 2-5 years: 12.4-14.9 % 6-11 years: 12.2-14.4 % 12-17 years: 12.3-14.6 % 18+ years: 10.8-14.9 %	**HEPB:** **HGBA** ≥95.0% **HGBA2** 2.1-3.3 % **HGBF** <1.0 % **HGBC** ≤0.0% **HGBS** ≤0.0% **HGB OTHER** ≤0.0% **GCBCH:** **RBC** 0-14 days: 4.10-5.55 M/uL 15-30 days: 3.16-4.63 M/uL 31-60 days: 3.02-4.22 M/uL 61-179 days: 3.43-4.80 M/uL 180 days-2 years: 4.03-5.07 M/uL 2-5 years: 3.89-4.97 M/uL 6-11 years: 3.96-5.03 M/uL 12-17 years: 4.03-5.29 M/uL 18+ years: 4.38-5.83 M/uL **HGB** 0-7 days: 13.9-19.1 g/dL 8-14 days: 13.9-19.1 g/dL 15-30 days: 10.0-15.3 g/dL 31-60 days: 8.9-12.7 g/dL 61-179 days: 9.6-12.4 g/dL 180 days-2 years: 10.1-12.5 g/dL 2-5 years: 10.2-12.7 g/dL 6-11 years: 10.7-13.4 g/dL 12-17 years: 11.0-14.5 g/dL 18+ years: 13.4-16.8 g/dL **MCH** 0-14 days: 31.3-35.6 pg 15-30 days: 29.9-34.1 pg 31-60 days: 27.8-32.0 pg 61-179 days: 24.4-28.9 pg 180 days-2 years: 22.7-27.2 pg 2-5 years: 23.7-28.3 pg 6-11 years: 24.9-29.2 pg 12-17 years: 25.2-30.2 pg 18+ years: 26.1-33.3 pg **MCV** 0-14 days: 91.3-103.1 fL 15-30 days: 89.4-99.7 fL 31-60 days: 84.3-94.2 fL 61-179 days: 74.1-87.5 fL 180 days-2 years: 69.5-81.7 fL 2-5 years: 71.3-84.0 fL 6-11 years: 74.4-86.1 fL 12-17 years: 76.7-89.2 fL 18+ years: 79.0-94.5 fL **RDW** 0-14 days: 14.8-17.0 % 15-30 days: 14.3-16.8 % 31-60 days: 13.8-16.1 % 61-179 days: 12.4-15.3 % 180 days-2 years: 12.9-15.6 % 2-5 years: 12.5-14.9 % 6-11 years: 12.3-14.1 % 12-17 years: 12.4-14.5 % 18+ years: 10.9-14.3 %		**HEPB** High-Performance Liquid Chromatography (HPLC) **GCBCH** The Sysmex XN performs hematology analysis according to the hydrodynamic focusing (DC detection), flow cytometry method (semiconductor laser), and sodium lauryl sulfate (SLS)-hemoglobin method.	Package Insert Textbook	HGBA2: 1.0-7.0 % HGBF: 1.0-40.0 % RBC: See individual analyte HGB: See individual analyte MCHC: See individual analyte MCV: See individual analyte RDW: See individual analyte	HGBA2: 1.0-7.0 % HGBF: 1.0-40.0 % RBC: See individual analyte HGB: See individual analyte MCHC: See individual analyte MCV: See individual analyte RDW: See individual analyte
Hepatitis A Ab, Total (IgG + IgM)	HAAGM			Negative	Competitive direct chemiluminescent immunoassay	Package Insert		Negative, Positive, Indeterminate
Hepatitis A IgM Ab	HAABM			Negative	Two-step IgM capture immunoassay	Package Insert		Negative, Positive, Indeterminate
Hepatitis B Core Ab, Total (IgG + IgM)	HBCOM			Negative	Two-wash antigen sandwich immunoassay	Package Insert		Negative, Positive, Indeterminate
Hepatitis B Core IgM Ab	HBCBM			Negative	Two-step IgM capture immunoassay	Package Insert		Negative, Positive, Indeterminate

Hepatitis B Surface Antibody	HBSAB			Negative	Sandwich direct chemiluminescent immunoassay	Package Insert		Negative, Positive
Hepatitis B Surface Antigen	HBSAG			Negative	Sandwich direct chemiluminescent immunoassay	Package Insert	Negative, Positive, Initially reactive, to be confirmed by neutralization	
Hepatitis Battery, Acute	HEP1B			**HBSAG:** Negative **HBCGM:** Negative **HBCBM:** Negative **HAABM:** Negative **HCAB:** Negative	Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes
Hepatitis Battery, Chronic	HEP3B			**HBSAG:** Negative **HBSAB:** Negative **HBCGM:** Negative **HCAB:** Negative	Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes
Hepatitis Be Antibody	HBEB			Non Reactive	Chemiluminescent immunoassay.	Package Insert		Nonreactive, Reactive
Hepatitis Be Antigen	HBEG			Negative	Two-step sandwich immunoassay	Package Insert		Negative, Positive
Hepatitis C Antibody	HCAB			Negative	Indirect sandwich immunoassay	Package Insert		Negative, Positive, Indeterminate
Hepatitis Infectious	HEPIF			**HBSAG:** Negative **HBCGM:** Negative **HBSAB:** Negative	Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes
HIV 1 and 2 Antibodies/p24 Antigen	HIV12			Non Reactive	Two-step sandwich immunoassay	Package Insert		Non Reactive, Reactive
HIV-1/HIV-2 Differentiation	HIV12C			**HIV-1:** Non Reactive **HIV-2:** Non Reactive	Immunochromatographic assay	Package Insert		HIV-1: Non Reactive, Reactive, Indeterminate HIV-2: Non Reactive, Reactive, Indeterminate
HPV Human Papilloma Virus Genotyping w/o Pap Smear	HPVG			**HPVG16:** Negative **HPVG18:** Negative **HPVGO:** Negative The assay detects HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.	Polymerase chain reaction (PCR)	Package Insert		HPVGI6: Negative, Positive HPVG18: Negative, Positive HPVGO: Negative, Positive
HPV Testing, Reflex to Cytology for All Positive Results	HPVGSF HPVCYT HPV			**HPVG16:** Negative **HPVG18:** Negative **HPVGO:** Negative The assay detects HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.	Polymerase chain reaction (PCR)	Package Insert		HPVGI6: Negative, Positive HPVG18: Negative, Positive HPVGO: Negative, Positive
HPV Testing, Reflex to Cytology for HPV Positive Other Category	HPVGOTH HPVCYT HPV			**HPVG16:** Negative **HPVG18:** Negative **HPVGO:** Negative The assay detects HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.	Polymerase chain reaction (PCR)	Package Insert		HPVGI6: Negative, Positive HPVG18: Negative, Positive HPVGO: Negative, Positive
HSV 1 and 2 IgG Antibody	HSVGI2			**HSVG1:** Negative **HSVG2:** Negative	Multiplex flow immunoassay.	Package Insert Textbook		HSVGI: Negative, Positive, Indeterminate HSVG2: Negative, Positive, Indeterminate
HSV 2 IgG Antibody	HSVG2			Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive, Indeterminate
HSV IgM Antibody	HSVM			Negative	ELISA manual method	Textbooks, HSV-1&2 IgG procedure, Package Insert		Negative, Positive, Equivocal
Immune Status Hepatitis Battery	HEP2			**HBCGM:** Negative **HBSAB:** Negative **HCAB:** Negative	Chemiluminescent immunoassay.	See individual analytes	See individual analytes	See individual analytes
Immunofixation, Serum	SIMFX SIMFXB Serum Protein Electrophoresis with Immunofixation and Serum Total Protein	**MPRO1** ≤0.0 mg/dL **MPRO2** ≤0.0 mg/dL **MPRO3** ≤0.0 mg/dL **MPRO4** ≤0.0 mg/dL			Capillary electrophoresis	Package Insert		MPRO1: ≥0.0 mg/dL MPRO2: ≥0.0 mg/dL MPRO3: ≥0.0 mg/dL MPRO4: ≥0.0 mg/dL
Immunoglobulin Free Chains	IFLC	**KFLC** 3.9-26.0 mg/L **LFLC** 6.4-22.1 mg/L **RATIO** 0.51-1.72			Turbidimetry	2017 OSU Study	KFLC: 2.9-127.0 mg/L LFLC: 5.2-139.0 mg/L	KFLC: 0.6-63,500.0 mg/L LFLC: 1.3-139,000.0 mg/L
Immunoglobulin IgE	IGE IgE, Total	≤165.3 IU/mL			Two-site sandwich direct chemiluminescent immunoassay	Reference Range Study 11.3.2016	2.5-3,000.0 IU/mL	2.5-3,000.0 IU/mL
Insulin	INSL	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin Glucose Tolerance Minus 5 Min	INSUL1	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin Glucose Tolerance 0 Minute	INSUL2	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin Glucose Tolerance 2 Minute	INSUL3	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin Glucose Tolerance 5 Minute	INSUL4	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin Glucose Tolerance 10 Minute	INSUL5	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin Glucose Tolerance 30 Minute	INSUL6	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Insulin-Like Growth Factor 1	IGF1 Somatomedin C	All Reference Ranges			Chemiluminescent immunoassay.	Package Insert	10.0-1,000.0 ng/mL	10.0-1,000.0 ng/mL
Intact PTH (Intraoperative)	RPTH Intact PTH Rapid Parathyroid Hormone	14.0-72.0 pg/mL			Two-site sandwich immunoassay	Atellica product insert (PTH) REV 4, 2020/11	6.3-2,000.0 pg/mL	6.3-160,000.0 pg/mL
JO-1 Antibody	JO1 JOIT			Negative	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive
Lyme Antibody	LYME			Negative	Chemiluminescent immunoassay.	Package Insert		Negative, Positive
Legionella Urinary Ag	LEGIONU			Negative	Enzyme Immunoassay (EIA)	Package Insert		Negative, Positive
M Tuberculosis By Quantiferon	QFTB QFT M. Tuberculosis Antigen			Negative	Chemiluminescent immunoassay.	Package Insert		MTUBERQUANT: Negative, Positive, Indeterminate MTB TB1-NIL: 0.00-10.00 IU/mL MTB TB2-NIL: 0.00-10.00 IU/mL MTB MITOGEN-NIL: 0.00-10.00 IU/mL MTB NIL: 0.00-10.00 IU/mL
Maternal Hepatitis B Surface Ag	MHBSAG			Negative	Sandwich direct chemiluminescent immunoassay	Package Insert	Negative, Positive, Initially reactive, to be confirmed by neutralization	
Maternal Rubella, IgG/Hep B Ag	MHBSAG RUBAB			**MHBSAG:** Negative **RUBAG:** Positive	Multiplex flow immunoassay.	See individual analytes	See individual analytes	See individual analytes

Monoclonal Prot Imfx, Urine 24 Hr	Urine Immunofixation - 24 Hour UIMFXB UPRO	**MPROU1** ≤0 mg/24hrs **MPROU2** ≤0 mg/24hrs **MPROU3** ≤0 mg/24hrs **MPROU4** ≤9 mg/24hrs **PROT4** 40-225 mg/24 hrs			Electrophoresis	Package Insert		
Monoclonal Prot Immuno, Serum	SERUM TP PSE QIMM SIMFX	**PROTEIN** 0-30 days: 4.2-6.2 g/dL 31-182 days: 4.4-6.6 g/dL 183-365 days: 5.6-7.9 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL **ALBUMIN** 3.5-5.0 g/dL **ALPHA 1** 0.2-0.4 g/dL **ALPHA 2** 0.5-1.0 g/dL **BETA** 0.5-1.1 g/dL **GAMMA** 0.6-1.5 g/dL **IGA** 0-30 days: 0-10 mg/dL 31-182 days: ≤42 mg/dL 183-365 days: 6-68 mg/dL 1-3 years: 15-111 mg/dL 4-6 years: 33-166 mg/dL 7-9 years: 28-180 mg/dL 10-12 years: 55-193 mg/dL 13-15 years: 62-241 mg/dL 16-18 years: 69-262 mg/dL 19-59 years: 66-433 mg/dL 60+ years: 90-410 mg/dL **IGG** 0-30 days: 162-872 mg/dL 31-182 days: 311-664 mg/dL 183-365 days: 325-647 mg/dL 1-3 years: 451-1,202 mg/dL 4-6 years: 560-1,319 mg/dL 7-9 years: 485-1,473 mg/dL 10-12 years: 586-1,609 mg/dL 13-15 years: 749-1,640 mg/dL 16-18 years: 804-1,817 mg/dL 19-59 years: 600-1,714 mg/dL 60+ years: 600-1,560 mg/dL **IGM** 0-29 days: 1-57 mg/dL 30-182 days: <128 mg/dL 183-365 days: <131 mg/dL 1-3 years: 35-184 mg/dL 4-6 years: 42-184 mg/dL 7-9 years: 30-165 mg/dL 10-12 years: 42-211 mg/dL 13-15 years: 34-225 mg/dL 16-18 years: 45-224 mg/dL 19-59 years: 45-281 mg/dL 60+ years: 30-360 mg/dL **MPRO1** ≤0.0 mg/dL **MPRO2** ≤0.0 mg/dL **MPRO3** ≤0.0 mg/dL **MPRO4** ≤0.0 mg/dL	**PROTEIN** 0-30 days: 4.1-6.3 g/dL 31-182 days: 4.7-6.7 g/dL 183-365 days: 5.5-7.0 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL **ALBUMIN** 3.5-5.0 g/dL **ALPHA 1** 0.2-0.4 g/dL **ALPHA 2** 0.5-1.0 g/dL **BETA** 0.5-1.1 g/dL **GAMMA** 0.6-1.5 g/dL **IGA** 0-30 days: ≤11 mg/dL 31-182 days: ≤40 mg/dL 183-365 days: 1-82 mg/dL 1-3 years: 9-137 mg/dL 4-6 years: 44-187 mg/dL 7-9 years: 58-204 mg/dL 10-12 years: 46-218 mg/dL 13-15 years: 29-251 mg/dL 16-18 years: 68-259 mg/dL 19-59 years: 66-433 mg/dL 60+ years: 90-410 mg/dL **IGG** 0-30 days: 197-833 mg/dL 31-182 days: 140-533 mg/dL 183-365 days: 130-823 mg/dL 1-3 years: 413-1,112 mg/dL 4-6 years: 468-1,328 mg/dL 7-9 years: 582-1,441 mg/dL 10-12 years: 685-1,620 mg/dL 13-15 years: 590-1,600 mg/dL 16-18 years: 522-1,703 mg/dL 19-59 years: 600-1,714 mg/dL 60+ years: 600-1,560 mg/dL **IGM** 0-29 days: 0-65 mg/dL 30-182 days: 6-84 mg/dL 183-365 days: 15-117 mg/dL 1-3 years: 30-146 mg/dL 4-6 years: 31-151 mg/dL 7-9 years: 21-140 mg/dL 10-12 years: 27-151 mg/dL 13-15 years: 26-184 mg/dL 16-18 years: 28-179 mg/dL 19-59 years: 45-281 mg/dL 60+ years: 30-360 mg/dL **MPRO1** ≤0.0 mg/dL **MPRO2** ≤0.0 mg/dL **MPRO3** ≤0.0 mg/dL **MPRO4** ≤0.0 mg/dL	Capillary electrophoresis	See individual analytes	See individual analytes	See individual analytes
Mumps, IgG Ab, Immune Status	MUMPSB			Positive	Multiplex flow immunoassay.	Package Insert Textbook		Negative, Positive, Indeterminate
Myeloperoxidase Antibodies	MPO			Negative	Multiplex flow immunoassay.	IFU		Negative, Positive
Post-Distal Splenic Artery	DISTSPART30 DISTSPART60 DISTSPART90 DISTPART120 DISTPART180	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Post Gastroduodenal Artery	GASTART30 GASTART60 GASTART90 GASTART120 GASTART180	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Post Miscellaneous Artery	MISC30 MISC60 MISC90 MISC120 MISC180	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Post Proximal Splenic Artery	PROXSPART30 PROXSPART60 PROXSPART90 PROXSPART120 PROXSPART180	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Post Superior Mesenteric Artery	SUPMART30 SUPMART60 SUPMART90 SUPMART120 SUPMART180	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Pre-Distal Splenic Artery	DISTSPARTB1 DISTSPARTB2	3.0-25.0 uIU/mL			Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL

Pre Gastroduodenal Artery	GASTARTB1 GASTARTB2	3.0-25.0 uIU/mL		Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Pre Miscellaneous Artery	MISCB1 MISCB2	3.0-25.0 uIU/mL		Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Pre-Proximal Splenic Artery	PROXSPARTB1 PROXSPARTB2	3.0-25.0 uIU/mL		Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Pre Superior Mesenteric Artery	SUPMARTB1 SUPMARTB2	3.0-25.0 uIU/mL		Two-site sandwich chemiluminescent immunoassay	Siemens Insulin Package Insert 10997752_EN Rev. 05, 2021-06	0.5-300.0 uIU/mL	0.5-1,500.0 uIU/mL
Protein Electrophoresis Serum, with Reflex	SERUM TP SPE Serum Electrophoresis PSE Serum Protein Electrophoresis with Reflex to Immunofixation and serum total protein	**PROTEIN** 0-30 days: 4.2-6.2 g/dL 31-182 days: 4.4-6.6 g/dL 183-365 days: 5.6-7.9 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL **ALBUMIN** 3.5-5.0 g/dL **ALPHA 1** 0.2-0.4 g/dL **ALPHA 2** 0.5-1.0 g/dL **BETA** 0.5-1.1 g/dL **GAMMA** 0.6-1.5 g/dL	**PROTEIN** 0-30 days: 4.1-6.3 g/dL 31-182 days: 4.7-6.7 g/dL 183-365 days: 5.5-7.0 g/dL 1-18 years: 5.7-8.0 g/dL 19+ years: 6.4-8.3 g/dL **ALBUMIN** 3.5-5.0 g/dL **ALPHA 1** 0.2-0.4 g/dL **ALPHA 2** 0.5-1.0 g/dL **BETA** 0.5-1.1 g/dL **GAMMA** 0.6-1.5 g/dL		Capillary electrophoresis	Package Insert	PROTEIN: 3.0-12.0 g/dL ALBUMIN: ≤0.0 g/dL ALPHA 1: ≤0.0 g/dL ALPHA 2: ≤0.0 g/dL BETA: ≤0.0 g/dL GAMMA: ≤0.0 g/dL	PROTEIN: 3.0-24.0 g/dL ALBUMIN: >0.0 g/dL ALPHA 1: >0.0 g/dL ALPHA 2: >0.0 g/dL BETA: >0.0 g/dL GAMMA: >0.0 g/dL
PTH Intact	IPTH Parathyroid Hormone	14.0-72.0 pg/mL		Two-site sandwich immunoassay	Atellica product insert (PTH) REV 4, 2020/11	6.3-2,000.0 pg/mL	6.3-160,000.0 pg/mL
Renin	RENIN Direct	0-39 years: 4.2-52.2 pg/mL 40+ years: 3.6-81.6 pg/mL		Chemiluminescent immunoassay.	Package Insert	2.1-300.0 pg/mL	2.1-3,000.0 pg/mL
Ribosomal P Antibody	RIBOPT			Negative	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive
RNP Antibody	RNP			Negative	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive
RPR	Rapid Plasma Reagin RPRC			Non Reactive	Macroscopic nontreponemal flocculation	Package Insert		SCREEN: Non Reactive, Reactive TITER: 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024, ≥1:2048
RPR with Titer	RPRT			Non Reactive	Macroscopic nontreponemal flocculation	Package Insert		SCREEN: Non Reactive, Reactive TITER: 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024, ≥1:2048
Rubella IgG With Reflex To IgM	RUBAGR			Positive	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive, Indeterminate
Rubella Immune Status IgG Antibody	RUBAB			Positive	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive, Indeterminate
Rubeola IgG Ab (Immune Status)	RUBOIB			Positive	Multiplex flow immunoassay.	BioPlex 2200 MMRV IgG Procedure March 2010		Negative, Positive, Indeterminate
Sex Hormone Binding Globulin	SHBG	18.00-144.00 nmol/L	10.00-57.00 nmol/L		Sandwich immunoassay	Siemens IMMULITE 2000 SHBG (PIL2KSH-20, 2018-03-15)	1.60-180.00 nmol/L	1.60-360.00 nmol/L
Sm Antibody	SMA SMT			Negative	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive
Sm/RNP Antibody	SMRNPT			Negative	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive
SS-A/RO Antibody	SSAT			Negative	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive
SS-B/LA Antibody	SSBT			Negative	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive
Syphilis Ab w/ Reflex RPR	SYPHT Syphilis IgG/IgM Antibody			Non Reactive	Direct sandwich assay	Package Insert		SYPHG: Non Reactive, Reactive, Equivocal RPR SCREEN: Non Reactive, Reactive RPR TITER: 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024, ≥1:2048
Toxoplasma IgG Antibody	TOXOG			Negative	Sandwich direct chemiluminescent immunoassay	Package Insert		Negative, Positive, Equivocal
Urine Immunofixation, Random	UIMFXR Monoclonal Prot Immfx, Urine - Random UIMFXR				Electrophoresis	Package Insert		
Varicella IgG Ab (Immune Status)	VZISB			Positive	Multiplex flow immunoassay.	Package Insert Textbook	Negative, Positive, Indeterminate
Vitamin D (25-Hydroxy,Total)	D25OH Vitamin D, Total	30.0-100.0 ng/mL			Chemiluminescent immunoassay.	Package Insert	4.0-150.0 ng/mL	4.0-150.0 ng/mL
Vitamin D, (1,25 Dihydroxy)	D125	20.0-79.0 pg/mL			In vitro chemiluminescent immunoassay.	Package Insert	5.0-180.0 pg/mL	5.0-540.0 pg/mL
ABO/RH(D) Typing	ABORH Blood Type	A, B, O, AB Rh Negative, Rh Positive			Agglutination			
ABORH - Not Valid for Transfusion	ABORHD ABOD Blood Type	A, B, O, AB Rh Negative, Rh Positive			Agglutination			
Antibody Titer	ABTIT	Negative			Agglutination	Alloimmunization Committee		
Antigen Testing	AGID Antigen typing				Agglutination			
Baby Type and DAT (Direct Antiglobulin Test)	HEELS Heelstick Evaluation	**ABORH** A, B, O, AB Rh Negative, Rh Positive **DAT** Negative			Agglutination			
Cold Agglutinin Titer	COLD	Negative			Agglutination			
Cord Blood Evaluation	CORDB CORDH	**ABORH** A, B, O, AB Rh Negative, Rh Positive **DAT** Negative			Agglutination			

Cordocentesis	CORDO			Agglutination			
Direct Antiglobulin Test (DAT)	DATO DAT	Negative		Agglutination			
Rhoig Evaluation	RHEV Rhogam Evaluation			Agglutination			
Transfusion Reaction Battery	TRXN			Agglutination			
Type and Screen	XM	**ABORH** A, B, O, AB Rh Negative, Rh Positive **ANTIBODY SCREEN** Negative		Agglutination			
Type and Screen - Not for Transfusion	TYSC	**ABORH** A, B, O, AB Rh Negative, Rh Positive **ANTIBODY SCREEN** Negative		Agglutination			
Type and Screen - Preadmission	XMPO	**ABORH** A, B, O, AB Rh Negative, Rh Positive **ANTIBODY SCREEN** Negative		Agglutination			
BMT Panel 1	BMT1R			Flow cytometry immunophenotyping			
CD19 CAR T	CAR19T CD19 probe CAR 19 CART19 Chimeric antiuen recentor T detection			Flow cytometry immunophenotyping	Known value, circulating CAR T can only be found in infused patients		CD3PERCENTTL: 0.1-100.0 % CD3PERTOT: 0.1-100.0 % CAR19PERTL: 0.1-100.0 % CARPLYM: 0.1-100.0 % CAR19PERCD3: 0.1-100.0 %
CD3EN	CD3EN CD3 Enumeration			Flow cytometry immunophenotyping			
Helper/Suppressor Quant	HSFB HSF CD4/CD8 T helper T suppressor	**CD4/CD3 DUAL (T HELPER)%** 0-179 days: 50.0-57.0 % 180-365 days: 49.0-55.0 % 1-2 years: 46.0-51.0 % 2-3 years: 38.0-46.0 % 3+ years: 32.0-62.0 % **CD4/CD3 DUAL (T HELPER)** 266-2,213 ABS/mm3 **CD4/CD3 DUAL (T SUPPRESSOR)%** 11.0-40.0 **CD4/CD3 DUAL (T SUPPRESSOR)** 91-1,428 ABS/mm3		Flow cytometry immunophenotyping	OSU Flow Lab established		

Immune Reconst Panel Flow Cytometry	IRP PBIRPD PBIRP	**CD3+**: 59.0-92.0% **CD19+**: 2.0-21.0% **CD5616+/CD3-**: 3.0-25.0% **CD13+/HLA DR-**: No established reference range **CD13+/HLA DR+**: No established reference range **CD3+/CD69+**: 0.0-2.9% **CD3+/CD134+**: 0.0-0.5% **CD3+/HLADR+**: 0.0-5.6% **CD3+/CD69+/HLADR+**: 0.0-0.2% **CD3+/CD134+/HLADR+**: 0.0-0.1% **CD3+/CD69+/*CD134+**: 0.0-0.1% **CD3+/CD69+/CD134+/HLADR+**: 0.0-0.0% **CD3+/CD80+**: 0.0-0.2% **CD3+/CD86+**: 0.0-0.5% **CD3+/CD80-**: 59.8-86.5% **CD3+/CD86-**: 59.7-86.3% **CD19+/CD80+**: 0.0-0.4% **CD19+/CD86+**: 0.0-0.5% **CD19+/CD80-**: 3.6-20.5% **CD19+/CD86-**: 2.9-20.7% **CD19+/CD80-/CD86-**: 3.2-19.8% **CD19+/CD80+/CD86+**: 0.0-0.0% **CD3+/CD80-/CD86-**: 59.3-85.8% **CD3+/CD80+/CD86+**: 0.0-0.0% **CD4+/CD45RA+**: 6.4-36.3% **CD4+/CD45RO+**: 12.2-41.8% **CD8+/CD45RA+**: 14.3-45.8% **CD8+/CD45RO+**: 5.2-31.8% **CD4+/CD45RA+/*CD27-**: 0.0-0.8% **CD4+/*CD27+/CD45RA-/CD45RO-**: 0.0-12.7% **CD4+/CD45RA+/*CD27+**: 4.6-30.2% **CD4+/CD45RO+/*CD27-**: 0.0-8.0% **CD4+/CD45RO+/*CD27+**: 9.9-36.1% **CD8+/CD45RA+/*CD27-**: 0.0-15.0% **CD8+/*CD27+/CD45RA-/CD45RO-**: 0.0-0.1% **CD8+/CD45RA+/*CD27+**: 0.8-18.3% **CD8+/CD45RO+/*CD27-**: 0.0-4.7% **CD8+/CD45RO+/CD27+**: 0.0-12.9% **CD4+/CD45RA+/*CD29-**: 2.5-26.1% **CD4+/*CD29+/CD45RA-/CD45RO-**: 0.0-0.7% **CD4+/CD45RA+/*CD29+**: 0.3-5.9% **CD4+/CD45RO+/*CD29-**: 0.9-8.4% **CD4+/CD45RO+/*CD29+**: 8.7-34.6% **CD8+/CD45RA+/*CD29-**: 0.0-14.2% **CD8+/*CD29+/CD45RA-/CD45RO-**: 0.0-0.1% **CD8+/CD45RA+/*CD29+**: 2.6-18.1% **CD8+/CD45RO+/*CD29-**: 0.0-2.6% **CD8+/CD45RO+/*CD29+**: 0.0-14.4% **CD4+/CD31+**: No established reference range **CD8+/CD31+**: No established reference range **CD3+/CD49a+**: No established reference range **CD4+/CD49a+**: No established reference range **CD8+/CD49a+**: No established reference range **CD4+/*CD193+**: 0.0-0.1% **CD4+/*CD294+**: 0.0-0.8% **CD4+/*CD183+**: 6.7-30.5% **CD4+/*CD193+/*CD294+**: 0.0-0.0% **CD4+/*CD193+/*CD183+**: 0.0-0.0% **CD4+/*CD193+/*CD294+/*CD183+**: 0.0-0.0% **CD4+/*CD194+**: 0.0-27.8% **CD4+/*CD193+/*CD194+**: 0.0-0.0% **CD4+/*CD294+/*CD194+**: 0.0-0.2% **CD4+/*CD193+/*CD294+/*CD194+**: 8.9-32.5% **CD4+/CD25+**: 0.0-3.2% **CD4+/CD127+**: 30.6-53.9% **CD8+/CD25+**: 0.0-0.1% **CD8+/CD127+**: 6.7-24.6% **CD8+/CD127+/CD25-**: 6.3-24.3% **CD8+/CD25+/CD127-**: 0.0-0.0% **CD4+/CD25+/CD127-**: 0.0-2.1% **CD4+/CD25+/CD127+**: 0.0-1.4% **CD3+/AlphaBeta+**: 47.3-80.4% **CD3+/GammaDelta+**: 0.0-7.3% **CD3+/CD158b+**: 0.0-4.4% **CD3-/CD5616-/CD69+**: 0.0-0.2% **CD3+/CD69+/CD158b+**: 0.0-0.1% **CD3-/CD5616+/CD158b+**: 0.0-7.1% **CD3-/CD5616+/CD69+**: 0.0-1.1% **CD3-/CD5616+/CD69+/CD158b+**: 0.0-0.2% **CD3+/CD159a+**: 0.0-6.8% **CD3+/CD107a+b+**: 0.0-0.3% **CD3+/CD159a+/CD107a+b+**: 0.0-0.0% **CD3-/CD5616+/CD107a+b+**: 0.0-0.0% **CD3-/CD5616+/CD159a+**: 0.0-11.6% **CD3-/CD5616+/CD159a+/CD107a+b+**: 0.0-0.0% **CD3+/CD314+**: 10.3-36.2% **CD3-/CD5616-/CD63+**: 0.0-2.1% **CD3-/CD5616-/CD314+**: 0.0-0.2% **CD3+/CD63+/CD314+**: 0.0-0.5% **CD3-/CD5616+/CD314+**: 0.0-14.8% **CD3-/CD5616+/CD63+/CD314+**: 0.0-0.2% **CD16-/CD56-/CD3-/CD117-**: 5.2-23.0% **CD16+CD56-/CD3-/CD117-**: 0.0-5.2% **CD16-/CD56+/CD3-/CD117-**: 0.2-1.1% **CD16+/CD56+/CD3-/CD117-**: 0.0-17.9% **CD16-/CD56-/CD3+/CD117-**: 57.2-82.8% **CD16+/CD56-/CD3+/CD117-**: 0.0-1.6% **CD16-/CD56+/CD3+/CD117-**: 0.0-7.0% **CD16+/CD56+/CD3+/CD117-**: 0.0-2.1% **CD16+/CD56-/CD3+/CD117+**: 0.0-0.0% **CD16-/CD56+/CD3-/CD117+**: 0.0-0.2% **CD16+/CD56+/CD3-/CD117+**: 0.0-0.0%	**CD3+**: 590-4416 ABS/mm3 **CD19+**: 17-750 ABS/mm3 **CD5616+/CD3-**: 25-893 ABS/mm3 **CD13+/HLA DR-**: No established reference range **CD13+/HLA DR+**: No established reference range **CD3+/CD69+**: No established reference range **CD3+/CD134+**: 0-95 ABS/mm3 **CD3+/HLADR+**: 0-139 ABS/mm3 **CD3+/CD69+/HLADR+**: 0-4 ABS/mm3 **CD3+/CD134+/HLADR+**: 0-2 ABS/mm3 **CD3+/CD69+/*CD134+**: 0-2 ABS/mm3 **CD3+/CD69+/CD134+/HLADR+**: 0-0 ABS/mm3 **CD3+/CD80+**: 0-5 ABS/mm3 **CD3+/CD86+**: 0-10 ABS/mm3 **CD3+/CD80-**: 607-2519 ABS/mm3 **CD3+/CD86-**: 607-2517 ABS/mm3 **CD19+/CD80+**: 0-11 ABS/mm3 **CD19+/CD86+**: 0-14 ABS/mm3 **CD19+/CD80-**: 121-557 ABS/mm3 **CD19+/CD86-**: 113-554 ABS/mm3 **CD19+/CD80-/CD86-**: 114-554 ABS/mm3 **CD19+/CD80+/CD86+**: 0-0 ABS/mm3 **CD3+/CD80-/CD86-**: 602-2502 ABS/mm3 **CD3+/CD80+/CD86+**: 0-0 ABS/mm3 **CD4+/CD45RA+**: 58-842 ABS/mm3 **CD4+/CD45RO+**: 146-1011 ABS/mm3 **CD8+/CD45RA+**: 187-1078 ABS/mm3 **CD8+/CD45RO+**: 132-816 ABS/mm3 **CD4+/CD45RA+/*CD27-**: 0-18 ABS/mm3 **CD4+/*CD27+/CD45RA-/CD45RO-**: 0-252 ABS/mm3 **CD4+/CD45RA+/*CD27+**: 0-783 ABS/mm3 **CD4+/CD45RO+/*CD27-**: 0-163 ABS/mm3 **CD4+/CD45RO+/*CD27+**: 94-901 ABS/mm3 **CD8+/CD45RA+/*CD27-**: 0-341 ABS/mm3 **CD8+/*CD27+/CD45RA-/CD45RO-**: 0-1 ABS/mm3 **CD8+/CD45RA+/*CD27+**: 0-426 ABS/mm3 **CD8+/CD45RO+/*CD27-**: 0-122 ABS/mm3 **CD8+/CD45RO+/CD27+**: 0-291 ABS/mm3 **CD4+/CD45RA+/*CD29-**: 131-666 ABS/mm3 **CD4+/*CD29+/CD45RA-/CD45RO-**: 0-17 ABS/mm3 **CD4+/CD45RA+/*CD29+**: 0-145 ABS/mm3 **CD4+/CD45RO+/*CD29-**: 2-201 ABS/mm3 **CD4+/CD45RO+/*CD29+**: 83-848 ABS/mm3 **CD8+/CD45RA+/*CD29-**: 0-331 ABS/mm3 **CD8+/*CD29+/CD45RA-/CD45RO-**: 0-2 ABS/mm3 **CD8+/CD45RA+/*CD29+**: 30-408 ABS/mm3 **CD8+/CD45RO+/*CD29-**: 0-56 ABS/mm3 **CD8+/CD45RO+/*CD29+**: 0-343 ABS/mm3 **CD4+/CD31+**: No established reference range **CD8+/CD31+**: No established reference range **CD3+/CD49a+**: No established reference range **CD4+/CD49a+**: No established reference range **CD8+/CD49a+**: No established reference range **CD4+/*CD193+**: 0-3 ABS/mm3 **CD4+/*CD294+**: 0-23 ABS/mm3 **CD4+/*CD183+**: 84-696 ABS/mm3 **CD4+/*CD193+/*CD294+**: 0-0 ABS/mm3 **CD4+/*CD193+/*CD183+**: 0-0 ABS/mm3 **CD4+/*CD193+/*CD294+/*CD183+**: 0-0 ABS/mm3 **CD4+/*CD194+**: 0-560 ABS/mm3 **CD4+/*CD193+/*CD194+**: 0-0 ABS/mm3 **CD4+/*CD294+/*CD194+**: 0-4 ABS/mm3 **CD4+/*CD193+/*CD294+/*CD194+**: 64-836 ABS/mm3 **CD4+/CD25+**: 0-68 ABS/mm3 **CD4+/CD127+**: 318-1487 ABS/mm3 **CD8+/CD25+**: 0-1 ABS/mm3 **CD8+/CD127+**: 55-624 ABS/mm3 **CD8+/CD127+/CD25-**: 50-616 ABS/mm3 **CD8+/CD25+/CD127-**: 0-0 ABS/mm3 **CD4+/CD25+/CD127-**: 0-43 ABS/mm3 **CD4+/CD25+/CD127+**: 0-30 ABS/mm3 **CD3+/AlphaBeta+**: 50-2158 ABS/mm3 **CD3+/GammaDelta+**: 0-135 ABS/mm3 **CD3+/CD158b+**: 0-89 ABS/mm3 **CD3-/CD5616-/CD69+**: 0-5 ABS/mm3 **CD3+/CD69+/CD158b+**: No established reference range **CD3-/CD5616+/CD158b+**: 0-178 ABS/mm3 **CD3-/CD5616+/CD69+**: 0-24 ABS/mm3 **CD3-/CD5616+/CD69+/CD158b+**: 0-6 ABS/mm3 **CD3+/CD159a+**: 0-170 ABS/mm3 **CD3+/CD107a+b+**: 0-6 ABS/mm3 **CD3+/CD159a+/CD107a+b+**: 0-0 ABS/mm3 **CD3-/CD5616+/CD107a+b+**: 0-0 ABS/mm3 **CD3-/CD5616+/CD159a+**: 0-0 ABS/mm3 **CD3-/CD5616+/CD159a+/CD107a+b+**: 0-0 ABS/mm3 **CD3+/CD314+**: 80-929 ABS/mm3 **CD3-/CD5616-/CD63+**: 0-48 ABS/mm3 **CD3-/CD5616-/CD314+**: 0-6 ABS/mm3 **CD3+/CD63+/CD314+**: 0-11 ABS/mm3 **CD3-/CD5616+/CD314+**: 0-356 ABS/mm3 **CD3-/CD5616+/CD63+/CD314+**: 0-48 ABS/mm3 **CD16-/CD56-/CD3-/CD117-**: 1-619 ABS/mm3 **CD16+CD56-/CD3-/CD117-**: 0-122 ABS/mm3 **CD16-/CD56+/CD3-/CD117-**: 3-24 ABS/mm3 **CD16+/CD56+/CD3-/CD117-**: 0-446 ABS/mm3 **CD16-/CD56-/CD3+/CD117-**: 570-2430 ABS/mm3 **CD16+/CD56-/CD3+/CD117-**: 0-36 ABS/mm3 **CD16-/CD56+/CD3+/CD117-**: 0-157 ABS/mm3 **CD16+/CD56+/CD3+/CD117-**: 0-49 ABS/mm3 **CD16+/CD56-/CD3+/CD117+**: 0-0 ABS/mm3 **CD16-/CD56+/CD3-/CD117+**: 0-3 ABS/mm3 **CD16+/CD56+/CD3-/CD117+**: 0-0 ABS/mm3		Flow cytometry immunophenotyping	OSU Flow Lab established		

Immunodeficiency Batt Phas NK	PBIDB2	**AlphaBeta** 47.0-80.0% **CD13** No established reference range **CD14** No established reference range **CD19** 2.0-21.0% **CD2** 70.0-92.0% **CD20** 2.0-21.0% **CD3** 59.0-92.0% **CD4** 32.0-62.0% **CD45RA** No established reference range **CD45RO** No established reference range **CD56/16** 3.0-25.0% **CD8** 11.0-40.0% **GammaDelta** 0.0-.7.0% **HLA DR** No established reference range	**AlphaBeta** 550-2,158 ABS/mm3 **CD13** No established reference range **CD14** No established reference range **CD19** 17-750 ABS/mm3 **CD2** 581-3,284 ABS/mm3 **CD20** 17-750 ABS/mm3 **CD3** 490-3,284 ABS/mm3 **CD4** 266-2,213 ABS/mm3 **CD45RA** No established reference range **CD45RO** No established reference range **CD56/16** 25-893 ABS/mm3 **CD8** 91-1,425 ABS/mm3 **GammaDelta** 0-135 ABS/mm3 **HLA DR** No established reference range		Flow cytometry immunophenotyping			
Immunophenotyping	GIPP	**CD10** No established reference range **CD13** No established reference range **CD14** No established reference range **CD19** 2.0-21.0% **CD2** 70.0-92.0% **CD20** 2.0-21.0% **CD23** No established reference range **CD3** 59.0-92.0% **CD4** 32.0-62.0% **CD5** No established reference range **CD56/16** 3.0-25.0% **CD7** No established reference range **CD8** 11.0-40.0% **HLA DR** No established reference range **KAPPA** No established reference range **LAMBDA** No established reference range	**CD10** No established reference range **CD13** No established reference range **CD14** No established reference range **CD19** 17-750 ABS/mm3 **CD2** 581-3,284 ABS/mm3 **CD20** 17-750 ABS/mm3 **CD23** No established reference range **CD3** 490-3,284 ABS/mm3 **CD4** 266-2,213 ABS/mm3 **CD5** No established reference range **CD56/16** 25-893 ABS/mm3 **CD7** No established reference range **CD8** 91-1,425 ABS/mm3 **HLA DR** No established reference range **KAPPA** No established reference range **LAMBDA** No established reference range		Flow cytometry immunophenotyping			

TCRV Beta by Flow Cytometry, Blood	TKIT TCRVB TCR PBTCR	**CD13/14** No established reference range **CD19** 2.0-21.0% 17-750 ABS/mm3 **CD2** 70.0-92.0% 581-3,284 ABS/mm3 **CD26** No established reference range **CD3** 59.0-92.0% 490-3,284 ABS/mm3 **CD4** 32.0-62.0% 266-2,213 ABS/mm3 **CD56/16** 3.0-25.0% 25-893 ABS/mm3 **CD7** No established reference range **CD8** 11.0-40.0% 91-1,425 ABS/mm3 **Vb1** 1.89-11.70% **Vb11** 0.25-5.11% **Vb12** 1.00-4.76% **Vb13.1** 1.62-8.16% **Vb13.2** 0.80-5.28% **Vb13.6** 0.84-8.80% **Vb14** 1.33-8.03% **Vb16** 0.42-1.90% **Vb17** 2.28-12.61% **Vb18** 0.58-5.23% **Vb2** 4.03-23.48% **Vb20** 0.00-9.73% **Vb21.3** 1.08-5.97% **Vb22** 1.99-9.89% **Vb23** 0.26-4.76% **Vb3** 0.52-15.71% **Vb4** 0.79-3.26% **Vb5.1** 3.19-14.93% **Vb5.2** 0.49-4.98% **Vb5.3** 0.37-2.98% **Vb7.1** 0.64-20.01% **Vb7.2** 0.05-5.45% **Vb8** 2.26-29.47% **Vb9** 1.10-9.30%		Flow cytometry immunophenotyping	Beckman Coulter-verified		

Transplant Battery	TRBAT	**CD4/CD3 DUAL (T HELPER)%** 0-179 days: 50.0-57.0 % 180-365 days: 49.0-55.0 % 1-2 years: 46.0-51.0 % 2-3 years: 38.0-46.0 % 3+ years: 32.0-62.0 % **CD4/CD3 DUAL (T HELPER)** 266-2,213 ABS/mm3 **CD4/CD3 DUAL (T SUPPRESSOR)%** 11.0-40.0 **CD4/CD3 DUAL (T SUPPRESSOR)** 91-1,428 ABS/mm3		Flow cytometry immunophenotyping	OSU Flow Lab established		
Transplant Battery Plus	PBSOT Transplant battery plus CD20	**CD19** 2.0-21.0% 17-750 ABS/mm3 **CD2** 70.0-92.0% 581-3,284 ABS/mm3 **CD20** 2.0-21.0% 17-750 ABS/mm3 **CD3** 59.0-92.0% 490-3,284 ABS/mm3 **CD4** 32.0-62.0% 266-2,213 ABS/mm3 **CD8** 11.0-40.0% 91-1,428 ABS/mm3		Flow cytometry immunophenotyping	OSU Flow Lab established		
Acid Fast Culture	AFBCX	No acid fast bacillus seen.	Organisms growing in pure culture are identified to the species level whenever possible.	Culture Susceptibility (if appropriate)			No acid Fast Bacillus Seen Acid Fast Bacilli, Few Acid fast Bacilli, Rare Acid Fast Bacilli, Moderate Acid Fast Bacilli, Heavy
Acid Fast Culture, Tissue	BKR AFB TISS	No acid fast bacillus seen.	Organisms growing in pure culture are identified to the species level whenever possible.	Culture			No acid Fast Bacillus Seen Acid Fast Bacilli, Few Acid fast Bacilli, Rare Acid Fast Bacilli, Moderate Acid Fast Bacilli, Heavy
Acinetobacter Culture, MICU Only	ACINSC	No growth	Organisms growing in pure culture are identified to the species level whenever possible.	Surveillance Culture			
Actinomyces, Screen	ACISCN			Gram Stain			
Anaerobe Culture	ANACX	No growth	Isolation of anaerobes in significant numbers from well-collected specimens including blood, aspirates, tissues or sterile body fluids, indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
Atypical Bacterial Pneumonia, PCR	Atypical Bac	Not Detected (for all targets)	Results should be used in conjunction with other clinical and laboratory findings. This result does not rule out co-infections with pathogens that are not screened for by the Respiratory Panel(RP). This RP assay was performed using a Film Array multiplex nucleic acid assay.	Multiplex polymerase chain reaction (PCR)	Package Insert		MINCP: Not Detected, Detected MINBP: Not Detected, Detected MINBPP: Not Detected, Detected MINMP: Not Detected, Detected
Bacterial Culture and Direct Smear, Lesion, Tissue, Device	General Cult Routine culture and smear	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Smear Culture Susceptibility (if appropriate)	Validation		
Bacterial Vaginosis Panel	BVAG BV	Negative	This test was performed using Transcription Mediated Amplification for the detection of ribosomal RNA from bacteria associated with bacterial vaginosis.	Transcription-mediated amplification (TMA)	Package Insert Clinical Data		Negative, Positive
BAL Consult	BAL CONSULT						
Beta Strep, Vaginal Screen	GBSP Group B Streptococcus Testing by PCR	Negative	This test was performed using a real-time PCR assay. Results should be interpreted in conjunction with other clinical and laboratory findings.	Concentration in LIM broth for > 18 hours followed by real-time polymerase chain reaction (PCR) testing for Group B Streptococcus (GBS) DNA sequence	Validation		SCREEN: Negative for Group B Strep, Positive for Group B Strep PCR: Negative, Positive
Beta Strep, Vaginal Screen, Reflex Susceptibility for Penicillin Allergy	GBS REFLEX GBS Streptococcus agalactiae	Negative	This test was performed using a real-time PCR assay. Results should be interpreted in conjunction with other clinical and laboratory findings.	Concentration in LIM broth for > 18 hours followed by real-time polymerase chain reaction (PCR) testing for Group B Streptococcus (GBS) DNA sequence	Validation		SCREEN: Negative for Group B Strep, Positive for Group B Strep PCR: Negative, Positive
BK Virus DNA PCR, Quant, Urine	BKBU BKBP	<500 copies/mL	This test was performed using a real time PCR assay. The dynamic range for this assay is 500-10,000,000,000 copies/mL.	Real-time polymerase chain reaction (RT-PCR)	Validation	BKBUT: 500-10,000,000,000 copies/mL	BKBUT: ≥500 copies/mL CAT: >10,000,000 copies/mL
BK Virus DNA Qn, PCR, Plasma	BKBP	<500 copies/mL	This test was performed using a real time PCR assay. The dynamic range for this assay is 500-10,000,000,000 copies/mL.	Real-time polymerase chain reaction (RT-PCR)	Validation	BKBPT: 500-5,000,000,000 copies/mL	BKBPT: ≥500 copies/mL CAT: >5,000,000 copies/mL
Blood Culture	BLDCX	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
Blood Culture, AFB, Mycobacteria	AFBBCX Acid fast blood culture	Negative A final negative report will be issued after 42 days of incubation.	A positive result may support the diagnosis of mycobacteremia.	Culture Susceptibility (if appropriate)			
Blood Culture, Pediatric	PEDI	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
Body Fluid Culture and Direct Smear	BFCX Sterile fluid culture	No growth	Isolation of anaerobes in significant numbers from well-collected specimens including sterile body fluids, indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
C difficile 2 Step	CD2STEP	**C DIFFICILE BY PCR** Negative		Polymerase chain reaction (PCR)	Package Insert		C DIFFICILE BY PCR: Negative, Positive C DIFFICILE TOXIN A/B: Negative, Positive
Candida Auris Screen by PCR	CAAUPCR	Not Detected	This test was performed using a real-time PCR assay.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Literature		Not Detected, Detected
Candida/Trichomonas Panel	CVTV	Not Detected (for all targets)	This test was performed using Transcription Mediated Amplification for the detection of ribosomal RNA from microorganisms associated with vulvovaginal candidiasis and trichomoniasis.	Transcription-mediated amplification (TMA)	Package Insert Clinical Data		Not Detected, Detected, Invalid
CAPD Fluid Bacterial Culture	BFCX	No growth	Isolation of anaerobes in significant numbers from well-collected specimens including sterile body fluids, indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
Chlamydia & Gonorrhea Amplified Probe	Chlam and Go Chlamydia trachomatis & Neisseria gonorrhoeae NAAT Testing	Not Detected (for all targets)		Transcription-mediated amplification (TMA)	Package Insert		Not Detected, Detected

Chlamydia Amplified Probe	CT	Not Detected A negative test result for Chlamydia trachomatis does not preclude the possibility of infection. Results should be considered in conjunction with other clinical and laboratory findings.	This test was performed using Transcription Mediated Amplification for the detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae nucleic acid. This assay is not intended for the evaluation of suspected sexual abuse or other medico-legal indications.	Transcription-mediated amplification (TMA)	Package Insert		Not Detected, Detected
CMV by PCR, Quantitative, Blood	CMVPCR CMV Viral Load CMV PCR	<50 IU/mL	This test was performed using a real time CMV PCR assay. The dynamic range for this assay is 50-156,000,000 IU/mL. Results should be interpreted in conjunction with other clinical and laboratory.	Real-time polymerase chain reaction (RT-PCR)	Literature History	50-156,000,000 IU/mL	50-156,000,000 IU/mL
EBV by PCR, Quantitative, Blood	EBVPCR EBV Viral Load EBV PCR	<1,000 IU/mL	This test was performed using a real time PCR assay. The dynamic range for this assay is 1000-5,000,000 IU/mL. A result <1000 IU/mL does not rule out the presence of EBV DNA in quantities below the sensitivity of this assay.	Real-time polymerase chain reaction (RT-PCR)	Validation	1,000-5,000,000 IU/mL	1,000-5,000,000 IU/mL
EBV Rapid PCR, CSF Only	EBVFLD EBV PCR EBV CSF	Not Detected	This test was performed using a real time PCR assay. The limit of detection for this assay is 1,165 IU/mL. This assay is only to be used for patients with a clinical history and symptoms consistent with EBV infections, and should be interpreted in conjunction with other clinical findings. This test should not be used to screen asymptomatic patients.	Real-time polymerase chain reaction (RT-PCR)	Validation	Not Detected, Detected: <10,000 IU/mL, Detected: ≥10,000 IU/mL	
Fungus Culture	FUNCX	No growth	Positive cultures of yeast and filamentous fungi are reported with the organism identification.	Culture Susceptibility (if appropriate)			
Fungus Culture (Skin, Hair, Nails)	SHNCX	No growth	Positive cultures of yeast and filamentous fungi are reported with the organism identification.	Culture			
Fungus Smear	CALCOFLUOR Calcofluor White fluorescent stain			Smear			
Genital Culture, Bacterial	GENICX Vaginal Culture Cervical Culture Urethral Culture	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Smear (if appropriate) Culture Susceptibility (if appropriate)			
Gonorrhea Amplified Probe	NG Chlamydia trachomatis & Neisseria gonorrhoeae NAAT Testing	Not Detected A negative test result for Chlamydia trachomatis does not preclude the possibility of infection. Results should be considered in conjunction with other clinical and laboratory findings.	This test was performed using Transcription Mediated Amplification for the detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae nucleic acid. This assay is not intended for the evaluation of suspected sexual abuse or other medico-legal indications.	Transcription-mediated amplification (TMA)	Package Insert		Not Detected, Detected
H. Pylori Urea Breath Test	UBTB UBT for H. pylori			Infrared Spectrophotometry	Package Insert		Negative, Positive
Hepatitis B DNA	HBDNAB HBV Viral Load	**HBV QUANT** <10 IU/mL **HBV QUANT LOG** <1.00 IU/mL	This test was performed using a real time HBV PCR assay. The dynamic range for this assay is 10-1,000,000,000 IU/mL (1.00-9.00 Logs). Results should be interpreted in conjunction with other clinical and laboratory findings.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Validation	HBDNA: 10-1,000,000,000 IU/mL HBDNAL: 1.00-9.00 IU/mL	HBDNA: ≥10 IU/mL HBDNAL: 1.00-9.00 IU/mL
Hepatitis C by PCR, Quant	HEPCQP HCV Viral Load	**HCV QUANT** <12 IU/mL **HCV QUANT LOG** <1.08 IU/mL	This test was performed using a real time PCR assay. The dynamic range for this assay is 12-100,000,000 IU/mL.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Validation	HEPCQ: 12-100,000,000 IU/mL HEPCQL: 1.08-8.00 IU/mL	HEPCQ: ≥12 IU/mL HEPCQL: 1.08-8.00 IU/mL
HIV Viral Load RNA PCR Quant	HVRNAB HIV Viral Load	**HIV QUANT** <40 copies/mL **HIV QUANT LOG** <1.60 copies/mL	This test was performed using the Abbott RealTime HIV-1 PCR assay. The dynamic range for this assay is 40-10,000,000 copies/mL (1.60-7.00 Logs). This test is designed to provide information for monitoring disease progression and is not intended for use in the diagnosis of HIV-1 infection or Acquired Immune Deficiency Syndrome (AIDS).	Real-time polymerase chain reaction (RT-PCR)	Package Insert Validation	HVRNA: 40-10,000,000 copies/mL HVRNAL: 1.60-7.00 copies/mL	HVRNA: ≥40 copies/mL HVRNAL: 1.60-7.00 copies/mL
HSV by PCR, Fluid/Lesion	HSVPCR Herpes Simplex Virus 1 and 2 Testing by PCR	Not Detected (for all targets)	This test was performed using a real time PCR assay.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Literature		HSV1: Not Detected, Detected HSV2: Not Detected, Detected
Immunocompromised Respiratory Panel	ICRESP BioFire RP2.1	Not Detected (for all targets)	Results should be used in conjunction with other clinical and laboratory findings. This result does not rule out co-infections with pathogens that are not screened for by the Respiratory Panel(RP). This RP assay was performed using a Film Array multiplex nucleic acid assay.	Multiplex polymerase chain reaction (PCR)	Package Insert Literature	All Targets: Not Detected, Detected, Indeterminate	
Influenza A/B Rapid Molecular	FLUABM Rapid Flu	Not Detected (for all targets)	This test utilizes isothermal nucleic amplification technology for the differential qualitative detection of influenza A and influenza B viral nucleic acids.	Isothermal nucleic acid amplification	Alere-I Influenza A+B package insert	All Targets: Not Detected, Detected, Indeterminate	
Influenza A/B, RSV By PCR	RVPCR Flu PCR RSV PCR	Not Detected (for all targets)	This test was performed using a multiplex real time PCR assay. This result does not rule out co-infections with pathogens that were not screened for by this test. Results should be used in conjunction with other clinical and laboratory findings.	Polymerase chain reaction (PCR)	Validation	All Targets: Not Detected, Detected, Indeterminate	
Lactoferrin, Qualitative, Stool	WBCSTL Fecal Leukocytes Stool for WBCs	Negative		Immunochromatographic	Package Insert		Negative, Positive
Legionella Culture	LEGCX	No growth	Identification of Legionella species from respiratory specimens provides a definitive diagnosis of Legionnaires disease.	Culture			
Lower Respiratory Culture, Bacterial	RESPCX Respiratory Culture	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
M Tuberculosis Complex by PCR	MTBCOM TB PCR MTB	Not Detected	This test should always be performed in conjunction with AFB (acid fast bacilli) smear and culture. This test was performed using a Multiplex PCR Test.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Reference Materials		Not Detected, Detected

Macroscopic Arthropod	Macroscopic Arthropod	Negative, Artifact (not arthropod)		Macroscopic exam			Negative, Bedbug, Centipede, Flea, Flea, Tunga sp, Flea, Ctenocephalides sp, Flea, Xenopsylla sp, Flea, Pulex sp, Fly larva (myiasis causing), Kissing Bug (Reduviid, Triatomine), Louse, Louse, Nit, Louse, Pediculus humanus, Louse, Pthirus pubis, Mite, Demodex sp, Mite, not Scabies, Mite-Sarcoptes scabei, Scorpion, Spider, Spider-Black Widow, Spider-Brown Recluse, Hard tick, Hard tick, not Ixodes, Soft Tick, Tick, Tick-Ixodes sp, Tick-Dermacentor sp, Tick-Amblyomma sp, Tick-Rhipicephalus sp, Artifact (not arthropod, Arthropod, Arthropod or worm, other than a human parasite, Arthropod not known to transmit human pathogens
Maternal High Risk Stat HIV	MHRHIV		**RHIV12:** Non Reactive **RPDP24:** Non Reactive				RHIV12: Non Reactive, Reactive RPDP24: Non Reactive, Presumptive Reactive, Reactive
Meningitis/Encephalitis Panel CSF	CSFMEP BioFire ME Panel	Not Detected (for all targets)	A negative result does not exclude the possibility of CNS infection and should not be used as the sole basis for diagnosis, treatment, or other management decisions. Negative results may occur when the concentration of organism(s), virus(es), or yeast in the specimen is below the limit of detection. The ME panel does not distinguish between latent and active herpesvirus infections(CMV, HHV-6). This test was performed using a film array method for the detection of: *Escherichia coli* K1, *Haemophilus influenza* , *Listeria monocytogenes* , *Neisseria meningitidis* , *Streptococcus agalactiae* , *Streptococcus pneumoniae* , Cytomegalovirus, Enterovirus, Herpes Simplex virus 1 and 2, Human Herpesvirus 6, Human parechovirus, Varicella zoster virus, and *Cryptococcus neoformans/gatti* .	Multiplex polymerase chain reaction (PCR)	Package Insert		All Targets: Not Detected, Detected
Molecular Enteric Panel, Stool	STLB Gastrointestinal Panel	Negative (for all targets)	This test was performed using a real time PCR assay. Results should be interpreted in conjunction with clinical findings. A positive result does not necessarily indicate the presence of viable organisms. Positive results do not rule out co-infection with other organisms that are not detected by this assay. For Shiga toxin, this assay detects Shiga toxin 1 / Shiga toxin 2 genes (found in Shiga toxin-producing E. coli as well as Shigella dysenteriae). This test should not be used as a test of cure.	Real-time polymerase chain reaction (RT-PCR)	Package Insert		All Targets: Negative, Positive
Molecular Stool Parasite Panel	SCPB O&P	Negative (for all targets)	This test was performed using a real time PCR assay. Results should be interpreted in conjunction with clinical findings. A positive result does not necessarily indicate the presence of viable organisms. Positive results do not rule out co-infection with other organisms that are not detected by this assay. This test should not be used as a test of cure.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Reference Materials		All Targets: Negative, Positive
Neisseria Gonorrhea Amplified Probe	NG	Not Detected A negative test result for Chlamydia trachomatis does not preclude the possibility of infection. Results should be considered in conjunction with other clinical and laboratory findings.	This test was performed using Transcription Mediated Amplification for the detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae nucleic acid. This assay is not intended for the evaluation of suspected sexual abuse or other medico-legal indications.	Transcription-mediated amplification (TMA)			Not Detected, Detected
Neisseria-Gonococcus Screen	SCN	No growth	Isolation of anaerobes in significant numbers from well-collected specimens including endocervix, urethra, rectum, upper respiratory tract (throat, nasopharynx), and conjunctiva indicates infection with the identified organisms.	Culture			
Novel Coronavirus PCR - Semi-Private Surveillance	COVID	Not Detected	Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 has not been determined. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation suggest that SARS-CoV-2 infection is probable, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. Collection of a new specimen and re-testing may be necessary if the patient is critically ill or clinically deteriorating.	Real-time polymerase chain reaction (RT-PCR)			Not Detected, Detected
Novel Coronavirus PCR - Nasopharyngeal	COVID	Not Detected	Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 has not been determined. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation suggest that SARS-CoV-2 infection is probable, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. Collection of a new specimen and re-testing may be necessary if the patient is critically ill or clinically deteriorating.	Real-time polymerase chain reaction (RT-PCR)			Not Detected, Detected
Novel Coronavirus PCR - Nasopharyngeal (Outreach)	COVID	Not Detected	Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 has not been determined. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation suggest that SARS-CoV-2 infection is probable, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. Collection of a new specimen and re-testing may be necessary if the patient is critically ill or clinically deteriorating.	Real-time polymerase chain reaction (RT-PCR)			Not Detected, Detected
Pinworm Exam	Pinworm Exam	Negative		Microscopic exam			Negative, Enterobius vermicularis (Pinworm) Eggs Seen, Enterobius vermicularis (Pinworm) Adult Worm(s) Seen, Enterobius vermicularis (Pinworm) adult worm(s) and eggs seen
Plesiomonas/Aeromonas Screen, Stool	SCF	Negative for Aeromonas species Negative for Plesiomonas species	Isolation of anaerobes in significant numbers from well-collected stool specimens indicates infection with the identified organisms.	Culture			
Quantitative Tissue Culture	BKR QUANTITA	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Tissue is weighed, serially diluted, and cultured for exact colony count.			

Rapid HIV-1/HIV-2 Ab With P24 Antigen	RHIV12 Alere Determination HIV 1/2 Ag/Ab Combo		**RHIV12:** Non Reactive **RPDP24:** Non Reactive	Qualitative immunoassay / immunochromatographic test for simultaneous and qualitative detection of free HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2.	Package Insert		RHIV12: Non Reactive, Reactive RPDP24: Non Reactive, Presumptive Reactive, Reactive
Rapid Malaria	MPBR EVDMAL Plasmodium	Negative for malaria antigens		Immunochromatographic membrane assay	Package Insert		Negative for malaria antigens, Positive rapid malaria test for P. falciparum protein antigen only, Positive rapid malaria test for malaria protein antigen, representing P. vivax or P. malariae or P. ovale or a mix of species, Positive rapid malaria test. Positive for P. falciparum protein antigen
Rapid Strep A, Molecular	STRPAM Rapid Strep Strep A	Negative Negative results do not preclude infection with Group A Streptococcus and should not be used as the sole basis for treatment.		Molecular in vitro diagnostic test utilizing isothermal nucleic acid amplification.			Negative, Positive
Rectal Screening for Cipro Resistance	BKR CIPROFLO Ciprofloxacin Resistance Screening	Negative for Ciprofloxacin Resistant Enterobacterales	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Culture			
SARS-COV-2 Rapid	COVID Rapid COVID	Not Detected	Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 has not been determined. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation suggest that SARS-CoV-2 infection is probable, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. Collection of a new specimen and re-testing may be necessary if the patient is critically ill or clinically deteriorating.	Isothermal nucleic acid amplification	Abbott ID NOW Rapid Covid package insert		Not Detected, Detected
Screen: MRSA Only	SCREEN: MRSA MRSA Screen	Negative		Culture			Negative, Positive
Screen: MRSA/MSSA	SCRSB Respiratory Staphylococcus Screen Staph Screen	**PCR** Negative **CULTURE** Negative for Staphylococcus aureus Negative for Methicillin Resistant Staphylococcus aureus	This test was performed using a real time PCR assay. Results should be interpreted in conjunction with other clinical and laboratory findings. A positive result does not necessarily indicate the presence of viable organism. This test should not be used as a test of cure.	Real-time polymerase chain reaction (RT-PCR)	Package Insert		PCR: Negative, Positive MSSA CX: Negative for Staphylococcus aureus Positive for Staphylococcus aureus MRSA CX: Negative for Methicillin Resistant Staphylococcus aureus Positive for Methicillin Resistant Staphylococcus aureus
Screen, VRE	SCREEN: VRE Vancomycin Resistant Enterococcus Screen	Negative		Culture on select agar			Negative, Positive
Screen, Yeast	YSTSCR	Negative		Culture			
Strep Pneumoniae Antigen, Urine	PNEUMU	Negative		Immunochromatographic membrane assay	Binax NOW Package Insert		Negative, Positive
Upper Respiratory Culture, Bacterial	THRCX Throat Culture RESN	No growth	Isolation of anaerobes in significant numbers from well-collected specimens indicates infection with the identified organisms.	Culture			
Urine Culture	URN CX	Negative	Isolation of anaerobes in significant numbers from well-collected urine specimens indicates infection with the identified organisms.	Culture Susceptibility (if appropriate)			
Vaginal Infection Panel	BVAG CV TV CT NG	BVAG: Negative CV: Not Detected TV: Not Detected CT: Not Detected NG: Not Detected	**BV:** This test was performed using Transcription Mediated Amplification for the detection of ribosomal RNA from bacteria associated with bacterial vaginosis. **CV/TV:** This test was performed using Transcription Mediated Amplification for the detection of ribosomal RNA from microorganisms associated with vulvovaginal candidiasis and trichomoniasis. **CT/NG:** This test was performed using Transcription Mediated Amplification for the detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae nucleic acid. This assay is not intended for the evaluation of suspected sexual abuse or other medico-legal indications.		See individual analytes	See individual analytes	See individual analytes
Varicella Zoster By PCR, Skin	VZVPCR	Not Detected	This test was performed using a real time PCR assay.	Real-time polymerase chain reaction (RT-PCR)	Package Insert Literature		Not Detected, Detected
ADAMTS13 Activity and IgG Ab w/ Reflex to Inhibitor	AD13A AD13IGG von Willebrand Factor Cleaving Protease Anti-ADAMTS13 antibodies	**ACTIVITY** ≥40 % **IGG** ≤12.0 U/mL		Technozym enzyme-linked immunosorbent assay (ELISA)	Technozym kit	ACTIVITY: 2-100 % IGG: 6.0-104.0 U/mL	ACTIVITY: 2-100 % IGG: 6.0-104.0 U/mL
Alternative Activation Pathway	APBBD Bb Complement Alternative complement pathway	695-1,974 ng/mL		Quidel enzyme-linked immunosorbent assay (ELISA)	Biomarker Reference Lab		
Terminal Activation Pathway	TPC5AB SC5b-9 Complement Membrane attack complex (MAC) Terminal complement complex (TCC)	6-598 ng/mL		Quidel enzyme-linked immunosorbent assay (ELISA)	Biomarker Reference Lab		